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ABSTRACT 
 
ENGINEERED MARROW MACROPHAGES FOR CANCER THERAPY: 
ENGORGEMENT, ACCUMULATION, DIFFERENTIATION, AND ACQUIRED 
IMMUNITY 
 
Cory M. Alvey 
 
Dennis E. Discher 
The ability of a macrophage to engulf and break down invading cells and other targets 
provides a first line of immune defense in nearly all tissues. This defining ability to 
‘phagos’ or devour can subsequently activate the entire immune system against foreign 
and diseased cells, and progress is now being made on a decades-old idea of directing 
macrophages to phagocytose specific targets such as cancer cells. Physical properties of 
cancer cells influence phagocytosis and relate via cytoskeleton forces to differentiation 
pathways in solid tumors. Here, SIRPα on macrophages from mouse and human marrow 
was inhibited to block recognition of CD47, a ‘marker of self.’ These macrophages were 
then systemically injected into mice with fluorescent human tumors. Within days, the 
tumors regressed, and fluorescence analyses showed that the more the SIRPα-inhibited 
macrophages engulfed, the more they accumulated within tumors. In vitro phagocytosis 
experiments on transwells revealed that macrophage migration through micropores was 
inhibited by eating. However, during the 1-2 weeks of tumor residency, donor 
macrophages quickly differentiated toward non-phagocytic, high-SIRPα tumor associated 
macrophage. Analyses of macrophages on soft or stiff collagenous gels demonstrated a 
stiffness-driven upregulation of SIRPα. Tissue stiffness also seems to have a role in the 
vi 
development of cancer. Meta-analyses suggest that genomic variation across tumors 
scales with the stiffness of the tumor tissue of origin. These genomic changes give rise to 
neoantigens that are important for the development of monocyte/macrophage 
immunotherapies. Indeed, marrow-derived macrophages can phagocytose melanoma cells 
and present neoantigens leading to the activation of T-cells. Unlike past injections of anti-
CD47 which cause anemia, no measurable impact on blood profiles, weight, or 
development of GvHD was observed from systemic injections of SIRPα-inhibited donor 
macrophages.  
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Chapter 1: Introduction 
  
2 
1.1 SIGNIFICANCE  
 
It was once thought that failure of a macrophage to engulf a cancer cell reflects the 
absence of an activation signal by surface opsonization from IgG molecules. However, it 
is now understood that ‘eat me’ signals are balanced by the presence of ‘don’t eat me’ 
signals or ‘self’ markers (Oldenborg et al., 2000). Within the last few decades, numerous 
‘self’ markers have been discovered that inhibit immune cell destruction of healthy cells. 
The ‘self’ markers, PD-L1 and CD47, have been of interest to researchers because of their 
inhibitory effects on T-cells and macrophages, respectively, and how these markers relate 
to cancer progression (Strickland et al., 2016). Macrophages are particularly exciting as 
they are abundant and motile in solid tumors (Chaturvedi et al., 2014; Condeelis & Pollard, 
2006; Lu-emerson et al., 2013) compared to T-cells which minimally infiltrate (Fousek & 
Ahmed, 2015; Joyce & Fearon, 2015; Salmon et al., 2012). These observations help 
explain the poor clinical trial outcomes for T-cell therapy of solid tumors (Kakarla & 
Gottschalk, 2014; Nicol et al., 2011). Unfortunately, macrophage-based therapy has its 
own challenges. It is well-established that the density of the ‘tumor associated macrophage’ 
(TAM) has been linked to promoting tumor growth, angiogenesis, and inhibiting other 
immune effector cells (Colegio et al., 2014; Fujiwara et al., 2011; Lan et al., 2012; Lu-
emerson et al., 2013; Y. Zhang et al., 2013). Clinical data supports these observations as 
high TAM density is correlated with poor prognosis (Leek et al., 1996). The term ‘tumor-
associated macrophage’ is perhaps a misnomer in the strict sense that a macrophage 
should ‘phagos’ or eat foreign or diseased (cancerous) cells. However, these cells seem to 
have lost most or all of their ability to destroy cancerous cells.  
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How any cell, including a cancer cell, avoids being engulfed by an activated 
macrophage could partially involve signaling by “marker of self” CD47 to the phagocyte’s 
receptor SIRPα (Bruce et al., 2002; P. Oldenborg et al., 2000; Tsai & Discher, 2008). It 
is now well established that cancer cells overexpress ‘self’ markers such as PD-L1 and 
CD47 (Majeti et al., 2009; Posey et al., 2016; Sockolosky et al., 2016; Willingham et al., 
2012). Recent studies suggest that common oncogenes, such as MYC, are selected for 
based on their transcriptional control over ‘self’ markers (Casey et al., 2016). In vivo 
knockdown of mCD47 in tumors can slow tumor growth with an implication for 
macrophages as the primary effector cell as systemic poisoning of macrophages eliminates 
the growth suppression (Wang et al., 2013). Human tumors in mice also shrink after 
systemic injection of anti-hCD47 in combination with a distinct Ab that opsonizes the 
human cancer cells (e.g. (Chao et al., 2010)).  
Based on these preclinical studies, human clinical trials using CD47 blockade for 
cancer therapy have been rapidly emerging. These trials rely on TAMs and perhaps 
infiltrating monocytes that are partially or fully inhibited from recognizing tumors as self 
(Chao et al., 2010; Willingham et al., 2012). Most preclinical models show CD47 
disruption alone is insufficient (Chao et al., 2010; Weiskopf et al., 2013), requiring an 
additional pro-phagocytic signal (like a foot on the gas pedal) to drive phagocytosis of 
cancer cells by TAMs. Anti-CD47 antibodies had once been thought sufficient to inhibit 
CD47 and activate phagocytosis through Fc engagement, but results are mixed, at best, 
even when combined with tumor pro-phagocytic signals such as calreticulin and 
phosphatidylserine (Chao et al., 2010; Feng et al., 2015; Lundqvist et al., 2008; Rettig et 
al., 1999). One recent study (Horrigan et al., 2017; Willingham et al., 2012) failed to 
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replicate any efficacy with anti-mCD47 inhibition alone and questioned the statistical 
significance of past data (Horrigan et al., 2017; Willingham et al., 2012). Direct 
measurements of cancer cell engulfment by macrophages in tumors could help address 
these conflicting reports, but these measurements are severely lacking. In addition to 
concerns of efficacy, safety is also an issue as CD47 is expressed on all cells, and so 
species-matched anti-CD47 injections (e.g. anti-mCD47 into mouse) cause rapid and 
reproducible depletion of blood cells (Willingham et al., 2012). Initial clinical trials of 
anti-hCD47 safety likewise motivate a concentrated and thorough study of the basic 
biology and coupling of macrophage trafficking, phagocytosis with ‘self’-inhibition, and 
differentiation in tumors. 
 
1.2 THESIS OUTLINE 
Given the concerns surrounding TAMs as possible effector cells in anti-CD47 
therapy, chapter 2 focuses on the progress made using adoptive transfer of macrophages 
to treat cancer and whether it could be a novel approach when combined with inhibition 
of CD47-SIRPα. Upon investigation of adoptive macrophage literature, it was clear that 
over the past four to five decades adoptive macrophages have been found to be safe, albeit 
ineffective, in anti-cancer therapy (Andreesen, Hennemann, & Krause, 1998; Chokri et 
al., 1992; Lacerna, Stevenson, & Stevenson, 1988). However, a majority of these studies 
were conducted prior to the discovery of ‘marker of self’ CD47 (Oldenborg et al., 2000), 
which inhibits phagocytosis by turning off cytoskeletal myosin-II (Tsai & Discher, 2008). 
One recent study reported that knockdown of SIRPα in macrophages accelerates tumor 
growth and alters macrophage phenotype (Pan et al., 2013), but it is unclear whether 
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antibody blockade of SIRPα along with tumor opsonization would produce the same effect. 
Furthermore, little is known about the effect of the tumor microenvironment on the 
differentiation of newly resident tumor macrophages that are engineered to eat cancer cells. 
Considerable progress over the past decade has been made toward understanding the 
broad plasticity of macrophages and their responses to microenvironments such as the 
tumor (Adlerz et al., 2016). Our initial analyses of at least one mechanosensitive nuclear 
protein in macrophages suggested that microenvironment stiffness could regulate 
macrophage differentiation.  
With an understanding of anti-CD47 therapy and adoptive transfer of macrophages, 
we started our initial phagocytosis assays by inhibiting only SIRPα on macrophages. 
Quickly, it became evident that blockade of SIRPα only was insufficient to stimulate 
engulfment of cancer cells by macrophages. Therefore, we needed an opsonization 
antibody that had high specificity toward cancer cell lines as safety concerns were already 
an issue with CD47 inhibition. Chapter 3 focuses on our investigation of possible 
neoantigen targets and how they arise in cancer cells. A meta-analysis of recently 
published sequencing data revealed that somatic mutation rate increased with normal 
tissue stiffness across cancer types. Among various hypotheses that seek to explain this 
scaling relationship, the one that we considered most promising holds that stiffer tissues 
have smaller extracellular matrix pores. This can increase DNA damage in invading 
cancer cells, perhaps leading to genomic variation and neoantigens. We went on to study 
different methods used to target these neoantigens, focusing on those using immune cells 
that infiltrate solid tumors. Since healthy cells lack these neoantigens, it seems plausible 
to target plasma membrane neoantigens with antibodies to drive Fc-dependent 
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phagocytosis of cancer cells without causing clearance of healthy cells. This is important 
in the case of treating mouse cancers in mice (chapter 5) rather than human cancers in 
mice (Chapter 4), as antibodies are often species-specific and, therefore, targeting human 
antigens in mice have substantially fewer off-target effects.  
Chapter 4 contains our study of the biophysically intensive processes of 
phagocytosis, migration, and differentiation. We simplified in vivo studies by using 
human-derived tumor models in NSG mice (non-obese diabetic/severe combined IL-2Rγ 
mice (Pearson et al., 2008)) that lacked T-cells, B-cells (and Ab’s), as well as NK-cells 
while maintaining functional monocytes, macrophages, and neutrophils (McIntosh et al., 
2015; Quintana et al., 2012). We systemically injected highly phagocytic marrow 
macrophages that were SIRPα inhibited and had their Fc-Receptors pre-loaded with 
cancer-targeting Ab’s (A’PB MФ) into mice with established tdTomato A549 tumors. We 
found that engineering macrophages in this way increased phagocytosis of tdTomato 
A549 cells in culture (Okazawa et al., 2005; Oldenborg et al., 2000) and, within days of 
A’PB MФ injection, tdTomato expressing A549 tumors regressed. During these studies, 
we found TAMs to be minimally phagocytic, even toward CD47-knockdown tumors. Past 
studies have opsonized tumors in situ with antibody and/or relied on mouse TAMs 
(Weiskopf et al., 2013; Willingham et al., 2012), but have not injected SIRPα-inhibited 
cells. Unlike past injections of anti-CD47, blood parameters remained normal with A’PB 
MФ treatment. Interestingly, we observed that A’PB MФ would accumulate in tumors 
rather than other tissues and seems to be dependent on phagocytic activity. Unfortunately, 
after 1-2 weeks of tumor residency, donor macrophages quickly differentiated toward 
non-phagocytic, SIRPα-high TAMs.  
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Although we found A’PB MФ alone to be sufficient to shrink solid tumors in 
immune incompetent mice, we hypothesized that a greater tumor response could be 
achieved in a fully immune competent model. Previous studies had shown TAMs to be 
poor activators of acquired immunity (Liu et al., 2015), but the ability of marrow-derived 
macrophages to initiate an acquired immune response in tumors was unknown. Therefore, 
in chapter 5 we studied whether marrow-derived macrophages (MDMs) accumulate in 
syngeneic orthotopic melanoma tumors, engorge on cancer cells, and activate T-cells. 
Engineered macrophages had sustained tumor shrinkage for 7 days despite T-cell 
depletion, but tumors eventually regrew. However, 60% of tumors treated in mice with 
intact T-cells had complete tumor regression. These ‘cured’ mice were re-challenged with 
melanoma 100 days after treatment and had significantly delayed tumor growth, whereas 
untreated mice grew tumors within days of being challenged. This suggested that MDMs 
can initiate long-term acquired immunity against melanoma tumors.  
8 
Chapter 2: Engineering macrophages to eat cancer:  
from ‘Marker of Self’ CD47 and phagocytosis to 
differentiation  
 
 
 
 
 
This chapter presents work featured in the review article: 
Alvey, C.M. and Discher, D.E. (2017) Journal of Leukocyte Biology. 102: 1-10. 
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ABSTRACT 
 
The ability of a macrophage to engulf and break down invading cells and other targets 
provides a first line of immune defense in nearly all tissues. This defining ability to 
‘phagos’ or devour can subsequently activate the entire immune system against foreign 
and diseased cells, and progress is now being made on a decades old idea of directing 
macrophages to phagocytose specific targets such as cancer cells. Engineered T-cells 
provide precedence with recent clinical successes against liquid tumors, but solid tumors 
remain a challenge and a handful of clinical trials seek to instead exploit the abundance 
of tumor associated macrophages (TAMs). Although macrophage differentiation into such 
phenotypes with deficiencies in phagocytic ability can raise challenges, newly recognized 
features of cancer cells that might be manipulated to increase the phagocytosis of these 
cells include at least one membrane protein, CD47, which broadly inhibits phagocytosis 
and is abundantly expressed on all normal cells. Physical properties of the target also 
influence phagocytosis and again relate – via cytoskeleton forces – to differentiation 
pathways in solid tumors. Such pathways extend to mechanosensing by the nuclear lamina, 
which is known to influence signaling by soluble factors that regulate macrophage SIRPα, 
the CD47 receptor. Here we highlight some of these past, present, and rapidly emerging 
efforts to understand and control macrophages for cancer therapy.   
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2.1. INTRODUCTION 
Phagocytosis is an ancient, cytoskeleton-intensive process of cell-level eating that 
is used by amoeba and that has continually evolved in higher organisms. In humans, it is 
the defining process of the mononuclear phagocyte system (MPS). The two principal cell 
types of the MPS are macrophages, which reside in every tissue, and monocytes, which 
differentiate to macrophages when exiting circulation to enter tissues (Gosselin et al., 
2014; Lavin et al., 2014). MPS cells, along with highly phagocytic neutrophils, must – for 
the health of the organism – selectively devour ‘foreign’ targets such as microbes rather 
than phagocytose the human ‘self’ cells or extracellular matrix that typically surround our 
phagocytes. Macrophages have a uniquely efficient capacity to phagocytose multiple 
targets, digest them, and search for more – including some types of diseased cells amongst 
healthy cells (Fidler & Kleinerman, 1984). However, macrophages fail to perceive and 
attack tumors as foreign (Condeelis & Pollard, 2006; Lu-emerson et al., 2013). 
Macrophages are abundant and motile in solid tumors (Chaturvedi et al., 2014; 
Condeelis & Pollard, 2006; Lu-emerson et al., 2013) compared to T-cells that minimally 
infiltrate (Fousek & Ahmed, 2015; Johanna A. Joyce & Fearon, 2015; Salmon et al., 2012). 
The latter observations might help explain the poor clinical trial outcomes for T-cell 
therapy of solid tumors (Kakarla & Gottschalk, 2014; Nicol et al., 2011). On the other 
hand, macrophages are not only ‘plastic’ in the sense that they exhibit a broad capacity to 
differentiate in different microenvironments, but the density of the ‘tumor associated 
macrophage’ (TAM) phenotype has been linked to promoting tumor growth, inducing 
angiogenesis, and inhibiting other immune effector cells (Colegio et al., 2014; Fujiwara 
et al., 2011; Lan et al., 2012; Lu-emerson et al., 2013; Y. Zhang et al., 2013). Clinical 
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data shows high TAM density is indeed correlated with poor prognosis (Leek et al., 1996). 
The ‘tumor associated macrophage’ is perhaps a misnomer in the strict sense of the 
macrophage as a giant eating cell because these cells seem to have lost most or all of their 
ability to phagocytose, and their low MHC-II expression likely hinders their activation of 
the adaptive immune system against tumor neoantigens (Lavin et al., 2014; Lu-emerson 
et al., 2013; D. Rodriguez et al., 2013). In efforts to address some of the above challenges, 
engineering of macrophages ex vivo for ‘adoptive transfer’ back into cancer patients had 
been pursued for many years (Andreesen et al., 1998; Lacerna et al., 1988), but some new 
insights into macrophage interactions and plasticity might prove useful in re-invigorating 
such approaches (Fig. 2.1A). 
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Figure 2.1. Anti-cancer macrophages and CD47 
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Figure 2.1. Anti-cancer macrophages and CD47. (A) Timeline of adoptive macrophage 
transfer and CD47 studies converging on anti-CD47 focused macrophage therapies. (B) 
Inhibition of cancer cell engulfment because of recognition of CD47 by a non-phagocytic 
phenotype despite the presence of a pro-phagocytic antibody. Addition of anti-CD47 
blocking antibody and a more phagocytic phenotype can drive engulfment. The Acto-
Myosin cytoskeleton has a key role in phagocytosis and linking the microenvironment to 
influence phenotype. (C) Antibody modification (blocking SIRPα and loading Fc receptor 
with targeting antibody) of marrow macrophages followed by systemic injection could be 
an effective method for adoptive macrophage cancer therapy. In circulation, A’PB 
macrophages could in principle migrate into tumors, phagocytose cancer cells, and then 
either exit the tumor or continue to destroy tumor cells. 
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2.2. Adopting macrophages as a cell therapy 
Adoptive macrophage transfer was first pursued decades ago in some of the 
earliest cell therapy efforts against cancer. Monocytes isolated from peripheral blood were: 
(1) cultured in conventional dishes for most preclinical studies and in Teflon bags for 
clinical trials, and then (2) ‘engineered’ by differentiation into some form of adherent 
macrophage with interferon-γ and lipopolysaccharide, before (3) ultimately being injected 
back into patients. Safety was established with injections of up to 1.5 x 109 cells 
(Andreesen et al., 1998). For comparison, roughly 105 white blood cells egress from 
human marrow every second, and only ~5% are monocytes (with ~106 red blood cells), 
so that the cited injections are equivalent to what would be normally produced over a few 
days as naïve cells. However, efficacy assessments in these early clinical trials showed 
little to no benefit of these in vitro engineered macrophages (Andreesen et al., 1990; 
Faradji et al., 1991; Hennemann et al., 1997; Lacerna et al., 1988).  
It was understood decades ago that for macrophages to destroy cancer cells they 
needed to be activated, and numerous soluble and/or surface bound factors could act as 
molecular cues to stimulate MPS destruction of foreign targets. Immunoglobulin-G (IgG) 
antibodies are among the most modular (and now designable), as they signal via the 
macrophage membrane receptor FcγR (for specific isoforms of FcγR and IgG). IgG’s 
produced by B cells perfuse and diffuse throughout the body and bind to a target surface 
so that when a macrophage contacts the target, the constant fragment (Fc) of the IgG binds 
the FcγR to signal phosphorylation of immunoreceptor tyrosine-based activating motifs 
(ITAMs), which then propagates a phosphorylation cascade that regulates adhesion and 
cytoskeletal remodeling (Cox & Greenberg, 2001). Phosphopaxillin, F-actin, and myosin-
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II are just a few among many such proteins that subsequently accumulate within minutes 
at this dynamic phagocytic synapse (Aderem & Underhill, 1999; Greenberg, Chang, & 
Silverstein, 1994; Tsai & Discher, 2008). Antibody dependent cell-mediated cytotoxicity 
(ADCC) and antibody dependent cellular phagocytosis by macrophages have indeed been 
reported to be crucial to anticancer mechanisms in vitro and in vivo (Pallasch et al., 2014). 
Studies often prove this by depletion of TAMs after systemic injection of clodronate 
particles, but the approach has shortcomings as highlighted below. Nonetheless, these pro-
phagocytic signals are also balanced by inhibitory signals. Engagement of FcγRIIB 
(CD32B) causes activation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) 
which promote internalization of pro-phagocytic IgGs preventing activation of ITAMs. 
Blocking FcγRIIB can prevent internalization of therapeutic antibodies such as rituximab 
increasing cell surface accessibility of such antibodies by macrophages (Dahal et al., 2015; 
Roghanian et al., 2015).  
Early studies of adoptive macrophage transfer explored ex vivo incubation of 
engineered antibodies that targeted the Fcγ receptors on macrophages and specific antigen 
on tumor cells (Boyer et al., 1999; Chokri et al., 1992; Ely et al., 1996; Michon et al., 
1995). The approach failed to control tumor growth (Andreesen et al., 1998) and might 
be explained by minimal activation of the macrophage Fcγ receptor, since the downstream 
response from IgGs varies greatly with engagement, antibody isotypes, and species 
(Overdijk et al., 2012). Unfortunately, the inability to strongly activate and control 
phagocytosis dampened interest in adoptive transfer approaches to treat cancer. 
 
2.3. CD47 signals “don’t eat me”  
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In watching a movie of phagocytosis, it is easy to assume that failure of an 
otherwise activated macrophage to engulf a target reflects a lack of surface ’opsonization’ 
by molecules such as IgG. However, it is now clear that in addition to ‘foreign’ signals 
there are also signals for specific recognition of ‘self’. If opsonization is analogous to 
putting your foot on the gas, then self-signaling is the brake that overrides the 
phagocytosis process. Indeed, a dominating and passivating interaction occurs between 
the ubiquitous ‘marker of self’ CD47 membrane protein on a candidate target cell (or 
particle) and the macrophage membrane receptor signal-regulatory protein alpha (SIRPα) 
(Brown & Frazier, 2001; Mawby et al., 1994; Oldenborg et al., 2000). Phagocytosis of 
cancer cells that are targeted by opsonizing IgG might thus benefit by blockade of CD47, 
even given the limited phagocytic capacity of TAMs (Fig. 2.1B). Alternatively, bone 
marrow derived macrophages are highly phagocytic when SIRPα has been blocked in in 
vitro studies (Oldenborg et al., 2000). However, it remains untested whether systemic 
injections of such “Antibody-primed Fc Receptor Plus anti-SIRPα Blocked (A’PB) MФ” 
can find their way in vivo to a tumor and subsequently phagocytose opsonized cancer cells 
(Fig. 2.1C). 
Within a macrophage that is phospho-activated through engagement of a target via 
an IgG-FcγR interaction, simultaneous engagement of CD47-SIRPα activates the tyrosine 
phosphatase SHP1, via SIRPα’s ITIMs, which de-activates the myosin-II contractile 
cytoskeleton among other structural targets to greatly impede phagocytosis (Rodriguez et 
al., 2013; Tsai & Discher, 2008). F-actin polymerization is uninhibited and filipodial 
protrusions tend to push a ‘self’ recognized target away from being engulfed (Sosale et 
al., 2015). More such structure-function signaling studies are certainly needed, as 
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understanding the balance of ‘eat me’ cues (e.g. IgG-FcγR interaction) and ‘don’t eat me’ 
signals (CD47-SIRPα) has become an active area of research, especially regarding 
therapeutic applications. Translation to the clinic is already focused on anti-cancer therapy 
(Lockhart et al., 2007), and pre-clinical studies demonstrating CD47 utility to reduce 
macrophage uptake of ‘foreign’ nanoparticles and lentiviral vectors for drug and gene 
delivery (Rodriguez et al., 2013; Sosale et al., 2016).  
Prior to the cloning and formal naming of ‘CD47’ in the mid-1990’s (Lindberg et 
al., 1994; Mawby et al., 1994), this ubiquitous membrane protein was already referred to 
as OA3 antigen due to abundant binding of a monoclonal IgG (OVTL3) to ovarian cancers. 
Even earlier, bivalent F(ab’)2 fragments of this monoclonal antibody against the single, 
extracellular, immunoglobulin-like domain of CD47/OA3 had already been used for 
targeted radio-imaging. Despite ubiquitous expression, imaging results were described as 
showing 80% specificity in 31 patients (Massuger et al., 1990). While any inhibition of 
‘self’ recognition is unlikely to have impacted the growth of the tumors in these studies 
decades ago (see below), retrospective analyses of the anti-CD47 injection protocols and 
outcomes can inform current concerns of the safety (or not) of anti-CD47 injections in 
cancer patients.  
Numerous human cancers and patients have since been reported to display CD47 
at levels >3-fold higher than expression on healthy tissue (Willingham et al., 2012; Zhang 
et al., 2015). High levels of CD47 seems to correlate with poor clinical outcomes (Chao 
et al., 2010; Majeti et al., 2009; Willingham et al., 2012). CD47 and another immune 
inhibitor, PD-L1, are either strongly turned on or are simply selected for during early 
cancer development, and both are transcriptionally controlled by MYC as a common 
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oncogene (Casey et al., 2016; Kaur et al., 2013). Low levels of CD47 on various cancerous 
and non-cancerous cells are typical of apoptosis and combine with various opsonizing 
factors to favor clearance by macrophages (Gardai et al., 2005; Gregory & Brown, 2005; 
Roos & Kaina, 2013). Despite this background knowledge, the processes that occur within 
the macrophage during phagocytosis continue to require study, particularly because most 
studies of macrophage involvement in tumor shrinkage have relied on systemic injection 
of clodronate particles to poison macrophages even though this approach can cause 
variability in tumor growth (Wang et al., 2013; Yanagita et al., 2017) (Fig. 2.2A) and 
assumes uptake is efficient in its effects on the desired cells (TAMs) but has no broader 
effect on other cells (eg. other macrophages, cancer cells). Isolation of macrophages from 
tumors followed by direct assessments of phagocytosis will be more compelling. 
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Figure 2.2. Tool kit for studying the effect of CD47 inhibition on tumor growth 
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Figure 2.2. Tool kit for studying the effect of CD47 inhibition on tumor growth. (A) 
Growth curve of syngeneic, orthotopic B16F10 tumors in C57 mice show the effects that 
si-mCD47 liposomes and clodronate liposomes have on tumor growth. Data adapted from 
(Wang et al., 2013). (B) Analysis of how long untreated orthotopic B16F10 tumors in C57 
mice take to reach 100 mm2 when challenged with either 200k or 500k. Data is adapted 
from: 1 Alvey and studies 2 (Wang et al., 2013), 3 (Bencherif et al., 2015), 4 (Ali et al., 
2009), and 5 (Sockolosky et al., 2016); (*) indicates p ≤ 0.05. (C) Growth curves of 
orthotopic B16F10 tumors in C57 mice treated with a combination of anti-CD47 
nanobodies and an antibody that binds tyrosinase-related protein 1 (Trp1). Data adapted 
from (Sockolosky et al., 2016). (i) Log-scale growth highlights differences in tumor sizes 
between treatment conditions near the start of treatment. (ii) Normalizing growth data to 
day 5 gives a different interpretation from the reported conclusions (i): anti-Trp1 has only 
a small effect, but combination with anti-CD47 nanobody can significantly reduce tumor 
growth.  
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2.4. Status of anti-CD47 therapy and safety assessments 
Clinical trials of CD47 blockade for therapy are rapidly emerging with anti-
human-CD47 antibodies (Table 2.1). These trials rely on TAMs and perhaps infiltrating 
monocytes that are partially or fully inhibited from recognizing tumors as self (Chao et 
al., 2010; Willingham et al., 2012). A few preclinical models with syngeneic tumors have 
shown complete inhibition of tumor growth when using either anti-mCD47 or siRNA 
knockdown of Cd47 with nanoparticles (Wang et al., 2013; Weiskopf et al., 2013). 
Success against human-derived xenografts has extended to human cancer stem cells in 
mice (Cioffi et al., 2015). However, most preclinical models show CD47 disruption alone 
is insufficient (Chao et al., 2010; Sockolosky et al., 2016; Weiskopf et al., 2013). Strongly 
pro-phagocytic signals (like a foot on the gas pedal) and effective inhibition of CD47 (to 
eliminate any braking) seem necessary in combination to drive phagocytosis of cancer 
cells by TAMs (Chao et al., 2010; Sockolosky et al., 2016; Weiskopf et al., 2013) (Fig. 
2.1B). Anti-CD47 antibodies had been thought sufficient to inhibit CD47 and activate 
phagocytosis through Fc engagement, but results are mixed at best even when combined 
with tumor pro-phagocytic signals such as calreticulin and phosphatidylserine (Chao et 
al., 2010; Feng et al., 2015; Lundqvist et al., 2008; Rettig et al., 1999).  
One recent study (Horrigan et al., 2017; Willingham et al., 2012) failed to replicate 
any efficacy with anti-mCD47 inhibition and questioned the statistical significance of past 
data (Horrigan et al., 2017; Willingham et al., 2012). An additional concern arose with 
the syngeneic orthotopic breast tumor model used in both studies in that the tumors were 
reported to spontaneously regress during the replication studies (Horrigan et al., 2017; 
Willingham et al., 2012). An alternative syngeneic orthotopic tumor model with well-
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documented robustness in terms of reproducibility is the melanoma model B16F10 
derived from and engrafted in C57 mice. This model shows consistent tumor growth rates 
between different labs and over time, which suggests it to be a very predictable and useful 
model (Bencherif et al., 2015; Wang et al., 2013) (Fig. 2.2B). Even with a reliable tumor 
model, another cause of uncertainty in the field seems to arise from the numerous ways 
tumor growth data is reported: publications commonly show either tumor volume (often 
assuming shape or height), tumor cross-sectional area (measured or estimated from shape), 
or normalized tumor area, but each can yield a different conclusion. In one recent study 
of B16F10 tumors, the authors reported that injection of an antibody against tyrosinase-
related protein 1 (Trp1) was sufficient to significantly reduce tumor growth in mice 
(Sockolosky et al., 2016). However, anti-Trp1 treated tumors were 2-3-fold smaller than 
control tumors within 1 day after treatment started (Fig. 2.2C(i)). When the data is 
normalized to that day 5-time point, anti-Trp1 shows no effect, whereas the combination 
of anti-Trp1 with anti-CD47 nanobody does seem to have inhibited tumor growth when 
normalized (Fig. 2.2C(ii)). Such re-analyzed findings again suggest that shrinkage of 
tumors with anti-CD47 requires at least a combination with another tumor opsonizing 
antibody, such as rituximab or trastuzumab in other studies (Chao et al., 2010; Weiskopf 
et al., 2013). 
Safety of anti-CD47 antibody injections remains a concern. Injections of anti-
mCD47 in mice and anti-hCD47 monkeys lead to a 30% decrease in RBC count within 
days following a single injection (Tseng et al., 2013; Weiskopf et al., 2013). Antibodies 
and other serum proteins bind both specifically and non-specifically to red blood cells 
(RBCs) (Franco et al., 2013; Turrini et al., 1991), to viruses (Wilflingseder et al., 2007), 
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and even particles coated with PEG (polyethylene glycol) (Discher et al. 2014), and so 
‘eat me’ signals are always present. Perhaps related, one strain of CD47 knockout mouse 
survives for only 6 months and has detectable IgG against mouse RBCs as well as anemia 
and organ failure (Oldenborg et al., 2002). Inhibiting the receptor for CD47 on 
macrophages, SIRPα, also enhances phagocytosis in vitro (Ho et al., 2015; Oldenborg et 
al., 2000) and in vivo (Rodriguez et al., 2013), and the latter studies show that systemic 
injection of anti-SIRPα antibodies leads to rapid clearance of circulating components 
(Rodriguez et al., 2013). Despite the caution required from this data, a growing number 
of clinical trials are using anti-CD47 antibodies in patients with diverse liquid and solid 
tumors that range from leukemia to colorectal cancer (Archambeaud et al., 2016; Burgess 
et al., 2015; Chao et al., 2016; Kang, et al., 2011; Sievers et al., 2016; Takimoto et al., 
2014) (Table 2.1).  
Blood analyses will likely provide the first evidence of safety in human trials with 
therapeutically relevant doses of anti-CD47 injected systemically. Based on animal 
studies, a short term mild anemia is expected, and anemia might even be already evident 
in a retrospective analysis of patient data from the early radio-imaging trial that used anti-
CD47 targeting of ovarian cancer (Massuger et al., 1990). Leukocytes as well as platelets 
in human circulation are all likely to be affected by systemic anti-CD47 because CD47 is 
displayed on all cells and is known for most cell types to prevent their phagocytosis. The 
abundance of RBCs makes them easiest to quantify, and the youngest blood cells are 
routinely quantified only for RBCs (i.e. reticulocytes) in providing the clearest measure 
of an ongoing perturbation. One can anticipate that RBC-clearing macrophages in the 
human spleen will initially phagocytose older RBCs that are the most IgG opsonized and 
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the stiffest (Sosale et al., 2015), but a new steady state for RBC lifespan is difficult to 
predict given that CD47 nulls exist only in mice and not in humans.  
In the normal steady state, every second ~1-million reticulocytes emerge from 
marrow to mature in about 1 day to discocyte-RBCs which replace old, opsonized, stiff 
RBCs that are cleared at ~100 days (reticulocytes are thus ~1% of RBCs). Within days of 
injecting anti-CD47 systemically, the oldest RBCs should decrease in age to about 70 days 
– based on noted mouse and primate studies (~30% loss in RBCs) (Tseng et al., 2013; 
Weiskopf et al., 2013). This will likely saturate engorgement of splenic macrophages 
(splenomegaly when chronic) which may limit clearance of even younger, CD47-blocked 
RBCs. Enhanced production of reticulocytes (perhaps increasing to ~10%) will 
compensate for the rapid loss of RBCs. This degree of compensation is also observed in 
humans who, secondarily to other genetic defects, lack ~90% of CD47 on their RBCs 
(Bruce et al., 2002; Dahl et al., 2004). Within weeks of continued anti-CD47 injections, 
the anemia is likely to become better compensated and reticulocyte production should 
gradually decrease with the oldest RBC age remaining low at ~90+ days. An over-
abundance of CD47 on RBCs allows for a half-max effectiveness at just ~10% of normal 
levels (i.e. 10% of ~250 molecules per sq. micron on RBC (Rodriguez et al., 2013)) that 
can still signal ‘self’ to macrophages. It will be important to therefore determine whether 
systemic anti-CD47 binds and blocks up to ~90% of CD47 and thereby mimics tolerable 
human deficiencies of CD47 or greatly exceeds such states. These projected estimations 
illustrate the careful consideration of CD47 quantities on various cells; determining how 
much anti-CD47 binds and blocks can thus make sense of past studies and new clinical 
results with humanized anti-CD47 IgG isotypes.  
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Table 2.1. CD47-SIRPα clinical trial data 
 
 
  
26 
Table 2.1. CD47-SIRPα clinical trial data. Chronological order of anti-CD47 antibody 
clinical trials on a variety of human cancers. Most of these trials were started in 2016 and 
include Phase II studies in combination with an additional opsonizing antibody.   
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2.5. Macrophage: a bridge to acquired immunity 
Although macrophage engulfment of cancer cells can contribute to tumor 
reduction, phagocytic cells can also present neoantigens to T-cells. Early hints of this have 
included (i) the noted presence of IgG against RBCs in some strains of Cd47 knockout 
mice, and also (ii) differences in the effects of mCD47 blockade between syngeneic and 
immune deficient tumor models (Oldenborg et al., 2002; Sockolosky et al., 2016; Wang 
et al., 2013; Zhang et al., 2015). Absent any targeting of mCD47, vaccination studies have 
certainly documented T-cell activation by macrophages and phagocytic dendritic cells in 
cancer therapies: for example, implanted scaffolds that contain tumor lysates and 
cytokines lead to acquired immunity – probably after being phagocytosed – in syngeneic 
models (Bencherif et al., 2015; Ly et al., 2013). With mCD47 blockade, T-cells are 
recruited to tumors by phagocytic macrophages even though tumor clearance seems 
dominated by macrophages (Sockolosky et al., 2016; Tseng et al., 2013). Surprisingly, 
even though PDL1 on cancer cells is primarily considered to inhibit T-cell interactions 
and thereby enhance T-cell responses, anti-PDL1 IgG can also engage macrophage Fc 
receptor and indeed has a major role in driving phagocytosis (Sockolosky et al., 2016; 
Tseng et al., 2013). With a standard melanoma model (in which initial treatments were 
begun before tumors became palpable), blockade of PDL1 also required blockade of 
mCD47 for long term mouse survival and re-challenge with cancer cells (Sockolosky et 
al., 2016; Tseng et al., 2013).  
Other syngeneic tumor models using mCD47 blockade have relied on endogenous 
opsonization (eg. calreticulin (Chao et al., 2010; Lundqvist et al., 2008; Rettig et al., 1999)) 
and showed shrinkage in days, but injection of anti-CD8 – which should deplete T-cells – 
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removes any therapeutic effect (Liu et al., 2015). This suggested to the authors that the 
primary effector cell is the T-cell. Alternatively, T-cells displaying an intact anti-CD8 IgG 
(typically IgG1 that strongly engages Fc receptor) could be the most opsonized cell in or 
near a tumor (assuming T-cell infiltration), and thus mCD47-blocked TAMs 
phagocytosing such T-cells would distract from phagocytosis of weakly opsonized tumor 
cells. Understanding the dominating imbalance is sometimes unclear, but such findings 
nonetheless question whether TAMs are always effective phagocytic cells and antigen 
presenters. TAMs certainly promote tumor growth and are weakly phagocytic, at least 
when compared to peritoneal macrophages (Fujiwara et al., 2011; Lan et al., 2012; 
Rodriguez et al., 2013; Zhang et al., 2013). TAMs also have low MHC-II, which is 
required for activation of T-cells (Franklin et al., 2014; Gosselin et al., 2014; Lavin et al., 
2014). Regardless of the extent to which T-cells contribute, the ability of macrophages to 
activate T-cells should be considered when evaluating efficacy as well as safety. The 
ubiquitous and abundant expression of CD47 on all cells has already given cause for 
concern over anti-CD47 therapy, first in terms of the massive amount of antibody that 
needs to be injected, but more important is the possibility of a chronic autoimmune 
response against healthy cells, such as the rapidly cleared RBCs.  
Concerns over TAMs could perhaps be addressed by adoptive macrophage therapy 
in combination with CD47-SIRPα blockade (Fig 2.1C). Macrophages and dendritic cells 
are isolated and/or differentiated as done in early adoptive transfer studies, but they are 
first engineered with antibodies and/or SIRPα knockdown or CRISPR knockout (Liu et 
al., 2016; Pan et al., 2013). When SIRPα depletion is combined with transfection of 
macrophages with presentable cancer antigens, implantation of both the macrophages and 
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melanoma cells are found to prevent tumor growth (Liu et al., 2016). Safety becomes a 
major concern, however, because SIRPα knockdown in macrophages, followed by 
systemic injection, enhances growth of liver cancers (Pan et al., 2013). SIRPα activates 
the Tyr-phosphatase SHP1, which has a multitude of targets and is therefore likely 
involved in multiple signaling pathways that affect phenotype (Tsai & Discher, 2008).  
 
2.6. Macrophage plasticity and mechanosensing  
Phenotypes of macrophages have classically been divided into two or three states: 
a pro-inflammatory state (M1), an immune inhibitory, angiogenetic state (M2) (Jablonski 
et al., 2015; Mantovani et al.,1992; Mantovani et al., 2002; Murdoch et al., 2008; 
Ramachandra et al., 1999), and a more passive M0 state. Macrophages are instead far 
more diverse and plastic: macrophages from different tissues indeed exhibit distinct 
expression profiles (Lavin et al., 2014). Studies of macrophage diversity use a variety of 
surface markers that should be factored into the interpretation of any study in human or 
mouse (Bencherif et al., 2015; Casey et al., 2016; Colegio et al., 2014; Dorward et al., 
2013; Jablonski et al., 2015; Lavin et al., 2014; Majeti et al., 2009; Hanna et al., 2015; 
Sockolosky et al., 2016; Swamydas et al., 2015) (Table 2.2). In mice, the most common 
macrophage antigen is F4/80, and the CD11b-positive subset is only sometimes used, 
which might explain some differences in phenotype. Importantly, macrophages taken 
from a donor tissue and transplanted into a different tissue partially convert over days or 
weeks to be increasingly like macrophages in the new host tissue (Lavin et al., 2014). 
Macrophage phenotype is thus plastic and controlled by the local microenvironment, with 
potential effects of both biochemical and biophysical cues. Any adoptive macrophage 
30 
approach used to treat solid tumors will therefore contend with their differentiation to 
TAMs. Broadly understanding and controlling such differentiation is thus key to 
macrophage-based therapies.  
Differentiation of cultured macrophages into the classic M1 phenotype was done 
biochemically in early trials of adoptive macrophage therapy prior to transfer into the host 
(Andreesen et al., 1998; Murdoch et al., 2008). Plastic culture dishes are rigid and are 
now known to affect differentiation, with stem cell phenotypes in culture affected by the 
softness of the underlying matrix in a mechanosensing process that depends on Myosin-
II contractions of the substrate (Engler et al., 2006) (Fig. 2.1B). Macrophages plated on 
soft gels exhibit a high M1/M2 ratio whereas stiff gels lead to a low M1/M2 ratio (Adlerz 
et al., 2016). Stiffening of tissues such as breast and liver is often associated with cancer 
(Boyd et al., 2007; Levental et al., 2009; Singh et al., 2013), and might even contribute to 
genomic heterogeneity of cancer (Irianto et al., 2017), which complicates therapies with 
a single molecular target. For macrophages, pre-malignant stiffening of tissue could favor 
conversion to a non-phagocytic phenotype with a reduced capacity to clear damaged cells, 
which again favors cancer.  
Mechanistically, transcriptional control is provided by the nuclear envelope 
protein, lamin-A, which regulates the nuclear localization of Retinoic Acid Receptor 
(RAR) transcription factors; the latter is interesting because epigenetic analyses have 
implicated RA in microenvironment regulation of macrophage phenotype (Lavin et al., 
2014). Different cell types exhibit different expression changes in response to tissue 
stiffness, but at least one common factor – lamin-A – appears mechanosensitive in most 
(perhaps all) cell types in tissues (Swift et al., 2013). Stiff tissues tend to be under high 
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mechanical stress, and that stress is transmitted from the cell surface through the actin-
myosin cytoskeleton and to the nuclear envelope, with lamin-A adjusting its level to 
sustain the stress (Buxboim et al., 2014) and ultimately protect chromatin from damage 
(Irianto et al., 2017). Average levels of lamin-A protein and transcript increase 
systematically from soft marrow and soft brain to stiffer muscle and rigid bone whereas 
the levels of lamin-B isoforms remain nearly constant. Macrophages can of course be 
isolated from any tissue or disease site and provide an in vivo test of the broader nuclear 
mechanosensing hypothesis. Meta-analysis of RNA-seq results for monocytes or 
macrophages isolated from different tissues show lamin-A increasing with tissue stiffness 
and lamin-B remaining nearly constant (Fig. 2.3A).  
Solid tumors are typically high in collagen, which generally determines tissue 
stiffness and has already been shown for numerous human cancer types xenografted into 
mice (Swift et al., 2013). TAMs that are isolated from such tumors using standard markers 
(F4/80, CD11b) have recently been subject to RNA-seq analysis, which shows that the 
ratio of lamin-A reads to lamin-B reads is similar in TAMs to the same ratio in stiff, normal 
tissues (Fig. 2.3B). Such results are thus consistent with mechanosensing of matrix 
microenvironments by macrophages, and such physical effects on the expression of other 
genes requires careful study. SIRPα is especially interesting because it was recently shown 
to be strongly regulated by RA (Zhu et al., 2013), which is mechanosensitive in its 
downstream effects according to the studies above. If the sensing of microenvironment 
and the affected gene circuits do drive an increase in SIRPα on TAMs within stiff solid 
tumors, then TAMs could recognize ‘self’ cancer cells more readily and thus be passivated. 
Knockdown of SIRPα would seem logical to counter such pro-tumorigenic effects, but 
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systemic injections of such engineered macrophages are found to enhance the growth of 
liver tumors in the absence of added tumor opsonization (Pan et al., 2013). 
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Table 2.2. Commonly used markers to identify mouse phagocytes 
Notes: Lavin et al’s study of macrophages in multiple tissues used the indicated markers 
and sometimes supplemented with additional markers. 
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Table 2.2. Commonly used markers to identify mouse phagocytes. Frequently used 
markers to identify phagocytic cells (macrophages, neutrophils, monocytes) and different 
macrophage polarizations organized by publication.  
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Figure 2.3. Stiff matrix regulation of Lamin-A   
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Figure 2.3. Stiff matrix regulation of Lamin-A. (A) RNA-seq reads per Million for 
lamin-A and lamin-B in tissue macrophages from (Lavin et al., 2014) plotted as a function 
of tissue stiffness measurements in (Swift et al., 2013). (B) Ratio of RNA reads for lamin-
A : lamin-B in macrophages including tumor associated macrophages isolated from human 
tumor xenografts per (Lavin et al., 2014; Swift et al., 2013). Subcutaneous A549 tumors 
were engrafted in NSG mice and allowed to grow to 80 mm2 before tumor stiffness was 
measured and macrophages were profiled.  
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2.7. Target cell rigidity and shape can override ‘self’ signaling  
Macrophages not only respond to physical cues such as the stiffness of their 
microenvironments, but also to the targets that they engulf. With spherical microparticles 
made of hydrogels and opsonized by IgG, engulfment is proportional to stiffness, which 
was also shown to drive focal adhesion protein assembly at the phagocytic synapse 
(Beningo & Wang, 2002). Stiffness changes occur with cancer cells and with 
chemotherapy (Cross et al., 2007; Lam et al., 2009); soft cancer cells might thus escape 
anticancer efforts aimed at inhibiting CD47-SIRPα interactions (Weiskopf et al., 2013). 
To test the relevance of cell stiffness and any modulation by CD47 signaling of ‘self,’ 
human RBCs were controllably stiffened with a dialdehyde crosslinker and both IgG 
opsonization and CD47 blockade were separately controlled (Sosale et al., 2015). 
Phagocytosis of rigidified, discocyte-shaped human RBCs exceeded that of flexible RBCs 
and proved almost independent of CD47 (Fig. 2.4A-C). Myosin-II contractile forces are 
again key in responding to target rigidity. 
Rigid, spherical CD47-beads signal self and thereby impede engulfment both in 
vitro and in vivo (Rodriguez et al., 2013), and sphered RBCs also recovered some ‘self’ 
signaling probably because the discocyte’s rigid concavities could not contact and signal 
‘self’ (Sosale et al., 2015). Target shape is therefore an additional factor in phagocytosis. 
Indeed, polystyrene microbeads melted and distorted into diverse shapes, for example, are 
engulfed by macrophages more readily as spheres than as non-spheres when IgG 
opsonized (Champion & Mitragotri, 2006). Such findings seem relevant to the diverse 
shapes of bacteria and fungi, which invariably have rigid cell walls. With cancer cells that 
are soft but CD47-blocked and IgG-opsonized for targeted engulfment by macrophages, 
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phagocytosis could distort and elongate the cells – as seen for RBCs (Sosale et al., 2015), 
and this would also tend to weakly oppose successful phagocytosis. Understanding the 
details of the various physical and chemical cues to macrophages therefore remains an 
important endeavor. 
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Figure 2.4. Target physical properties and molecular interactions at the cell surface 
determine the efficiency of human RBC engulfment by human macrophages   
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Figure 2.4. Target physical properties and molecular interactions at the cell surface 
determine the efficiency of human RBC engulfment by human macrophages (adapted 
from (Sosale et al., 2015)). (A) Phagocytosis increases with IgG opsonization and with 
crosslinker-based rigidification of hRBCs. Phagocytosis of rigid, opsonized RBCs is 
independent of hCD47 inhibition in contrast to ‘Soft’ native RBCs whose uptake is 
enhanced by a hCD47-blocking antibody. A ‘sphering’ treatment that gives a rounded and 
rigid hRBC shows reduced uptake relative to discocytes. (B) Time-lapse images of 
rigidified hRBC discocytes shows rapid engulfment and lack of deformation by the 
macrophage. (C) Surface interactions combine kinetically with physical properties of a 
candidate target in the calculus that determines phagocytic uptake. 
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2.8. CONCLUDING REMARKS 
Over the past four to five decades, macrophages have been found safe albeit 
ineffective in anti-cancer therapy, but the general approach is perhaps re-emerging based 
on the discovery of ‘marker of self’ CD47 signaling to macrophages. This signaling 
ultimately turns off cytoskeletal myosin-II, which otherwise makes the very active process 
of engulfing a foreign cell or particle efficient, and so inhibiting this signaling at various 
upstream or downstream points in the CD47-SIRPα pathway can likewise make 
engulfment of ‘self’ cells more efficient. Considerable progress over the past decade has 
separately been made toward understanding the broad plasticity of macrophages and their 
responses to microenvironments. Initial analyses of at least one mechanosensitive nuclear 
protein suggests that such responsiveness includes the stiffness of the microenvironment. 
Phagocytosis is also favored by the stiffness of a cell or particle, and myosin-II has again 
been shown to be key. Myosin-II thus has a vital role in multiple, cytoskeletal-intensive 
activities of macrophages.  
Complementary to these basic insights into pathways is a current focus on 
blockade of CD47-SIRPα to engineer macrophages in situ for therapy against cancer. The 
various clinical trials are likely to encounter some challenges in safety and efficacy, but 
injection of anti-hCD47 in cancer patients was conducted for decades for imaging 
purposes. Regardless of success in macrophage engineering in situ or ex vivo for specific 
applications, the ability of these fascinating and ubiquitous cells to migrate, engulf, digest, 
and perhaps activate the broader immune system against foreign and diseased cells merits 
the renewed interest in understanding their basic functions.  
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Chapter 3: Genome variation across cancers scales 
with tissue stiffness – implications for immune cell 
infiltration  
 
 
 
This chapter presents work featured in the review article: 
Pfeifer, C.R., Alvey, C.M, Irianto, J., and Discher, D.E. (2017) Current Opinion in 
Systems Biology. 2:102-113. 
 
 
Pfeifer, C.R. -meta analysis of somatic mutations in published exome sequencing 
(Figure. 3.1 and 3.2)  
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ABSTRACT 
 
Many different types of soft and solid tumors have now been sequenced, and meta-
analyses suggest that genomic variation across tumors scales with the stiffness of the 
tumors’ tissues of origin. The opinion expressed here is based on a review of current 
genomics data, and it considers multiple ‘mechanogenomics’ mechanisms to potentially 
explain this scaling of mutation rate with tissue stiffness. Since stiff solid tissues have 
higher density of fibrous collagen matrix, which should decrease tissue porosity, invasion 
of cancer cells into stiff tissues could squeeze the nucleus sufficiently to enhance DNA 
damage. Diversification of a cancer genome after constricted migration is now clear. 
Understanding genome changes that give rise to neoantigens is important to selection as 
well as to the development of immunotherapies, and we discuss engineered 
monocytes/macrophages as particularly relevant to understanding infiltration into solid 
tumors.  
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3.1. INTRODUCTION 
 
Tumors are often palpably stiffer than nearby normal tissue (Levental et al., 2010), 
with stiffness of breast and liver, among other organs, correlating with cancer risk (Boyd 
et al., 2007; Singh et al., 2014). Tissue stiffness likely contributes in normal cells to 
motility (Pelham & Wang, 1997) and differentiation (Engler et al., 2006), and in cancer 
cells to invasion (Przybyla, Muncie, & Weaver, 2016) and various epigenetic mechanisms 
(Spencer, Xu, & Bissell, 2007), including stiffness-dependent nuclear localization of 
oncogenic factors (e.g. YAP) (Dupont et al., 2011). It is unclear, however, if a physical 
attribute of the microenvironment such as stiffness could contribute—in a 
‘mechanogenomics’ type of process—to any of the many genetic changes that typically 
occur in cancer. 
Meta-analyses of recently published cancer mutation data begin to suggest that—
beyond some initial driver mutation(s)—the large genomic variation across diverse 
cancers scales with tissue stiffness. Stiffness-dependent cell biological mechanisms for 
genome variation are needed to substantiate any such correlation, and some molecular 
mechanisms are now emerging. One possible mechanism is based on the fact that stiffer 
tissues, including tumors, are enriched in collagen (Swift et al., 2013), and many studies 
of collagen gels show that denser collagen has smaller matrix pores (Yang, Leone, & 
Kaufman, 2009). Thus, as cancer cells invasively migrate into stiff, small-pore 
surroundings, the nucleus is damaged, which might ultimately contribute to genomic 
diversity.  
Invasion is a defining task of a cancer cell; the equal but opposite challenge of an 
immune cell—therapeutic or otherwise—is to confront stiffness barriers and infiltrate a 
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wound or disease site to attack ‘non-self’. In the cancer context, genome variation can 
produce novel protein sequences that might be perceived by the immune system as 
‘neoantigens’. Such sequences are by definition absent from normal cells, and so can be 
used to identify and eliminate cancerous cells if the neoantigen signals are sufficiently 
potent, accessible, and foreign to overwhelm ‘self’ recognition (Schumacher & Schreiber, 
2015). A moonshot-scale effort now seeks to employ neoantigens in various 
immunotherapy approaches. Some therapies use engineered T-cells to target neoantigens 
on the cancer cell membrane (Ramos, Savoldo, & Dotti, 2015), while other therapies 
exploit the major histocompatibility complex (MHC)—class I and class II—to target 
nuclear and cytoplasmic neoantigens (Hodi et al., 2010; Liu et al., 2016; Ly et al., 2013). 
Monocytes and macrophages are the focus here and are particularly interesting for 
targeting to neoantigens because these phagocytic cells exhibit a robust ability to infiltrate 
solid tissues, including tumors. The microenvironment-dependent plasticity of such cells, 
which is now being mapped by modern systems biology methods, could also be triggered, 
in part, by the stiffness or solidity of the tissue. 
 
3.2. Genomic variation scales with tissue stiffness 
Advances in genome sequencing have enabled cataloguing of the genomic 
variations that occur in cancers of many different types (Martin et al., 2015; Matsushita 
et al., 2016; Schumacher & Schreiber, 2015), and although oxidation artifacts can 
complicate such methods (Costello et al., 2013), somatic mutation rates are being 
collected in databases such as The Cancer Genome Atlas (TCGA) run by the National 
Cancer Institute (NCI). For the healthy tissues of origin of 36 types of cancer, tissue 
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microelasticity data were culled from numerous recent papers (Alexandrov et al., 2013; 
Chen et al., 2014; Cross et al. 2011; Fuhrmann et al., 2011; Guz et al., 2014; Hoyt et al., 
2008; Kawano et al., 2015; Lawrence et al., 2013; Lekka, Gil, et al., 2012; Lekka, Pogoda, 
et al., 2012; Lim et al., 2009; Lopez et al. 2011; Martincorena et al., 2015; Martincorena 
& Campbell, 2015; Mathur et al., 2001; Petrie et al., 2012; Prabhune et al., 2012; 
Schumacher & Schreiber, 2015; Shain et al., 2015; Shin et al., 2014; Xu et al., 2012) that 
used a variety of physical methods, including atomic force microscopy (AFM), micro-
indentation probes, micropipette aspiration, and imaging-based elastography (Table 3.1). 
Whereas AFM pushes on cells and tissues at the ~100-nanometer to multi-micron length 
scales in order to provide a measure of a microenvironment’s stiffness, the larger length 
scale imaging-based elastography methods that perturb and monitor by magnetic 
resonance imaging, for example, typically probe on a millimeter length scale that 
encompasses many cells and the matrix between them; in principle, all of these types of 
measurements should be made on fresh tissue, since the former add up to the latter. 
However, measurements on cultured cells are likely to have little relevance to the tumor, 
because culture conditions such as gel stiffness influence cell mechanics (Pelham & Wang, 
1997). Importantly, based on current tissue measurements, meta-analyses of genomics 
indicate that cancers arising in stiff tissues, such as lung and skin, exhibit 30-fold higher 
somatic mutation rates (as median per sequenced megabase) than cancers arising in soft 
tissues, such as marrow and brain (Fig. 3.1A). Importantly, the stiffness of a typical brain 
tumor or marrow tumor never increases to that of a typical bone tumor microenvironment 
even though tumors often stiffen — or, less frequently, soften — in tumorigenesis 
(Levental et al., 2010). The hierarchy of normal tissue stiffness is therefore likely to 
47 
prevail in cancer: that is, brain is softer than liver, which is softer then bone, etc. — 
regardless of cancer or not. 
Childhood muscle and bone cancers have only slightly elevated somatic mutation 
rates as compared to childhood marrow and brain cancers, but they have >10-fold more 
chromosome copy number changes and structural variants (Chen et al., 2014) (Fig. 3.1B). 
This disparity suggests that large-scale, chromosome-level amplifications and deletions 
— more so than somatic mutations — are signatures of some mutational processes that 
associate with tissue stiffness. In adult melanoma, fibrotic skin tends to be stiffer and 
exhibit more chromosome copy number changes than softer, less fibrotic skin (Diridollou 
et al., 2001; Shain et al., 2015) (Fig. 3.1C-i). Moreover, these copy number changes 
increase even faster with stiffness than do somatic mutation rates, and all mutations are 
most abundant in invasive melanoma (Shain et al., 2015) (Fig. 3.1C-ii). The relationship 
between chromosome-level mutations and stiffness thus holds even within a given tissue 
type, suggesting—in our opinion—a correlation between mutations and stiffness that 
cannot be entirely explained away by exposure to carcinogens. 
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Table 3.1. Cancer types and the microelasticities of the healthy tissues in which 
they arise  
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Figure 3.1. Genomic variation increases versus tissue stiffness across cancers and 
with melanoma progression  
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Figure 3.1. Genomic variation increases versus tissue stiffness across cancers and 
with melanoma progression. (A) Across different cancer types, somatic mutation rate—
the median number of somatic substitutions and small insertions/deletions per 
megabase—increases with normal tissue stiffness. The same trend persists, albeit more 
weakly, among childhood cancers. The stiffness scale varies >10-fold from softer tissues 
(green), such as marrow and brain, to stiffer tissues (red), including lung, skin, muscle, 
and bone. (B) Large-scale, chromosome-level mutations likewise increase with stiffness: 
childhood cancers in stiffer tissues have 10-to-20-fold more chromosome copy number 
changes and structural variants than do cancers in softer tissues, while somatic mutation 
rates differ much less. (C) (i) Melanomas from patients of ≤60 years have fewer copy 
number changes than melanomas from patients over 60. The younger patients also have 
softer, less fibrotic skin, as inferred from their lower average solar elastosis score; solar 
elastosis is the thickening of skin due to prolonged sun exposure. (ii) In skin cancer 
genomes, chromosome copy number changes increase strongly with somatic mutation rate 
and lesion stiffness, with all highest in “invasive melanoma.”  
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3.3. Mechanical causes of mutation in the correlation of genomic variation with tissue 
stiffness 
Scaling of genomic variation with tissue stiffness could result from at least three 
possible mechanical sources of mutations. First, stiff matrix enhances cell proliferation, 
as has been shown by an increase in BrdU incorporation with substrate stiffness in 2D 
cultures of normal human smooth muscle and breast epithelial cells as well as mouse 
embryonic fibroblasts (Klein et al., 2009). DNA replication in each cell division cycle 
carries with it some risk of spontaneous mutation (Lawrence et al., 2013; Seshadri et al., 
1987), accounting for about 67% of mutations in human cancers (Tomasetti, Li, & 
Vogelstein, 2017). Since these mutations accumulate over successive generations, more 
proliferation should mean more changes to the genome. Nowak and Waclaw (Nowak & 
Waclaw, 2017) recently pointed out for the case of one-hit, oncogenic initiation that 
cancer risk scales (in log-log plots) with the division rate of the resident tissue stem cells 
with a power law of 0.53, which is lower than linear scaling as expected for a simple stem 
cell contribution (Tomasetti et al., 2017). Tissue geometry was speculated to suppress the 
‘effective number of stem cell divisions’ (Nowak & Waclaw, 2017). More study is needed, 
especially in 3D, because a 3D stiff surrounding could, physically impact the fidelity of 
replication and chromosome segregation during mitosis. 
A second conceivable explanation for the scaling relationship is that stiffness 
increases the frequency of nuclear envelope rupture (Tamiello et al., 2013). Such rupture 
causes transient leakage into the nucleus of cytoplasmic factors, including perhaps 
nucleases, that might damage DNA and contribute to genome instability (Maciejowski et 
al., 2015). However, the increase of rupture frequency with substrate stiffness has been 
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observed only in cells with defects in lamin-A, which is one of the three intermediate 
filament proteins that confer strength and stability to the nucleus. Yet, cancer types vary 
widely in their lamin-A expression levels: it is downregulated in leukemia as well as in 
breast and lung cancers, whereas it is upregulated in colorectal and skin cancers (for 
review: (Irianto et al., 2016)). Lamin-A is highly mutated in multiple laminopathies, but 
cancer risk is not reported to be elevated. The inconsistency in lamin-A levels across 
cancer types argues against a simple stiffness-induced nuclear rupture hypothesis. 
A third explanation that we find more promising is based on invasion of cells 
through stiff tissues, given that invasion is a ‘hallmark’ of cancer. Tissue stiffness 
increases with fibrous protein (e.g. collagen) concentration (Swift et al., 2013), which, in 
turn, anti-correlates with extracellular matrix pore size (Yang et al., 2009) (Fig. 3.2A). 
Hence, cancer cells invading normal tissue, as during tumor growth (Liotta, Steeg, & 
Stetler-Stevenson, 1991), encounter higher collagen matrix levels and smaller pores in 
stiffer tissues than in softer ones (Irianto et al., 2016). Squeezing through small pores—
but not larger ones—greatly deforms the nuclei of invading cancer cells (Harada et al., 
2014) and has several consequences. For one, constricted migration segregates mobile 
nuclear factors away from DNA (Irianto et al., 2016). Among cells in static culture, 
hetero/eu-chromatin occupies roughly 50-70% of the nuclear volume per previous 
estimates from molecular mobility (Bancaud et al., 2009), and we have shown for various 
cancer cell lines that the chromatin volume fraction can increase locally to 100% as the 
nucleus enters a small constriction. Conversely, all mobile proteins in the nucleus, 
including those that function as key DNA repair proteins, are always seen to deplete within 
the constriction (Irianto et al., 2016). Such unavoidable ‘squeeze-out’ of mobile nuclear 
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factors away from the constriction, where DNA concentration is highest, has important 
implications for the repair of DNA damage that might occur during replication, for 
example. Inactivating mutations in repair factors such as BRCA1 and BRCA2 are well-
established risk factors for cancer and are sufficient cause for prophylactic mastectomy 
(i.e. preventative surgery), and so transient partial depletion of such factors could increase 
mutational probabilities. 
In addition to inevitable squeeze-out of mobile repair factors, constriction can also 
cause rupture of the nuclear lamina (Harada et al., 2014). Further studies with various 
cancer cell lines, immortalized epithelial cells, and primary dendritic cells, showed that 
migration through narrow channels can rupture the nuclear envelope and thereby permit 
cytoplasmic accumulation of GFP-tagged nuclear localization signal (NLS) constructs 
(Denais et al., 2016; Raab et al., 2016). Rupture—and the ensuing nucleo-cytoplasmic 
exchange—occurs more frequently after knockdown of lamin-A and is followed by focal 
enrichment of an overexpressed DNA damage factor, which the authors interpreted as 
evidence of DNA damage and speculated on the entry of cytoplasmic nucleases (Denais 
et al., 2016; Raab et al., 2016). If nuclease entry were responsible for constriction-induced 
DNA damage, then we would expect to see enrichment of damage foci near the site of 
nuclear envelope rupture. However, recent pore migration studies of an osteosarcoma line 
(U2OS), a lung carcinoma line (A549), and primary human mesenchymal stem cells have 
all shown by multiple measures of DNA damage (especially foci of γH2AX and phospho-
ATM) that constricted migration produces a pan-nucleoplasmic distribution of DNA 
damage foci. This distribution suggests a global—rather than rupture site-specific—DNA 
damage mechanism; the distribution is consistent with transient knockdown of DNA 
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repair proteins (Irianto et al., 2017; Irianto et al., 2016). Similar depletion on the hours-
long timescale of migration could likewise delay repair of replication errors, leading to 
the observed accumulation of DNA damage in migrated cells. 
Importantly, the recent studies of DNA damage incurred during constricted 
migration also provided the first evidence of propagatable mutations. The genomes of 
serially migrated clones were analyzed by comparative genome hybridization arrays 
(aCGH), single-nucleotide polymorphism arrays (SNPa), and whole-exome sequencing 
(as well as RNA sequencing). Compared to unmigrated control clones, the migrated cells 
exhibited elevated chromosome copy number changes (Irianto et al., 2017), suggesting 
that such chromosome-level abnormalities are characteristic of constricted migration. 
Recall that our meta-analysis showed that copy number changes and structural variants 
scale with normal tissue stiffness, perhaps more so than somatic mutations (Fig. 3.1B, C). 
Hence, constricted migration and stiffness seem to share a mutational signature, namely 
large-scale genome instability. This signature also resembles that of osteosarcomas and 
breast and ovarian cancers with BRCA deficiencies (Kovac et al., 2015), although more 
such analysis is needed. Taken altogether, these genomic analyses hint at a connection 
between stiffness, constricted migration, and repair factor depletion (Fig. 3.2C). Thus, 
these studies tentatively support the hypothesis that loss of DNA repair during migration 
of cancer cells through small pores in fibrous matrix could underlie the scaling relation 
between mutation rate and tissue stiffness (Fig. 3.1). 
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Figure 3.2. Tissue stiffness increases with matrix density, which anti-correlates 
with interstitial pore size   
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Figure 3.2. Tissue stiffness increases with matrix density, which anti-correlates with 
interstitial pore size. (A) Normal tissue microelasticity scales with collagen 
concentration. Blue shading indicates the range of stiffness values for 22 glioblastoma 
tumors, measured using multifrequency magnetic resonance elastography. Evidently, 
brain tumors remain soft in vivo despite intratumor heterogeneity. (inset plot) At the 
collagen concentration at which pure collagen-1 gels exhibit a high tissue-like stiffness, 
they have a mesh size of a few microns or less. (B) Cancer cells sustain severe nuclear 
stress during tumorigenic invasion into small holes in stiff, fibrous tissues. This stress 
causes global loss of DNA repair factors via both ‘squeeze-out’ and nuclear envelope 
rupture. Perhaps due to repair loss, migrated cells exhibit elevated DNA damage, which 
ultimately leads to genome instability. (C) Somatic mutation rate (μ), structural variant 
(SV) number, and lamin-A expression all correlate with tissue stiffness.  
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3.4. Genomic variation gives rise to targetable neoantigens 
Genome changes, including those induced by a stiffness-related mechanism, can 
affect gene expression and lead to protein changes, which can contribute to a cancerous 
phenotype or merely be recognizable passenger mutations (Martin et al., 2015; Matsushita 
et al., 2016; Schumacher & Schreiber, 2015). For example, in our studies of genome 
variation caused by constricted migration, one clone acquired after migration a spindle 
shape and migrated through pores much faster than other clones. Further experiments 
attributed this distinct phenotype to upregulation of the transcription factor GATA4 
(Irianto et al., 2017), which influences a program for microtubule organization. 
Microtubules are well known to be the most rigid polymers in cells and help direct cell 
migration. 
Stiffness can also directly affect the expression of genes, so in a cancer like 
melanoma where tissue stiffness increases with invasiveness (Fig. 3.1C), some genes are 
expected to be upregulated. If these genes are also mutated — by a ‘mechanogenomics’ 
process or otherwise, then they could present neoantigens to the immune system. 
Neoantigens, or altered proteins, are ‘foreign’ in being distinct from anything in healthy 
cells and can thus be used therapeutically to target diseased cells. As an example, tissue 
stiffness causes systematic upregulation of lamin-A over a 20-to-30-fold range (Swift et 
al., 2013) (Fig. 3.2B). Mutations in lamin-A have been reported in The Cancer Genome 
Atlas (TCGA): one case study showed about 4% of 287 melanoma patients exhibited 
either amplifications (2%) or mis-sense passenger mutations (2%) in lamin-A’s coding 
sequence, with no statistically significant impact on patient survival 
(http://bit.ly/2oUMGyL). Lamin-A is nonetheless one conceivable source of neoantigen 
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that – when mutated – associates with tissue stiffness. Future studies of such upregulated, 
mutated genes should yield other candidates. 
Efforts to therapeutically target neoantigens, including those that arise in a 
stiffness-dependent way, are complicated by intratumor heterogeneity: different cells 
from a single tumor have been found to vary widely in their somatic mutations (Gerlinger 
et al., 2012; Lawrence et al., 2013). This heterogeneity reduces the probability of finding 
a ubiquitous, targetable mutation present in all a patient’s cancer cells. Promising 
candidates—mutations that are relatively common among tumor cells—are those that 
occur early in cancer development (Bruin et al., 2013), as tumor heterogeneity increases 
with cancer progression (Gerlinger et al., 2012). Conceivably, heterogeneity rises because 
cancer cells sustain additional mutations as they invade small pores in surrounding tissue 
during tumor growth. Of course, therapies designed against even the most widely 
expressed neoantigen will likely produce negative selection, leading to the survival of 
cancer cells that are largely or wholly deficient in that neoantigen. The ideal therapy must 
therefore target several different neoantigens, which requires cancer cells to have a high 
mutation burden since not all neoantigens are targetable (Martin et al., 2016). Indeed, in 
non-small cell lung cancer, high mutation load is associated with improved clinical 
response to immunotherapy (Rizvi et al., 2015). 
Though next-generation sequencing offers a means to identify neoantigens, more 
development is needed before this technology can be implemented clinically, as 
neoantigens vary within individual tumors as well as between patients (Heemskerk, 
Kvistborg, & Schumacher, 2013; Rajasagi et al., 2014; Robbins et al., 2013). Cancers of 
a given type often share mutated driver genes (McGranahan et al., 2015), which yield 
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similar abnormal protein phenotypes, but changes can vary between patients. Hence, 
therapies for different patients must target different peptide sequences (Jo et al., 2016; 
Schumacher & Schreiber, 2015; Segal et al., 2008). This variability makes it necessary to 
isolate and sequence every individual tumor to identify its unique neoantigen profile, 
which remains a resource-intensive challenge for current sequencing (Li et al., 2015). If 
the technology continues to advance, it is exciting to consider that personalized 
neoantigen-based therapy could enter clinical practice (LeBlanc & Marra, 2015; 
Schwaederle et al., 2014). 
 
3.5. Diverse neoantigen-based immunotherapies are currently under development 
Neoantigen-based therapies can take various approaches. Some therapies target 
proteins expressed on the plasma membrane, relying on surface protein expression level 
to distinguish cancerous cells from healthy ones. In one of the most-used such therapies, 
chimeric antigen receptor (CAR) T cells target the B-lymphocyte antigen CD19 (Ramos 
et al., 2015). While CD19 is expressed on over 95% of B-cell malignancies, it is also 
expressed on healthy B cells, making the latter susceptible to off-target effects (Turtle et 
al., 2016). However, the ongoing discovery of surface neoantigens, such as mucin-1 
(MUC1, which is also in the extracellular matrix and leaks into serum), that have irregular 
glycosylation patterns in cancer cells makes it possible to engineer CARs to target these 
unique glycosylations, thus minimizing deleterious side effects (Posey et al., 2016; 
Sabbatini et al., 2007). Most neoantigens are not expressed on the plasma membrane, but 
rather in the nucleus or cytoplasm of the cell (Kandoth et al., 2013), so chemotherapeutics, 
which readily penetrate the cell membrane, can be effective against them. However, 
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chemotherapeutic agents are difficult to modify against different peptide sequences since 
any change in their structural chemistry can radically alter pharmacokinetics. Although 
the chemotherapy drug Vemurafenib effectively targets the BRAF V600 mutation, it is 
ineffective against other BRAF mutations (Klein et al., 2013; McArthur et al., 2014), 
which reinforces the need to identify each patient’s unique mutation profile.  
Other approaches use nuclear and cytoplasmic neoantigens to develop vaccines 
and checkpoint inhibitors (Hodi et al., 2010). These approaches take advantage of the 
major histocompatibility complex class I (MHC I), which presents peptide fragments—8-
10 amino acids long—that are continuously screened by the immune system for foreign 
peptide sequences (Schumacher et al., 2014). Unfortunately, mutated peptide sequences 
in cancerous cells often go undetected because they either have poor MHC I affinity, differ 
little from their wild-type counterparts, or are abetted by high levels of the cancer cell-
derived immune inhibitory ligand PD-L1 (Assarsson et al., 2007; Matsushita et al., 2016; 
Paul et al., 2013; Strickland et al., 2016; Verdegaal et al., 2016; Wick et al., 2014). PD-
L1 inhibitors can counteract this tumor-induced immune suppression (Pardoll, 2016). 
Sequencing is now being used to identify cancerous mutations in oncogenic drivers like 
KRAS and p53 that might also have high MHC I affinity as needed for vaccination therapy 
(Carbone et al., 2005; Rahma et al., 2014). 
An alternative vaccination approach exploits MHC class II molecules expressed 
by macrophages (Liu et al., 2016; Ly et al., 2013). Like MHC I, MHC II presents peptide 
fragments at the cell surface. But whereas detection of a foreign sequence triggers cell 
destruction by the immune system in the MHC I case, it triggers activation of the adaptive 
immune system—against other cells weakly presenting that same foreign sequence—in 
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the MHC II case. Macrophages use MHC II to present peptide sequences from foreign 
organisms or viruses that they have phagocytosed. Unfortunately, macrophages do not eat 
cancerous cells in part because the latter overexpress CD47 (Willingham et al., 2012), 
which is a ‘marker of self’ that inhibits phagocytosis (Tsai & Discher, 2008). The immune 
system is therefore not activated by MHC II presentation of neoantigens (Liu et al., 2015). 
However, macrophages have long been engineered ex vivo for anti-cancer purposes and 
can be made to express patient-specific cancer neoantigen peptide sequences loaded into 
MHC II (Liu et al., 2016). Upon injection back into the patient, these engineered 
macrophages activate the immune system against cancer cells that display the special 
peptide sequence. Numerous clinical trials conducted over the past two decades 
demonstrate that adoptive transfer of macrophages into humans shows little to no toxicity 
at doses of 1.5 billion cells (Andreesen et al., 1998; Faradji et al., 1991; Hennemann et 
al., 1998). Strategic engineering of ‘self’ markers like CD47 should further reduce 
autoimmune toxicity by eliminating the need for systemic inhibition of CD47, which leads 
to rapid loss of red blood cells (RBCs) and in some mice to autoimmune responses, 
including production of anti-RBC antibodies (Oldenborg et al., 2000; Willingham et al., 
2012). 
One new macrophage-based therapy aims to exploit neoantigens without the need 
for extensive sequencing or artificial targeting vectors (e.g. CARs). Tumor associated 
macrophages (TAMs) can, through inhibition of CD47, phagocytose cancer cells 
(Weiskopf et al., 2013), and then present neoantigens from those cells to activate the 
adaptive immune system (Liu et al., 2015). However, TAMs promote tumor growth, are 
weakly phagocytic even with CD47 disruption, and have low MHC II expression, which 
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hinders their ability to activate an adaptive immune response (Liu et al., 2016; Lu-
Emerson et al., 2013; Rodríguez et al., 2013). A cell therapy approach using marrow-
derived monocytes and macrophages could be an alternative, as these cells have low 
SIRPα (i.e. the inhibitory receptor that interacts with CD47) and high MHC II expression 
(Lavin et al., 2014). In addition, marrow-derived monocytes and macrophages are highly 
migratory and can traffic into solid tumors (Pan et al., 2013) (Fig. 3.3A). However, like 
cancer cells invading nearby tissue, these ‘invading’ immune cells might also suffer DNA 
damage, with consequences yet unknown. The absence of oncogenic driver mutations 
probably limits the cancerous potential of infiltrating monocytes and macrophages; any 
DNA damage in these cells might instead contribute to senescence (Zglinicki et al., 2005). 
Lastly, while novel cell therapy approaches with infiltrating immune cells seems 
an encouraging but challenging future direction for the field of neoantigen-based 
immunotherapy, the microenvironment-dependent plasticity of such cells is also emerging 
from modern systems biology methods (Fig. 3.3B) and must be factored into cell function. 
Interestingly, for monocytes and macrophages, at least some genes in published profiles 
(e.g. lamin-A) increase with tissue stiffness, consistent with mechanically regulated epi-
genetic processes in normal cells (Swift et al., 2013) and likely also in cancer cells 
(Dupont et al., 2011; Spencer et al., 2007). Further RNA profiling of tissue macrophages, 
including TAMs, needs to be done using identical markers across different tissues, as 
macrophage transcriptomics would be expected to change when sorted on different 
markers (Fig. 3.3B). 
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Figure 3.3. Monocyte/macrophage-based immunotherapies target neoantigens while 
exploiting the ability of phagocytic cells to infiltrate solid tumor tissues 
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Figure 3.3. Monocyte/macrophage-based immunotherapies target neoantigens while 
exploiting the ability of phagocytic cells to infiltrate solid tumor tissues. (A) Immune 
cells must first migrate into tumors to attack ‘non-self’ cancer cells. Then, macrophages 
use MHC II to present neoantigens from cancer cells that they have phagocytosed. (B) 
Systems biology approaches are beginning to illuminate the microenvironment-dependent 
plasticity of monocytes and macrophages. Adapted from (Lavin et al., 2014).  
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3.6. CONCLUSION  
The meta-analysis here of recently published sequencing data reveals that somatic 
mutation rate increases with normal tissue stiffness across cancer types, while the rate of 
larger-scale, chromosome-level mutations increases even faster. Among various 
hypotheses that seek to explain this scaling relationship, the one that we consider most 
promising holds that stiffer tissues have smaller extracellular matrix pores, which can 
increase DNA damage in invading cancer cells, leading perhaps to genomic variation. In 
the case of immune cells that might infiltrate solid tumors—and go on to recognize 
neoantigens—similar damage has not yet been observed. Since such healthy cells lack 
driver mutations, they are unlikely to become oncogenic, but they can be expected to 
differentiate, perhaps even in relation to tissue stiffness. 
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Chapter 4: SIRPα-inhibited, marrow-derived 
macrophages engorge, accumulate, and differentiate  
in antibody-targeted regression of solid tumors 
 
 
 
 
This chapter presents work featured in the research article: 
Alvey, C.M., Spinler, K.R., Irianto, I., Pfeifer, C.R., Hayes, B., Xia, Y., Cho, S., Dingal, 
D., Hsu, J., Smith, L., Tewari, M., and Discher, D.E. (2017) Current Biology, online 
June 29.  
 
Spinler, K. R. – CD47 KD A549 studies (Figure. 4.3) 
Irianto, I. – mRNA analysis, confocal imaging, and FRAP experiments (Fig. 4.4, Fig. 4.1, 
and 4.S1) 
Pfeifer, C.R. – Transwell experiments (Fig. 4.2 and Fig. 4.S4) 
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ABSTRACT 
Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into 
solid tumors and engulf cancer cells is questionable, given the well-known limitations of 
tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and 
human marrow was inhibited to block recognition of its CD47 ligand, a ‘marker of self’ 
on all other cells. These macrophages were then systemically injected into mice with 
fluorescent human tumors that had been antibody targeted. Within days, the tumors 
regressed, and fluorescence analyses showed that the more the SIRPα-inhibited 
macrophages engulfed, the more they accumulated within regressing tumors. Human 
marrow-derived macrophages engorged on the human tumors, while TAMs were 
minimally phagocytic, even toward CD47-knockdown tumors. Past studies have 
opsonized tumors in situ with antibody and/or relied on mouse TAMs but have not injected 
SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters 
remained normal here. Consistent with tumor-selective engorge-and-accumulate 
processes in vivo, phagocytosis in vitro inhibited macrophage migration through 
micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited 
macrophages in tumors favored tumor regression for 1-2 weeks, but donor macrophages 
quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of 
macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels 
demonstrated a stiffness-driven, retinoic acid-modulated upregulation of SIRPα and a 
mechanosensitive nuclear marker, lamin-A. Mechanosensitive differentiation was also 
evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of 
tumor regression by fresh injections of SIRPα-inhibited macrophages.  
68 
4.1 INTRODUCTION 
Macrophages and monocytes engorge and accumulate within solid tissues in 
various inflammatory diseases (Bogdanik et al., 2016; Moore, Sheedy, & Fisher, 2013), 
but general mechanisms are obscure and any relevance of ‘engorge and accumulate’ to 
solid tumors is unclear. Tumor associated macrophages (TAMs) are highly motile even 
within highly collagenous solid tumors (Condeelis & Pollard, 2006), but TAMs are 
differentiated and less phagocytic than macrophages in other tissues (Rodriguez et al., 
2013), with a high density of TAMs correlating with poor clinical prognosis (Fujiwara et 
al., 2011; Lan et al., 2012; Lu-emerson et al., 2013; Zhang et al., 2013). Recent studies 
show blood-borne ‘patrolling monocytes’ pinch off tumor material within hours of cancer 
cells lodging in the lung after intravenous injection of the tumor cells (Hanna et al., 2015), 
but it is unclear whether such bone marrow derived phagocytes can be made to migrate 
into a well-established solid tumor, completely engulf a cancer cell, and maintain 
phagocytic phenotype. Injections into humans of ~109 macrophages (or ~106 for mouse) 
together with tumor-targeting antibodies can be safe, but have little impact on tumors 
(Andreesen et al., 1998; Chokri et al., 1992; Hennemann et al., 1997; Lacerna et al., 1988).  
How any cell avoids being engulfed by a macrophage could partially involve 
signaling by “marker of self” CD47 to the phagocyte’s receptor SIRPα (Oldenborg et al., 
2000; Willingham et al., 2012). SIRPα signaling at a phagocytic synapse ultimately 
inhibits myosin-II that otherwise makes engulfment highly efficient (Tsai & Discher, 
2008). Systemic injection of anti-mSIRPα binds to splenic macrophages and indeed 
causes rapid clearance of circulating components (Rodriguez et al., 2013). However, 
SIRPα contributes to other processes (Alenghat et al., 2012), and the viability of Cd47 
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knockout mice shows “marker of self” signaling is non-essential (Oldenborg et al., 2000; 
Willingham et al., 2012). Nonetheless, in situ knockdown of mCD47 starting ~1 wk after 
tumor engraftment (Wang et al., 2013) can slow tumor growth for ~2 wks even without 
added TAM-activating factors (eg. tumor-opsonizing Ab); and systemic poisoning of 
macrophages also ameliorates this tumor suppression. Additionally, in mice with human 
tumor xenografts, systemic injection of anti-hCD47 plus a distinct Ab that opsonizes 
human cancer cells can shrink tumors (Chao et al., 2010; Weiskopf et al., 2013). In such 
studies, however, direct measurements are lacking for cancer cell engulfment by 
macrophages in tumors. Also, CD47 is expressed on all cells, and so species-matched anti-
CD47 injections understandably cause rapid and reproducible (Horrigan et al., 2017) 
depletion of blood cells in primates (Weiskopf et al., 2013) and mice (Willingham et al., 
2012). Such side effects and complexity in phagocytic synapse interactions have been 
reviewed in our recent summary of nascent clinical trials (Alvey & Discher, 2017) and all 
together motivate deeper study of the basic biology of macrophage trafficking, 
phagocytosis, and differentiation in tumors.  
Here we study these biophysically intensive processes by systemically injecting 
highly phagocytic marrow macrophages after inhibiting their SIRPα and pre-loading their 
Fc-Receptors with cancer-targeting Ab’s. Such preparations increase phagocytosis in 
culture (Okazawa et al., 2005; Oldenborg et al., 2000), but systemic trafficking and 3D 
microenvironments add considerable complexity. Some simplicity is gained here with 
human-derived tumor models in NSG mice (non-obese diabetic/severe combined IL-2Rγ 
mice) that lack T-cells, B-cells (and Ab’s), as well as NK-cells while maintaining 
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functional monocytes, macrophages, and neutrophils (McIntosh et al., 2015; Quintana et 
al., 2012).  
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4.2 MATERIALS AND METHODS 
Antibodies: Receptor inhibition was done with anti-hSIRPα antibody (SIRP-A1, SE7C2, 
Santa Cruz, sc-23863) and with anti-mSIRPα antibody (rat anti-mouse CD172a, P84, BD 
Pharmingen). Opsonization of human cells was done with anti-human antibody (anti-hum, 
rabbit polyclonal IgG made against human RBCs, Rockland, 109-4139). Anti-hum 
antibody has been found to bind to the following human cell types: A549 (Fig. S2), RBC 
(Fig. S2), Huh7, and HepG2. However, it does not bind to any mouse cell type tested: 
RBC (Fig. S2), EC4 (Fig.S2), and C2C12. Furthermore, mouse blood cells do not deplete 
following repeated systemic injection of 600 µg of anti-hum (Fig. 6D, S8). Primary 
antibodies used for flow cytometry and imaging included anti-human CD41-FITC 
(Biolegend), CD47-APC (B6H12, Biolegend), CD47-Alexa Fluor 647 (B6H12, BD 
Pharmingen), CD235a-PE (Biolegend), and CD11b-APC (Biolegend) as well as anti-
mouse F4/80-APC/Cy7 (Biolegend) and CD11b-PE/Cy7 (Biolegend). Secondary 
antibodies included donkey anti-rabbit Alexa Fluor 488 (Invitrogen) and donkey anti-
rabbit Alexa Fluor 647 (Invitrogen). When required, nuclei were stained by either 7-
Amino-actinomycin D (7-AAD, Sigma) or Hoechst 33342 (Invitrogen). 
 
Human Specimens: Fresh human bone marrow was purchased from AllCells (Cat#: 
ABM001-1) in 3 mL quantities from healthy donors. AllCells received IRB approval from 
Alpha (Protocol #7000-SOP-046) which includes donor consent. In total, there were 4 
different donors. Donors were all anonymous to the authors of this study, and experiments 
were all conducted at the University of Pennsylvania with IRB approval (Protocol # 
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808191) from review board IRB#7. Subject 1: Female age 30, subject 2: Female age 31, 
subject 3: Male age 31, subject 4: Male age 22 with additional details provided by AllCells 
per (Fig. 4.7A). Marrow was pooled and divided among the different experimental 
conditions in Fig. 4.7.  
 
Murine Specimens: Male and female NSG mice that >6 weeks old were purchased from 
either The Jackson Laboratory or the Stem Cell and Xenograft Core at the University of 
Pennsylvania under IACUC approved protocols (#805977 and #804455) which adhere to 
all regulatory standards. Blood, lung, liver, spleen, and marrow were obtained from these 
mice following the same IACUC approved protocols. The health of the mice was assessed 
prior to the start of each experiment by veterinary technician and was not used if unhealthy. 
Mice were never used for more than one experiment. Mice are housed in dedicated BSL-
2 animal barrier space equipped for all necessary procedures.  
 
Cell Lines: ATCC (American Type Culture Collection, Manassas, VA, USA) is a 
biological materials resource and standards organization with external accreditation from 
the International Organization for Standardization (ISO), and ATCC provides cell line 
authentication test recommendations per Tech Bulletin number 8 (TB-0111-00-02; yr. 
2010). This bulletin recommends five types of tests (underlined) for the authentication of 
cell lines. Cell morphology check by microscopy, growth curve analysis, and mycoplasma 
detection by DNA staining (for filaments or extracellular particulates) were conducted on 
all cell lines used in these studies, and all cell lines maintained the expected morphology 
and standard growth rates with no mycoplasma detected. Two additional, ATCC-
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recommended authentication tests were conducted on the A549 cell line as the A549 cells 
were used in all of the main and supplemental figures. Species verification of A549 cells 
as human by RNA sequencing detection of uniquely human sequence (Figure 4), by mass 
spectrometry detection of uniquely human sequence (Figure S1), and by antibody 
targeting with anti-human Abs (Figures 1-4,5-6; Figures S1-S6). Identity verification from 
DNA of A549 was confirmed using SNP arrays (SNPa). DNA was isolated by using the 
Blood and Cell Culture DNA Mini Kit (QIAGEN) per the manufacturer’s instructions, 
and DNA samples were sent to The Center for Applied Genomics Core in The Children’s 
Hospital of Philadelphia for the SNPa HumanOmniExpress-24 Bead Chip Kit (Illumina), 
with >700,000 probes along the entire human genome. For each sample, the Genomics 
Core provided the data in the form of GenomeStudio ﬁles (Illumina). Chromosome copy 
number was analyzed in GenomeStudio with the cnvPartition plugin (Illumina). SNP 
array experiments also provide genotype data, which was used to give SNV data. 
Genotyping in this Illumina system relies on the correlation between total intensity and 
intensity ratio of the two probes, one for CG and another for AT. These correlations were 
mapped to a standard clustering ﬁle (Illumina) to give the SNP calls. Consistent with 
ATCC ‘s karyotype analysis, SNPa show the A549 cells have a hypotriploid chromosome 
copy number of 66 with 2 copies of X and Y chromosome and 4 copies of chromosome 
17. Further consistent with ATCC’s descriptions of this cell line as Caucasian in origin, 
SNPa analyses also show that the cells have mostly European ancestry (~90%) 
(Dodecad2.1 an ancestry lineage algorithm based mostly on Illumina SNPa data). 
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Experimental Design: All experiments were replicated. Measurements and analysis, 
when applicable, were conducted blindly with stratified sampling. In the case of tumor 
growth and regression studies, mice were not stratified, but separated by tumor size to 
ensure all groups had the same average tumor size at the start of treatment. No data was 
excluded from any data set.  
 
F(ab’)2 Production: Anti-hum F(ab’)2 were produced using a Thermo Scientific 
PierceTM F(ab’)2 Preparation Kit. Briefly, immobilized pepsin was used to cleave full-
length anti-hum antibody. After a 3-hour incubation, the pepsin was removed by 
centrifugation at 5000 g for 1 minute. A SDS-PAGE was then used to assess complete 
digestion. Following successful cleavage, Fc fragments were removed via an Amicon 
Ultra centrifugal filter device with a 50,000-molecular weight cut-off. F(ab’2) product 
from above was centrifuged in a filter at 5000 g for 30 minutes. After centrifugation, 
F(ab’)2 was collected, and the filter membrane was washed with PBS. To verify that Fc 
fragments had been removed, the recovered F(ab’)2 was run on a SDS-PAGE along with 
the filtrate. 
 
Mass spectrometry to determine anti-human antigens: Mass spectrometry (MS) 
samples were prepared using the same procedures outlined in (Swift et al., 2013). Briefly, 
~1 mm3 gel sections were excised from SDS–PAGE gels and were washed in 50% 0.2 M 
ammonium bicarbonate (AB), 50% acetonitrile (ACN) solution for 30 minutes at 37°C. 
The washed slices were lyophilized, incubated with a reducing agent [20 mM TCEP in 25 
mM AB solution], and alkylated [40 mM iodoacetamide (IAM) in 25 mM AB solution]. 
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The gel sections were lyophilized again before in-gel trypsinization [20 mg/mL 
sequencing grade modified trypsin, Promega] for 18 hours at 37°C with gentle shaking. 
The resulting tryptic peptides were extracted by adding 50% digest dilution buffer (60 
mM AB solution with 3% formic acid) and injected into a high-pressure liquid 
chromatography system coupled to a hybrid LTQ-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) via a nano-electrospray ion source.  
Raw data from each MS sample was processed using MaxQuant (version 1.5.3.8, Max 
Planck Institute of Biochemistry). MaxQuant’s built-in Label-Free Quantification (LFQ) 
algorithm was employed with full tryptic digestion and up to 2 missed cleavage sites. 
Peptides were searched against a FASTA database compiled from UniRef100 (June 2011) 
human, plus mouse and contaminants. The software’s decoy search mode was set as 
‘revert’ and a MS/MS tolerance limit of 20 ppm was used, along with a false discovery 
rate (FDR) of 1%. The minimum number of amino acid residues per tryptic peptide was 
set to 7, and MaxQuant’s ‘match between runs’ feature was used for transfer of peak 
identifications across samples. All other parameters were run under default settings. The 
MaxQuant output tables were then fed into its custom bioinformatics suite, Perseus 
(version 1.5.2.4), for protein annotation and sorting. 
 
Development of THP-1 SIRPα-KD Cell Lines: Stable SIRPα-KD cell lines were 
established using a standard transduction protocol, as described above. Briefly, human 
SIRPα shRNA lentiviral transduction plasmids were purchased from Santa Cruz (sc-
44106-SH). Plasmid was transfected into bacteria, allowed to replicate, and then harvested 
using a maxi plasmid isolation kit. Plasmid was sent to Wistar Institute to produce active 
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lentiviral particles. THP-1 cells were transduced with viral particles, and stable clones 
were generated by puromycin selection. The SIRPα knockdown efficiency was 
determined by antibody staining and flow cytometry. 
 
Phagocytosis Assay: THP-1s were incubated in RPMI medium with 100 ng/mL phorbol 
myristate acetate (PMA) for 2 days. Where anti-hSIRPα antibody was used, macrophages 
were pre-incubated at 5.32 nM at 37°C for 1 hour prior to the addition of A549 cells. All 
conditions were supplemented with non-specific IgG (~30ug/mL) from FBS. A549s were 
prepared as follows: the cells were first removed using cell dissociation buffer Hanks 
(Invitrogen), and then incubated with anti-hum and B6H12 antibodies at 1 μM and 83 nM, 
respectively. The A549s were then combined with the THP-1s at a ratio of 5 to 1; this 
mixture was incubated for 75 minutes at 37°C, and then rinsed with PBS. Three-minute 
trypsin incubation was used to remove non-ingested A549s. The remaining cells were 
scraped off the plate and stained with CD11b (label THP-1s) and anti-rabbit-AF488 
antibody (to distinguish non-ingested A549s). The cells were washed two times with PBS 
and resuspended in 5% FBS/PBS before being analyzed by a BD LSRII cytometer. 
Phagocytosis of human red blood cells followed the same protocol as described in (Sosale 
et al., 2015). Briefly, RBC were opsonized with anti-hum and CD47 blocked with 0 to 
270 nM anti-CD47 (B6H12). After shaking (Argos RotoFlex, 45 minutes, room 
temperature), RBCs were pelleted and labeled with PKH26 dye (room temperature, 30 
minutes). RBCs were added to THP-1 and incubated for 30 mins. After, RBCs were lysed 
and THP-1 were removed with Trypsin followed by staining (10 minutes with Hoechst 
33342). 
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Immunofluorescence: A549 cells were seeded on 18 mm circular microscope cover slips 
in a 6-well plate and allowed to adhere overnight. Cells were fixed with 4% 
paraformaldehyde for 15 minutes at room temperature (RT), and then washed three times 
with PBS. Next, cells were blocked for 30 minutes using 3% BSA + 0.05% Tween-20, 
followed by a 2-hour RT primary antibody incubation in blocking buffer. These primary 
antibodies were used at a 1:100 concentration. After incubation, cells were again washed 
three times with PBS. A 1:400 PBS dilution of donkey secondary antibodies (Alexa Fluor 
488 and 647) was added for 1 hour at RT. Hoechst 33342—at a concentration of 1 
μg/mL—was used to stain DNA for 15 minutes at RT. Cover slips were washed a final 
three times with PBS before being mounted on slides with ProLong Gold Antifade 
Reagent (Life Technologies), cured for 24 hours, and sealed with nail polish prior to 
imaging. Images were acquired by an Olympus IX71 inverted microscope with a 300W 
Xenon lamp illumination using 40×, 60×, or 150× objectives with or without 1.6× 
magnification. Image analysis was done in ImageJ (NIH).  
 
Flow Cytometry of In Vitro Cultured Cells: A549 cells were dissociated using 10 mM 
trypsin in PBS, washed, and re-suspended in 2% FBS in PBS. Antibody incubation was 
done at RT for 1 hour, followed by washing and resuspension in 2% FBS. Samples were 
run on a BD LSRII.  
 
Confocal Imaging: For confocal imaging and fluorescence recovery after photobleaching 
(FRAP) experiments, an inverted laser scanning confocal microscope (SP8, Leica) was 
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used, with a 63×/1.4NA oil immersion objective (Leica). FRAP time-lapse imaging was 
acquired at 37°C with 5% CO2 in a humidified chamber for up to 10 minutes after 
photobleaching. Meanwhile, samples were cultured in phenol-red free complete DMEM 
medium. Image sequences were analyzed using ImageJ. 
 
Establishment of A549 Tumors In Vivo: CD47 knockdown and wild-type A549s were 
dissociated from tissue culture flasks using 10 mM trypsin in PBS. For each injection, 106 
or 2x106 cells were suspended in 100 μL ice-cold PBS and 25% Matrigel (BD) and 
injected subcutaneously into the flank or intraperitoneal of non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice with null expression of interleukin-2 
receptor gamma chain (NSG mice). Treatment groups were a mix of male and female 
mice. Mice were obtained from the University of Pennsylvania Stem Cell and Xenograft 
Core or Jackson Laboratory. All animal experiments were planned and performed 
according to IACUC protocols. 
 
In Vivo Tumor Imaging: Mice were anesthetized via inhalation of isoflurane at 3 L/min 
and maintained at 1.5 L/min. Images were acquired using a Perkin Elmer IVIS Spectrum 
with excitation and emission filters set at 535 nm and 580 nm, respectively, optimized for 
tdTom imaging. Images of each face of the sagittal plane were taken to capture both left 
and right flanks. Mouse fur was soaked with ethanol to reduce auto fluorescence prior to 
imaging. Three fluorescent standards were used to subtract background fluorescence and 
calibrate IVIS Images were analyzed in ImageJ, where the length and width of the tdTom 
tumor was measured. Analysis of tdTom intensity was done using Living Image (Perkin 
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Elmer), which involved spectral unmixing of 10-13 images to sufficiently remove any 
tdTom auto-fluorescence from the mice.  
 
Adoptive Transfer of NSG Bone Marrow: Femurs and tibias of donor NSG were 
removed, and bone marrow was flushed with 5% FBS/PBS. Red cells were lysed by 
incubation with RBC lysis buffer (Sigma) in 4% FBS/PBS for 12 minutes at RT. Cells 
were washed twice and resuspended in warm 5% FBS/PBS. Following the addition of 
1:1000 CFDA-SE (Invitrogen), cells were incubated for 15 minutes at 37°C, and then 
centrifuged again, resuspended in warm complete DMEM medium, and incubated for an 
additional 30-40 minutes at 37°C. When applicable, anti-mSIRPα antibody was added 
during this incubation period. Cells were then washed, resuspended in 5% FBS/PBS, 
counted, and volume adjusted to allow injection of 106 cells. Remaining cells were 
analyzed by flow cytometry to establish initial composition.  
 
Antibody Treatment: Mice were warmed under a heat lamp prior to tail vein injection. 
Opsonization of human cells was done with anti-human antibody (anti-hum, rabbit 
polyclonal IgG made against human RBCs, Rockland, 109-4139). Anti-hum antibody has 
been found to bind to the following human cell types: A549 (Fig.4.S1), RBC (Fig.4.S1), 
Huh7, and HepG2. However, it does not bind to any mouse cell type tested: RBC (Fig. 
4.S1), EC4 (Fig. 4.S1), and C2C12. Furthermore, mouse blood cells do not deplete 
following repeated systemic injection of 600 µg of anti-hum (Fig.4.6D, 4.S6). Anti-hum 
Ab and serum purified rabbit IgG (Sigma, pre-immune) were reconstituted per 
manufacturer’s direction and further diluted using sterile PBS. Mice were injected with 
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anti-hum 600 μg per animal (~20 mg/kg) twice a week. Mouse anti-human Mucin 1 
(MA5-15131, ThermoFisher) and cetuximab (InVivogen) were administered twice a week 
at 10 µg each per mouse.  
 
Engineered Human Marrow: Fresh human bone marrow (ABM001-1, AllCells) was 
incubated with 3 mL of red blood cell lysing buffer hybrid-Max (R7757, Sigma) for 12 
minutes in a 15mL conical tube. Cells were then centrifuged at 2,000 rpm for 2.5 minutes, 
the lysate was removed, and the remaining cells were suspended in 3 mL of red blood cell 
lysis buffer for a second 12-minute lysis phase. After another 2,000 rpm, 2.5-minute 
centrifugation, cells were resuspended in 500 µL of PBS with 1 µL of 10 mM CFDA SE 
solution (prepared per kit instructions). Cells were incubated for 40 minutes at 37oC and 
inverted 2-3 times every 5 minutes. After this incubation period, SIRPα-inhibiting and Fc-
priming anti-human antibodies (109-4139, Rockland) were added to cells at 4 µg/mL and 
100 µg/mL concentrations, respectively. Then, cells were twice centrifuged at 2,000 rpm 
for 2.5 minutes: the first time, they were resuspended in 1 mL of 5% FBS/PBS, and the 
second time, in 100 µL of 5% FBS/PBS. A cell count was performed using a 
hemocytometer, and cells were diluted to 40,000 cells per µL (8×106 cells total per mouse) 
for intravenous tail vein injection in tumor bearing mice. Mice that were treated with 
unprimed cells were injected intravenously with 600 µg (6 µg/µL) of human red blood 
cell antibody (Rockland) 4-6 hours prior to injection of engineered marrow cells.  
 
Ex Vivo Tumor Flow Cytometry Analysis: On the day of analysis, mice in the treatment 
cohort were injected with the standard antibody dose, as described above. Mice were 
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euthanized by cervical dislocation 1.5-2 hours after injection. Tumors and spleens were 
removed and placed in 20% FBS, and tumor core and periphery tissue were segregated. 
Tumor tissue was cut into 1-3 mm pieces, transferred to 15 mL centrifuge tubes, and 
centrifuged to remove media. Tissue was then resuspended in 3 mL warm Dispase 
(STEMCELL Technologies) supplemented with 3 mg/mL Collagenase (Sigma) and 200 
µL of 1 mg/mL DNase I (Roche). Samples were mixed by pipetting for 1-3 minutes until 
cloudy but not stringy. Dissociation was quenched by addition of 10 mL room temperature 
PBS, and then the suspension was filtered through a 70 µm cell strainer. The filtrate was 
centrifuged, the supernatant discarded, and the pellet resuspended in 2% FBS for antibody 
incubation. Spleens were prepared by mechanical dissociation, filtration, and red blood 
cell lysis using Red Cell Lysing Buffer (Sigma). Lysed samples were washed and 
resuspended in 2% FBS for antibody incubation. Prior to antibody incubation, samples 
were blocked with 1:500 Fc Block (BD Pharmingen) for at least 5 minutes at RT. CD47-
AF647 (1:25), donkey anti-rabbit AF488 or AF700 (1:400), donkey anti-rat AF647 
(1:400), F4/80 APC-Cy7 (3:50), CD11b PE-Cy7 (1:25), Gr-1 APC (1:25), hCD47 AF647 
(1.5:50), and Hoescht 33342 (1:1250) were incubated at RT for 1 hour. Following 
incubation, cells were washed and resuspended in 2% FBS.  
 
Analysis of Mouse Blood Profiles: 100 µL of blood was isolated from anesthetized mice 
by retro-orbital bleeds. Blood was collected in Eppendorf tubes containing EDTA. Blood 
was kept at room temperature and immediately analyzed using a Drew Scientific Hemovet 
(HV950).  
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Graft vs Host Disease: Mice were monitored 3 times a week by researchers and 
veterinarian technicians at the University of Pennsylvania Perelman School of Medicine 
mouse facilities for general health and for development of GvHD. Classic signs of GvHD 
include weight loss (>15%), ruffled fur, loss of fur on the head and rear of the mouse, 
hunch posture, and reduced activity (Ali et al., 2012; King et al., 2009). Development of 
GvHD is a common occurrence at these facilities as numerous users study CAR T-cell 
therapies, which frequently cause GvHD (Jacoby et al., 2016). 
 
Sorting of Marrow Cells: In some experiments, marrow phagocytes were sorted from 
non-phagocytes and dendritic cells. FACS Aria (Biosciences (Helft et al., 2015)) was used 
to sort 60 million marrow cells using anti-CD135-BV421 (Biosciences,) and anti-SIRPα 
– FITC (P84, Biosciences) into 15 mL conical tubes containing 1mL FBS. This sorting 
process generated 20 tubes, which were subsequently centrifuged for 10 minutes at 4,000 
rpm. After the supernatant was aspirated, cells were resuspended in 5% FBS/PBS, 
incubated with targeting antibody for 1 hour, and centrifuged again. Finally, cells were 
resuspended in 200 µL of 5% FBS/PBS per 10×106 cells and put on ice for tail-vein 
injection. 
 
3D Migration Assay: Migration assays were performed using 24-well inserts with 3 m-, 
5 m-, and 8 µm-pore filters with 2×106, 4×105, and 1×105 pores per cm2, respectively. 
Either tdTom A549s or 900 nm, 2.1 µm, or 6.7 µm beads (Thermofisher, streptavidin 
coated) were mixed with engineered marrow cells in a 10:1 ratio; 3×105 total cells were 
seeded on top of the pore filters. Beads were opsonized with anti-streptavidin antibody 
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(S6390, Sigma). The same 1:1 mixture of DMEM and F-12, supplemented with 15% FBS 
and 1% penicillin-streptomycin, was added to both the top and bottom of each 24-well 
insert such that there was no nutrient gradient across the pore filter. After incubating for 
approximately 24 hours at 37C and 5% CO2, cells were harvested from the tops of the 
filters using Trypsin and from the bottoms using both Trypsin and scraping. In some 
experiments, beads were pre-incubated with anti-SIRPα macrophages for 150 minutes 
prior to being plated on tops of transwells.  
 
RNA Isolation and Sequencing: For RNA isolation, an RNeasy plus Mini Kit (Qiagen) 
was used. For RNA-seq analyses, RNA samples were sent to the Next-Generation 
Sequencing Core at the Perelman School of Medicine, University of Pennsylvania, PA. 
Libraries for RNA-seq were made using the TruSeq Stranded mRNA Library Prep kit 
(Illumina) per manufacturer instructions, followed by 100 bp paired-end sequencing with 
HiSeq 2500 (Illumina). Ten cDNA libraries were pooled together, resulting in 
~16,000,000 reads for each sample. 
 
Synthesis of soft and stiff polyacrylamide gels: Round glass coverslips (18 mm, Fisher 
Scientific) were cleaned in boiling ethanol and RCA solution (H2O:H2O2:NH4OH = 2:1:1 
in volume) for 10 minutes each, and then functionalized in ATCS solution (chloroform 
with 0.1% allytrichlorosilane (Sigma) and 0.1% trimethylamine (Sigma)) for an hour. 
Fresh precursor solution for 0.3 kPa soft gels (3% acrylamide + 0.07% bis-arylamide in 
DI water) and 40 kPa stiff gels (10% acrylamide + 0.3% bis-acrylamide in DI water) were 
prepared. Afterwards, 0.1% N,N,N’,N’-tetramethylethylenediamine (Sigma) and 1% 
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ammonium persulphate (Sigma) were added to each precursor solution, and 20 µL of the 
resulting mixture were added to each coverslip to allow gel polymerization. To achieve 
collagen-I coating, crosslinker sulpho-sanpah (50  μg/ml  in 50mM HEPES, G-
Biosciences) was applied over the whole gel surface and photoactivated under 365nm UV 
light for 7 minutes. Excess sulpho-sanpah was washed away following UV activation, and 
then collagen-I solution (100 μg/ml in 50mM HEPES) was applied overnight at RT with 
gentle shaking. 
 
Quantification and Statistical Analysis: All statistical analyses were performed using 
GraphPad Prism 4. Unless otherwise noted, all statistical comparisons were made by 
unpaired two-tailed Student t test and were considered significant if p < 0.05. Unless 
mentioned, all plots show mean ± SEM. “n” indicates the number of tumors, cells, or wells 
quantified in each experiment and is ≥3 in all experiments, except for RNA sequencing 
data which is for ≥ 2 samples per condition. Figure legends specify the exact meaning of 
“n” for each figure. 
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4.3 RESULTS 
Engorge and accumulate: Donor MФ in tumors are more phagocytic than TAMs 
Two key issues to address first were (i) whether tail-vein injected marrow 
monocytes and macrophages (MФ) traffic into a human solid tumor, and (ii) whether such 
cells can efficiently phagocytose human tumor cells. NSG mouse marrow cells were 
fluorescently labeled with the green dye (CFDA) and incubated with anti-SIRPα plus 
priming of Fc receptors with targeting Ab (Fig. 4.1A – left). Anti-mSIRPα clone P84 is 
well-known to promote phagocytosis of targets opsonized with other IgG’s (Okazawa et 
al., 2005; Oldenborg et al., 2000; Rodriguez et al., 2013; Yanagita et al., 2017) even 
though P84 does not directly inhibit mCD47 binding to mSIRPα (Motegi et al., 2008). 
P84 instead inhibits SIRPα diffusion, focal accumulation, and signaling at phagocytic 
synapses (Fig. 4.S1), which disrupts the normal ‘self’ signaling by CD47 (Tsai & Discher, 
2008). Our opsonizing Ab’s are simpler in function and are all human specific (Fig. 4.S2): 
monoclonal Ab’s against MUC1 and EGFR (Cetuximab) have been clinically tested 
against lung cancers (Kufe, 2009; Pirker, 2013), and a polyclonal anti-human IgG (anti-
hum) binds multiple antigens and can minimize selection of cancer cells that lose some 
antigens. Ten million freshly made “Antibody-primed Plus anti-SIRPα Bound 
macrophages”, denoted as A’PB MФ were tail vein injected into NSG mice bearing large 
solid tumors of human lung carcinoma A549 cells expressing tdTomato (tdTom) (Fig. 
4.1A - middle); studies with engineered T-cells likewise inject ~107 cells (Garcia-
Hernandez et al., 2010; Sample et al., 2008; Zoon et al., 2015). Mice were sacrificed 3 
days after MФ injections and systemic injections of targeting Ab’s (Table 4.S1 lists the 
standard amounts). Tumors and other tissues were quickly isolated, disaggregated, and 
86 
analyzed with a focus on immune cells that were tdTom+ using the surface markers F4/80 
and (when possible) CD11b for tissue MФ (Lavin et al., 2014) (Fig. 4.S3).  
Confocal imaging (Fig. 4.1B) of such a dispersed tumor from mice treated with 
A’PB MФ’s reveals adhesive interactions with cancer cells and cancer cell internalization 
into phagosomes. Complete engulfment is evident from an absence of secondary stain for 
opsonizing Ab which is otherwise abundant on tdTom+ A549 cells (Fig. 4.S3). The result 
indicates the MФ are internalizing Ab together with Fc receptor, and the images of 
adherent aggregates are consistent with flow cytometry showing high Forward and Side 
Scatter for tdTom+ MФ compared to tdTom- MФ (Fig. 4.S3). All tdTom+ MФ showed a 
similar average tdTom intensity equivalent to ~one A549 cell (Fig. 4.1C), with the most 
phagocytic cells (SIRPα inhibition; with green CFDA dye) showing higher intensity at a 
single cell level in flow cytometry than the least phagocytic cells (TAMs engulfing WT 
tumors). The distribution of tdTom intensities in MФ is much broader and skewed to lower 
signal than the tight distribution for cancer cells (Fig. 4.1C, histogram); this suggests 
cancer cell degradation after engulfment. Human nuclei are also particularly prominent in 
imaging, and DNA-Hoechst stain intensities show recipient and donor tdTom+ MФ have 
more DNA by about one cancer cell nucleus compared to tdTom negative MФ (Fig. 4.1C). 
TdTom+ donor MФ were detected in tumors but not in marrow, spleen, or liver 
(Fig. 4.1D). This begins to suggest that donor MФ traffic into tumors and once they 
phagocytose a cancer cell(s) they do not traffic elsewhere. Maximum phagocytic activity 
was found for the A’PB MФ and for the ‘unprimed’ APB MФ, with 90% of these donor 
MФ in the tumors phagocytosing tdTom+ cancer (respectively: Fig. 4.1D - inset left 
panel). No difference in phagocytic activity of donor MФ subpopulations was detected as 
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nearly all CD11b+, F4/80+, and CFDA+ cells were tdTom+. Donor MФ without SIRPα 
inhibition, but with systemic anti-hum Ab were less phagocytic, with 30% of such donor 
cells in tumors showing phagocytosed tdTom+ cells. Donor MФ with SIRPα inhibition 
combined with pre-immune Ab primed on the Fc receptors were minimally phagocytic, 
with only 10% of MФ in the tumors phagocytosing cancer cells despite systemic injections 
of the pre-immune Ab. TAMs were the least phagocytic of these WT tumors, with <5% 
of recipient MФ in the tumors showing phagocytosis of cancer cells (Fig. 4.1E - inset 
right panel). This decreased by more than half in the absence of tail-vein injections of 
opsonizing Ab, but TAMs were clearly phagocytic toward CD47 knockdown tumors, with 
12% in these KD tumors phagocytosing cancer cells after Ab injections (Fig. 4.1F). In the 
same KD mice, donor MФ (without SIRPα inhibition) were 40% phagocytic upon tail-
vein injection plus opsonizing Ab. Compared to TAMs, donor MФ are more phagocytic. 
TdTom+ MФ were only detected in tumors and not in marrow, spleen, or liver, 
despite these tissues harboring some donor MФ in addition to the expected recipient MФ 
(Fig. 4.1G). Bone marrow has 35-50k monocyte or MФ per 105 cells, which makes this a 
reasonable source of donor MФ (Fig. 4.S3). The spleen and liver are known to filter out 
injected cells and particles, and bone marrow homing of at least some marrow-derived 
MФ seems sensible. Nonetheless, donor MФ injected shortly after systemic anti-hum Ab 
accumulate more so in tumors (per 105 cells) than the other tissues (Fig. 4.1G). Injections 
of 7.5M and 3.8M cells gave similar ~1.5k donor macrophages per 100k tumor cells. Our 
flow cytometry measurements of tumors are conducted on 2M total cells that constitute 
~0.5-5% of total tumor volume, which equates to ~600k-6M donor macrophages 
infiltrating the tumors, so that any excess macrophages disperse to other tissues and/or die. 
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Importantly, A’PB macrophage distribute relatively evenly between tumor periphery and 
core whereas TAMs are more abundant in the core (Table 4.S2). Donor neutrophils 
accumulate in tumors 30-fold less than donor MФ and are weakly phagocytic, and 
therefore, neutrophils likely contribute little to tumor shrinkage (Fig. 4.S3). Importantly, 
tumor accumulation increases linearly by almost 10-fold as donor MФ are made more 
phagocytic (i.e. SIRPα-inhibited plus anti-hum Ab) (Fig. 4.1G, upper inset plot). 
Engorge and accumulate trends proved similar in intraperitoneal (IP) tumors (Fig. 4.S3). 
Highest in donor abundance are the APB and A’PB MФ that achieve tumor numbers 
similar to resident TAMs. TAM abundance is nearly unaffected by tumor opsonization, 
consistent with minimal phagocytosis by TAMs.  
To assess whether MФ could impact tumor growth on their own, these cells were 
sorted from bulk marrow’s non-phagocytic cells (eg. stem and progenitor cells) plus 
mature dendritic cells (DCs). Addition of SIRPα-inhibition plus anti-hum Ab to each 
fraction was followed by tail-vein injections into NSG mice bearing both subcutaneous 
and intraperitoneal (IP) tumors. The latter tumors model the distal invasiveness of lung 
cancer in previous studies with A549 cells (Riihimaki et al., 2014). The non-phagocytes 
plus DCs failed to inhibit tumor growth, whereas the A’PB MФ fraction shrunk all tumors 
within 3 days (Fig. 4.1H). Decreases in tdTom intensities in vivo by day-13 with anti-hum 
Ab match flow cytometry results for decreased cancer cell numbers (per 105 total cells) 
(Fig. 4.S2). Pre-immune Ab on A’PB MФ had no effect on tumor growth (Fig. 4.S3). 
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Figure 4.1. In vivo tumor phagocytosis and accumulation of engineered donor 
MФ’s can shrink tumors   
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Figure 4.1. In vivo tumor phagocytosis and accumulation of engineered donor MФ’s 
can shrink tumors. (A) Schematic of NSG bone marrow harvest, labeling, and 
transfusion. Bone marrow cells taken from the femur and tibia were labeled with CFDA, 
their SIRPα receptor inhibited with anti-mSIRPα, Fc receptor loaded with a targeting 
antibody then tail-vein injected into tumor-bearing NSG mice. In some experiments, 
instead of preloading Fc receptor, targeting Ab was systemically injected. Recipient mice 
were given an Ab injection on day-3 and subsequently sacrificed ~3 hour later. Bone 
marrow, peripheral blood, spleen, liver and tumor tissue were harvested after and analyzed 
for macrophage eating by flow cytometry. (B) 3D reconstruction of a confocal image of a 
phagocytic macrophage, isolated directly from the tumor. One tdTom A549 tumor cell 
was completely engulfed inside the macrophage, while two additional A549s remained 
adherent to the macrophage. (C) Quantification of tdTom and Hoechst intensity in 
CD11b+ F4/80+ macrophages normalized to A549 tumor cells. Ratios not significant from 
1 indicate ~1-2 tumor cells per macrophage. (n ≥ 4 mice per group). (C, inset) 
Representative histograms of tdTom (red shade) and Hoechst (blue shade) intensity 
distribution. For upper histogram: tdTom positive macrophages (blue outline) and tdTom 
A549 tumor cells (black outline). Lower histogram: tdTom positive macrophages (red 
outline) and tdTom negative macrophages (black outline). (D) The level of phagocytosis 
as represented by the percentage of tissue-isolated macrophages with tdTom proteins of 
A549 tumor cells (n = 4–10 tumors per group). (D, inset) Representative flow-cytometry 
plots of macrophages that are tdTom positive, comparing APB MФ eating to recipient 
MФ eating. (E) Measuring A’PB MФ eating of tumor cells by determining the number of 
A’PB MФ that are tdTom positive and comparing it to recipient macrophages. (n = 4-8 
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mice per group). (F) Phagocytosis of CD47 KD++ tumor cells with donor cells and 
recipient TAMs (n = 6; *P<0.05). (G) Population count of macrophages per 105 cells 
isolated from tumors and other organs. Mice received 7.5 million monocytes and 
macrophages unless specified otherwise. (n ≥ 3 mice per group, n.m: not measured). (G, 
inset) Percentage of tdTom positive macrophages from panels B-D vs. number of 
macrophages per 105 cells. (H) In vivo tumor growth of tdTom A549 subcutaneous tumors 
treated with two sorted fractions NSG bone marrow. Tumor growth was measured by 
tdTom intensity. After tail-vein injection of sorted donor cells, mice were tail-vein 
injected 3 times per week with anti-human Ab. (n ≥ 4 mice per group).  
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Macrophages in vitro engorge and accumulate in 3D 
To begin to assess an ‘engorge and accumulate’ mechanism in which A’PB MФ 
eat more and thereby migrate less, antibody-coated beads ranging from 900 nm to 6.7 µm 
were added to SIRPα inhibited macrophages in culture for 150 minutes and then 
transferred to 5 µm transwell filters for 24 hours of three-dimensional migration (Fig. 
4.2A). For beads that were not opsonized, no engulfment occurred, and 32% of SIRPα-
inhibited macrophages squeezed through the filter independent of pre-incubation (Fig. 
4.2B). For any bead size that was opsonized, ~22% of macrophages engulfed beads in the 
150 minutes pre-incubation, and this increased ~4-fold after 24 hours of cell culture on 
the top of the transwell (Fig. 4.2C); importantly, migration was suppressed ~10-fold for 
the 900 nm bead and nearly 100-fold for the largest, 6.7 µm bead (Fig 4.2B). An inability 
to pull a large bead through a small hole (i.e. sterics) likely explains the latter large 
decrease, but since only two beads or fewer were engulfed per macrophage regardless of 
size, phagocytosis of even the smallest beads inhibits migration independent of sterics 
(Fig. 4.2D). Furthermore, without the 150 minutes pre-incubation, 5-10% fewer 
macrophages engulfed beads after the 24 hours on the transwell, and for incubations with 
900 nm beads ~5% more macrophages migrated through the transwell compared to just 
~1% more for 6.7 µm beads. Macrophages are thus unable to “eat and run” and rather 
prefer to “eat and stay”. This is perhaps because phagocytosis and migration depend on 
an overlapping set of cytoskeletal proteins as will be discussed. Furthermore, when given 
the choice between migrating or phagocytosing, MФ choose the latter when strongly 
activated. 
93 
 Cancer cells are large, but flexible and degradable. To assess whether engulfment 
of such targets could likewise hinder migration of macrophages, the human lung cancer 
A549 cells in mouse xenografts were disaggregated and compared in in vitro phagocytosis 
to disaggregated lung from the same mouse (lacking cancer cells). Samples were 
incubated for 24 hours on the tops of transwells with A’PB MФs. Flow cytometry 
scatterplots (Fig. 4.S4) show macrophages on top of a transwell have higher tdTom 
intensity and are much larger in size compared to macrophages on the bottom. The large 
size of macrophages relative to the transwell pores is confirmed by the scale bar in 
confocal imaging (Fig. 4.1B). Consistent with the above experiments using beads, A’PB 
MФs mixed with disaggregated tumors resulted in complete inhibition of migration 
whereas 47% of A’PB MФs mixed with disaggregated lung tissue migrated (Fig. 4.S4). 
Additional ex vivo studies (Fig. 4.S4) confirm the higher phagocytic activity of donor cells 
versus TAMs. The results are consistent with the hypothesis that phagocytic engorgement 
of cancer cells impedes 3D-migration within tumors to favor donor macrophage 
accumulation. 
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Figure 4.2. Phagocytosis inhibits 3D migration   
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Figure 4.2. Phagocytosis inhibits 3D migration. (A) Bone marrow from an NSG donor 
was engineered and mixed either with beads of diameter 900 nm to 6.7 μm or else with 
disaggregated tdTom A549 tumors. The streptavidin-coated beads are targeted with anti-
streptavidin except for a non-targeted control where anti-SIRPα bound macrophages were 
plated with 2.1 μm but no anti-streptavidin; for this control, no eating took place. These 
were cultured together or not in a 150 minutes pre-incubation, and then plated for 24 hours 
on top of 5 µm pore transwell filters. Cells collected from transwells were stained and 
analyzed by flow cytometry for CD11b+ F4/80+ MФ. (B-D) The % migrating MФ was 
determined from Top and Bottom cell counts, with the non-opsonized control indicated at 
‘0’ bead diameter. Migration for this control proves independent of pre-incubation, 
whereas pre-incubation with the 900 nm bead causes a ~5% decrease in migration. The % 
Eating indicates internalization of at least one bead in MФ on top of transwells (or else 
just after the pre-incubation), and pre-incubation causes ~5-10% more eating. The final 
plot indicates the number of beads eaten for a given bead size. (n = 3). (E) For similar in 
vitro studies of engulfment of disaggregated human lung cancer derived tdTom A549 
tumors, the negative control is disaggregated NSG lung. Marrow cells with A’PB MФ 
anti-hum were mixed with disaggregated tumor cells or tissue cells at 10:1 ratio. Nearly 
all A’PB MФ become tdTom positive and rarely migrate, whereas ~50-fold more of the 
same A’PB MФ successfully migrate through the pores when incubated with lung tissue. 
(n = 3).  
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Donor MФ with SIRPα inhibition and primed Fc receptor shrink tumors 
Tumor size measurements following tail-vein injection of A’PB MФ were made 
from the total tdTom signal from the cancer cells which was also used for the cross-
sectional area of the tumor. For the first three days no targeting Ab was injected 
systemically because A’PB is loaded directly with the targeting antibody. Tumors shrank 
-25% with anti-hum A’PB and -15% with anti-MUC1 A’PB, but in the same time 
Cetuximab (anti-EGFR) A’PB and pre-immune A’PB gave similar ~10% tumor growth 
as untreated tumors (Fig. 4.3A). Anti-MUC1 is a mouse IgG that binds very strongly to 
Fc receptors on mouse MФ compared to the humanized IgG Cetuximab (Fig. 4.S2). 
Tumor shrinkage is accompanied by decreases in tdTom intensity, which is consistent 
with phagocytosis and degradation of tdTom protein (Fig. 4.1C) on a timescale faster than 
days (Fig. 4.S3). Since the strongly bound targeting Ab on the A’PB is engulfed during 
eating (Fig. 4.1B, 4.S3), supplemental tail-vein injections of targeting Ab began after day-
3, with twice per wk injections being typical for multi-week chemotherapy. Untreated and 
pre-immune treated tumors grew 15-30% larger by day 10 while treated tumors continued 
to shrink almost linearly, by more than -50% with anti-hum, -38% with anti-MUC1, and 
-15% with Cetuximab. Binding of Cetuximab to A549 cells is strong after systemic 
injection (Fig. 4.S2), which provides for successful opsonization even though the A’PB 
lose their weakly associated Cetuximab before or shortly after injection. Anti-MUC1 
injections at >10-fold higher doses have been found completely ineffective at treating 
tumors (Kufe, 2009), which makes the findings here unique. Cetuximab injections at 50-
fold higher doses delay growth of A549 tumors by about half (Hsu et al., 2010). For 
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comparison, paclitaxel treatment of the same tumor model also shrinks almost linearly 
and to -25% by day 10 (Nair et al., 2016).  
To assess the effect of SIRPα inhibition, donor cells lacking SIRPα inhibition were 
tail-vein injected with systemic anti-hum Ab. Tumor growth was inhibited for 10 days 
(Fig. 4.3B, 4.S3). Subsequent injection of donor cells with SIRPα inhibition (APB MФ) 
decreased tumor size and tdTom intensity by -50% over 10 days (Fig. 4.3B – right half 
of plots, 4.S3). Mice treated with donor cells with only a pre-immune Ab continued to 
grow at the untreated rate. Ab opsonization of cancer cells is thus essential for cancer cell 
engulfment in vivo, and anti-SIRPα synergizes.   
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Figure 4.3. SIRPα inhibition on donor macrophages enhances tumor shrinkage 
while tumor associated macrophages selectively clear only CD47 knockdown tumor 
cells in WT/CD47 KD mosaic tumors   
99 
Figure 4.3. SIRPα inhibition on donor macrophages enhances tumor shrinkage while 
tumor associated macrophages selectively clear only CD47 knockdown tumor cells 
in WT/CD47 KD mosaic tumors. In vivo growth curve of subcutaneous tdTom A549 
tumors treated with either A’PB MФ in the absent of systemic Ab treatment (A) or marrow 
donor cells in presence of systemic Ab treatment (B) (n = 3-6 mice per group, *p<0.05). 
Tumor growth was measured by projected tumor area (C-left). Treatment of mosaic 
tumors with a ratio of 2:1 WT:CD47 KD tumor cells, with 600 μg anti-human twice a 
week. Dashed lines are the corresponding linear fits with R2>0.97. Dashed line is fit of 
average of final three points each of which are insignificant from day 15. (* P<0.05, 
compared to previous data point, within a treatment arm (n = 4-8). (C-Right) Ratio of 
GFP-:GFP+ as determined by flow cytometry following removal of tumors from sacrificed 
mice (n = 4-9). Day 0 was measured using cells reserved from xeno-transplantation. (D) 
In vivo growth curve of CD47 KD+ “deep knockdown” measure by cross-section tumor 
are (n ≥ 3 mice per group). (D, inset) Bar graph of anti-hum and anti-hum F(ab’2) binding 
constant (Kd) for A549s (n = 3). (E) TdTom A549 depletion from tumors as a function of 
cumulative phagocytosis by macrophages after two treatments of donor cells (n = 4-8). 
(E, inset) Representative flow cytometry plots of tdTom A549 abundance in untreated 
tumors (left plot) and treated tumor (right plot). (F) Correlating tumor shrinkage measured 
by cross-sectional tumor area to cumulative phagocytosis in donor and recipient 
macrophages (n = 4-8 mice per group). Analysis was done on mice injected with 7.5 
million monocytes and macrophages unless specified.  
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Tumor Associated Macrophages (TAMs) can only shrink CD47 knockdown tumors  
Our in vitro and in vivo studies indicated TAMs were minimally phagocytic 
toward wildtype tumors (Fig. 4.1B) but could engulf cancer cells after CD47 knockdown 
(Fig. 4.1D, 4.1E). Mosaic tumors were therefore generated with ~2:1 control cells (sh-
Control) that express GFP (Fig. 4.S4, Table 4.S3). No significant difference in tumor 
growth rate was observed between Mosaic, WT/shCtl and CD47 KD tumors for moderate 
knockdown (Fig. 4.3C, 4.S4). Deep knockdown of CD47 did, however, increase tumor 
growth (Fig. 4.S4). The result hints at re-programming (Kaur et al., 2013) and the 
potential dangers of knockdown therapies (Wang et al., 2013). Tail-vein injection of anti-
hum Ab was sufficient to shrink mosaic tumors to a small, stable size with tumor sizes for 
(untreated / treated) = (1.5 / 0.7) = 2.1 at day-18. To determine which cancer cells were 
engulfed, tumors were again analyzed by flow cytometry. Untreated tumors averaged 2:1 
KD : WT (as GFP:GFP+) versus treated tumors 0.4:1 KD:WT. The change in ratio agrees 
with the in vivo imaging results: for every 3 cancer cells in untreated tumors, only 1.4 are 
present after treatment, i.e. (3 / 1.4) = 2.1. The results thus show KD cancer cells are 
selectively engulfed (5-fold more) compared to WT. 
The Fc part of a targeting Ab should bind Fc receptors on macrophages (Fig. 4.S2, 
4.S3) and thereby activate phagocytosis, even though some IgG such as P84 show very 
weak affinity as noted. Calreticulin opsonization of cancer cells has also been proposed 
as contributing to macrophage-driven tumor shrinkage upon CD47 inhibition (Chao et al., 
2010; Feng et al., 2015; Gardai et al., 2005). To directly assess the Fc-driven pathway, 
the Fc fragment was cleaved off anti-hum Ab to generate a F(ab’)2 with similar binding 
affinity as the intact Ab (Fig. 4.3D inset). Neither F(ab’)2 nor the pre-immune Ab affected 
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growth of CD47 knockdown tumors (Fig. 4.3D). The result is consistent with a key role 
for Fc receptor activation and indicates binding of anti-hum Ab alone has no anti-tumor 
effect.  
Treatment of WT/shCtl tumors and KD tumors with varying doses of anti-hum Ab 
could provide more definitive evidence that anti-hum Ab shrinks only KD cells. WT 
tumors and KD tumors grow at similar rates over 10 wks (Fig. 4.S4), consistent with the 
mosaic tumors. Tail-vein injected anti-hum Ab with dose escalation showed no effect on 
WT tumors, but caused CD47 KD tumors to shrink 30% over three weeks (Fig. 4.S4). 
When anti-hum Ab treatment was stopped, tumors re-grew at a rate similar to pre-
treatment. After 25 days of re-growth, tail-vein injection of more Ab once again caused 
tumor shrinkage, and at rates similar to the first round of treatment.  
 
Engorge and Accumulate as a mechanism for tumor shrinkage  
A “cumulative phagocytosis index” is obtained by multiplying the percentage of 
tdTom+ macrophages (Fig. 4.1E-F) by the number of macrophages in the tumor (Fig. 
4.1G) and by the number of cancer cells engulfed per macrophage (Fig. 4.1B,C). 
Consistent with expectations, the number of tdTom A549 cells (per 105 total cells) that 
remain in the tumor decreases when plotted versus cumulative phagocytosis by the 
different macrophages (Fig. 4.3E). Untreated tumors consist of ~40% cancer cells (Fig. 
4.3E, left scatterplot), whereas A’PB MФ treatment decreases cancer cell numbers by 
~100-fold (Fig. 4.3E, right scatterplot). Such selective clearance of the tdTom cancer 
cells is not only consistent with the specific engulfment in mosaic tumors with CD47 
knockdown cancer cells (Fig. 4.3C) but also with overall shrinkage of WT tumors by 
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engineered donor MФ (Fig. 4.3A, B). Tumor shrinkage rate also increases with 
cumulative phagocytosis when determined for all the different macrophage types injected 
into mice with WT and with CD47-KD tumors (Fig. 4.3F). Tumor growth equates to a 
negative shrinkage rate, even though tumor cells remain at 40%. Treatments that relied on 
TAMs are all in the lower half of this plot, even with CD47 inhibition.  
To begin to clarify some of the differences between donor MФ and recipient 
TAMs, tumors were isolated 3 hours after treatment and stained for the so-called M1-
marker major histocompatibility complex II (Murdoch et al., 2008) as a ‘phagocytic 
phenotype’ (Ramachandra et al., 1999), and also the M2-marker mannose receptor 
(Mantovani et al., 2002) (MRC1 or CD206) indicating a relatively non-phagocytic 
phenotype (Mantovani et al., 1992). Recipient TAMs that were tdTom negative had a 
comparatively low M1/M2 ratio as were macrophages in spleen or liver, whereas recipient 
TAMs that had engulfed cancer cells (becoming tdTom) positive showed a higher M1/M2 
ratio (Table 4.1 last column). Fresh marrow-derived MФ as well as tumor-extracted 
donor and APB MФ always showed the highest M1/M2 ratio regardless of whether an 
internalized cancer cell was evident. High MHCII expression by DCs (and perhaps MФ 
also) increases their migration, enhancing presentation and activation of T cells and B 
cells (Faure-André et al., 2008). 
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Table 4.1. M1 and M2 analysis of macrophages   
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Table 4.1. M1 and M2 analysis of macrophages. Donor and recipient macrophages 
isolated from different tissues were stained for M1 (MHC II) and M2 (CD206) markers. 
Donor cells, regardless of SIRPα inhibition, had a high M1 to M2 ratio as did marrow 
macrophages. Recipient macrophages from the tumor were split depending if they were 
tdTom positive (M1) or negative (M2).  
  
105 
Donor MФ in Tumors differ from Marrow MФ and also TAMs that have highest 
SIRPα 
Macrophage phenotype depends strongly on microenvironment and is not 
adequately described by a few surface markers (Lavin et al., 2014) (Fig. 4.4A). RNA-Seq 
was done on marrow macrophages and tumor-extracted donor MФ (tdTom+) as well as 
splenic MФ and TAMs (tdTom+ or tdTom-). Although a small set of MФ surface markers 
were used to sort cells, marrow and spleen MФ still cluster with published profiles (Table 
4.S4). Hierarchical clustering shows donor MФ from day 2 cluster with all tissue 
macrophages and are completely distinct from marrow MФ (Fig. 4.4B). At day 3, these 
MФ cluster even closer to TAMs. Although recent reports have suggested CD47 blockade 
causes TAMs to polarize to the M1 phenotype (Zhang et al., 2016), the donor MФ begin 
to differentiate within days of accumulating in a new tissue, skewing toward non-
phagocytic TAMs.  
 Among transcripts most relevant to phagocytic activity, Sirpa increased 8-fold 
with decreasing phagocytic phenotype. Fresh marrow-derived MФ had the lowest Sirpa, 
donor MФ in tumors had intermediate Sirpa similar to splenic MФ, and TAMs had the 
highest Sirpa (Fig. 4.4C). Cd47 varies little between the different MФ. Flow cytometry 
for surface protein confirmed the trend for mSIRPα with Marrow < Spleen < TAMs, 
whereas mCD47 did not vary (Fig. 4.4D), with mSIRPα protein on day-3 donor MФ 
increasing slightly from marrow (Fig. 4.S5). High mSIRPα will tend to increase the 
sensitivity to cells expressing even low levels of CD47 and will therefore tend to passivate 
MФ, just as inhibiting SIRPα (or knocking down CD47) does the opposite in favoring 
phagocytosis. The increased mSIRPα on donor MФ relative to marrow MФ also equals 
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or exceeds the loss of anti-SIRPα inhibiting antibody with dissociation in the tumor (Fig. 
4.S1, 4.S5). Unfortunately, this data doesn’t establish a causal relationship between 
increased SIRPα and donor MФ differentiation into TAMs as M2 markers and SIRPα 
increase concurrently. RNA analysis of donor MФ at early time points is needed for such 
conclusions. Nonetheless, differentiation toward DCs is unlikely since DC markers Cd135 
and Cd86 are very low in marrow MФ (consistent with ~1 DC per 50 MФ in marrow) and 
these markers remain low after accumulation in tumors (Table 4.S4). Consistent with an 
effect of MФ differentiation and with the Hoechst staining of DNA in phagocytosis studies 
(Fig. 4.1C), marrow MФ exhibit higher Hoechst staining than TAMs.  
By aligning RNA-Seq data with the human transcriptome (rather than mouse), we 
find human RNA is most abundant in donor MФ taken from tumors, which is consistent 
with phagocytosis of human cancer cells (Table 4.2). This might be the first time that 
engulfed-target RNA has been separated from MФ RNA, and suggests that past profiling 
of MФ [eg. (Lavin et al., 2014)] has more complexity than usually assumed. For the fresh 
marrow and spleen MФ, a mouse : human alignment ratio of ~8:1 is inverted to ~1:7 for 
donor MФ taken from tumors. Whereas MФ markers are dominated by mouse sequence 
reads in all samples, epithelial markers (E-cadherin, keratin-18) that are typical of a lung 
cancer line are human and detected only in tumor MФ, both donor MФ and TAMs. The 
results provide novel, additional evidence of tumor engulfment. 
Microenvironments of solid tumor are highly collagenous and very different from 
the soft, low matrix microenvironment in marrow (Egeblad, Rasch, & Weaver, 2010). 
Differentiation might therefore be expected for marrow-derived MФ that engorge on 
cancer cells and accumulate in solid tumors. Among the transcripts that increased the most 
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were those for collagen-1 (Table 4.2), which is a heterotrimer (of Col1a1 and Col1a2) 
that self-assembles into fibers that determine the solidity of tissue (Swift et al., 2013). 
Matrix stiffness often alters cell phenotype (Engler et al., 2006) and can affect 
phagocytosis (Patel et al., 2012), with one intriguing mechanosensor being the nuclear 
structure protein lamin-A (Swift et al., 2013a). Lmna is indeed highest in donor MФ from 
the solid tumors here (Table 4.2). Combining our transcriptome results with those of 
others from many other tissues (Lavin et al., 2014) reveals a consistent increase in Lamin-
A : Lamin-B versus tissue or tumor solidity measured as micro-stiffness (Fig. 4.S5). 
Lamin-B isoforms are relatively constant compared to the increased collagen with tissue 
solidity (Swift et al., 2013). Importantly, profiling shows Sirpa : Cd47 also increases with 
tissue or tumor stiffness (Fig. 4.4E).  
For human-derived THP1 macrophages adhering in vitro either to a gel that is soft 
like marrow or a gel that is much stiffer like a tumor, protein increases are evident in both 
lamin-A : lamin-B and in SIRPα (Fig. 4.4F, 4.S5). The latter has functional implications 
because both anti-human-SIRPα inhibition and RNAi knockdown of SIRPα increase 
whole-cell engulfment of opsonized A549 cancer cells in vitro just as effectively as CD47 
inhibition on these cancer cells (Fig. 4.S7). Importantly, the anti-human-SIRPα Ab is 
distinct from the P84 clone anti-mSIRPα used on mouse-derived MФ, and illustrates a 
possible generality to the approach. 
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Figure 4.4. Phenotype difference of phagocytic and non-phagocytic cells is 
attributed to SIRPα expression   
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Figure 4.4. Phenotype difference of phagocytic and non-phagocytic cells is attributed 
to SIRPα expression. (A) Antibody modification (blocking SIRPα and loading Fc 
receptor with targeting antibody) of marrow macrophages followed by injection into 
circulation leads to A’PB MФs to migrate into tumors, phagocytose cancer cells, and 
become immobilized. Extended expose to the tumor microenvironment could lead to 
differentiation of A’PB MФs into TAMs. (B) Euclidian clustering analysis of RNA 
sequencing data generated from macrophages of different tissues. Macrophages isolated 
from tumors were further separated by their tdTom positivity. (isolation across 4 NSG 
mice, >8×106 reads for each group). (C) Quantification of RNA expression of Sirpa and 
Cd47 taken from RNA-seq data. Quantification was done by taking mRNA expression of 
Sirpa (which was the sum of 2 variants) and Cd47 (1 variant) and normalizing to the 
number of total mouse reads in each macrophage sample. (D) Quantification of Sirpa and 
Cd47 protein expression in macrophages verify mRNA expression (n = 2 mice). Displayed 
are representative histograms of fluorescent intensities from proteins expressed in 
macrophages isolated from the tumor, marrow, and spleen. (E) Sirpa:Cd47 ratios also 
increases in macrophages with increasing microenvironment stiffness. (F) In vitro 
experiment using PMA differentiating THP-1s on different matrix stiffness, (soft-marrow 
and stiff-tumor). After 7 days of culturing, THP-1s were fixed and stained for Lamin-B, 
and SIRPα. Fluorescent intensity for each protein was normalized to the soft condition. 
Lamin-B remained unchanged while SIRPα significantly increased (n = 3, *P<0.05).  
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Table 4.2. Donor macrophage mRNA contains an abundance of human RNA and 
expresses high levels of RNA encoding for matrix proteins   
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Table 4.2. Donor macrophage mRNA contains an abundance of human RNA and 
expresses high levels of RNA encoding for matrix proteins. RNA isolated from Figure 
4B was realigned to human sequences. top row: comparison of the total number of reads 
from each sample between mouse and human alignments; MФ markers: protein markers 
used to identify macrophages have low human alignment and high mouse alignment; 
epithelial makers: only macrophages in the tumor have high mRNA reads for human E-
cadherin and keratin with donor MФ having the highest; matrix to nucleus pathway: 
donor MФ have a significant amount of mRNA that aligns to mouse matrix mRNA 
compared to non-tumor macrophages and even TAMs. 
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Plateaus in shrinkage are corrected by multiple injections of mouse or human donor 
MФ  
A plateau in tumor shrinkage for both subcutaneous and IP tumors that had been 
apparent from day-9 to day-13 (Fig. 4.S2) suggested either donor MФ differentiation or 
perhaps tumor resistance (eg. loss of epitopes). In a longer duration study, injection of 
anti-hum Ab plus APB MФ caused 20% shrinkage by day 3 (Fig. 4.5A) but reached only 
40% by day 10 with a plateau up to day 14, despite Ab injections. Untreated tumors follow 
linear growth in terms of both projected area and tdTom intensity, and no effect was seen 
with pre-immune Ab plus APB MФ (i.e. SIRPα inhibited). On day 14, a second injection 
of APB MФ produced a rapid decrease in tumor size and tdTom intensity (Fig. 4.5A) as 
did first injection into the pre-immune controls. Systemic injections of anti-hum Ab 
stopped at day 24, and tumors stopped shrinking until a cell treatment at day 35, at which 
time tumors shrank once again. Plateaus suggest a loss of function of donor MФ.  
 Fresh marrow MФ from a diverse pool of human donors (Table 4.S5) were 
engineered with a human-specific anti-hSIRPα (Fig. 4.5B), before tail vein injections of 
cells (~12M). Tumors shrunk within days after human APB and A’PB MФ treatments, 
decreasing by ~40% within the first week (Fig. 4.5B) – similar to mouse donor results 
(Fig. 4.5A). No significant effects resulted from pre-immune injections combined with 
either APB MФ or human donor MФs lacking anti-hSIRPα (Fig. 4.5B). However, human 
donor injection with anti-hum Ab (and no SIRPα inhibition) did shrink tumors to a small 
extent (Fig. 4.5B), which is a slightly more positive effect than analogous treatments with 
mouse marrow which stop growth (Fig. 4.3B). Flow cytometry analyses of the CD14+ 
CD33+ CD66b- human MФ isolated from tumors showed human MФs are larger than 
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mouse MФ, and each typically engulfs two to three tdTom cancer cells (Fig. 4.S6). This 
exceeds the ~1:1 result for mouse MФ : human cancer (Fig. 4.1B,C) and indicates more 
human engorgement of more human cancer cells and more accumulation to cause greater 
tumor shrinkage as observed and expected (Fig. 4.3F).  
Beyond the initial phases of tumor shrinkage following treatment, plateaus in 
tumor size were again evident by ~day 15 despite continuous biweekly injections of anti-
hum Ab. No significant tumor growth was measured up to 55 days after donor cell 
injection but shrinkage could be re-initiated with additional injections of human donor 
cells. Sustained breaks in treatment with mouse marrow MФ also led to periods of no 
regrowth. Eventually tumors re-grow at rates approximating those of untreated tumors 
occurred (Fig. 4.S6). Human marrow MФ injections thus cause similar tumor shrinkage 
and have similar limits as injections of APB and A’PB mouse MФ.  
 Tumors with CD47 KD were treated with hAPB MФ or with human donor cells, 
both with anti-hum Ab, to assess whether hSIRPα inhibition on human donor MФ could 
be as effective as inhibiting CD47. Treated tumors shrunk at the same rate, consistent with 
SIRPα inhibition equating to CD47 inhibition (Fig. 4.S6). As with treatment by 
engineered mouse marrow MФ, the engineered human marrow MФ shrink tumors 
significantly more effectively than TAMs, with 12% tumor shrinkage per day versus 2%, 
respectively.  
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Figure 4.5. Single and multiple injections of mouse and human A’PB or APB MФ 
cause rapid shrinkage of subcutaneous and intraperitoneal tumors   
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Figure 4.5. Single and multiple injections of mouse and human A’PB or APB MФ 
cause rapid shrinkage of subcutaneous and intraperitoneal tumors. (A) In vivo 
growth curve of tdTom A549 tumor measured by cross sectional tumor area (upper) and 
tdTom intensity (lower). Mice were given biweekly antibody treatment and donor marrow 
on day 0, 14, and 35. Mice in pre-immune treatment group were switch to full treatment 
group on day 14 due to tumor burden. Approximately 10 million donor marrow cells were 
injected per mouse (n = 4-8 mice per group). (A, inset) Tumor imaging on treatment day 
28 after two full donor marrow treatment cycles. Red regions are tdTom signal acquired 
from tumors. Two mice (left) were treated with APB macrophage and the other two mice 
(right) were untreated. (B) Treatment of tdTom A549 subcutaneous tumors that grew for 
60 days with engineered human marrow. In vivo growth curve measure by tdTom intensity 
(n = 16 mice for each group). All tumors treated with human marrow + anti-hum reduced 
in size, but SIRPα inhibition further increased rate of shrinkage. Mice that received hA’PB 
MФ with a nonspecific antibody all continued to grow similar to untreated (n ≥ 4 mice 
per group). (B, inset) Representative tdTom images of treated and untreated mice on day 
52 of treatment. Mice are arranged by treatment effectiveness with hA’PB > hAPB > 
hdonor > ctrl. (C) Blood profiles of all mice before and after treatment. Gray area shows 
the pretreatment and untreated variance in blood profiles (normal range). All treated mice 
remain in the normal during the 60 days of multiple engineered human donor treatment.  
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Blood profiles remain normal with engineered marrow treatments of tumors 
Safety is a concern whenever inhibiting MФ recognition of ‘self’ based on past 
findings that systemic injection of anti-CD47 rapidly clears blood cells (Weiskopf, Ring, 
Ho, Volkmer, Levin, Volkmer, Ozkan, et al., 2013b; Willingham et al., 2012) and that 
Cd47-knockout mice (NOD strain) exhibit auto-immunity, anemia, and premature death 
(Per-Ame Oldenborg et al., 2002). Blood was therefore drawn periodically from the 
various mice before and after MФ injections (Fig. 4.5C, 4.S6), and RBC count, 
hemoglobin levels, percent hematocrit, platelet count, and WBC count all remained within 
the normal range for all treated mice over the ~ 9 wk experiment (Fig. 4.5C). For all mice, 
a slight upward increase in WBC count was seen and could reflect inflammation 
associated with retro orbital bleeds (Nemzek, Bolgos, Williams, & Remick, 2001). 
Furthermore, no anomalous mouse behavior or Graft versus Host Disease (GvHD) was 
observed in any mouse treated with engineered human or mouse marrow after multiple 
injections of each over 30+ days of experimentation in 30+ mice. Intravenous injection of 
engineered donor MФ thus appears safe during rapid and effective regression of solid 
tumors. 
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4.4 DISCUSSSION  
 
For the dozens of conditions studied, the extent of MФ phagocytosis of tumor cells 
in vivo as measured at the single cell level predicts initial rates of tumor shrinkage or 
growth (Fig. 4.3E-F, 4.S2). At least three features of a MФ might therefore be optimized 
for efficient engulfment of cancer cells in vivo. First, the phagocytic potential must be 
considered: marrow MФ – whether sorted or not from marrow (Fig. 4.1H) – can clearly 
be effective compared to TAMs (Fig. 4.1D). Second, CD47-SIRPα self-recognition 
should be inhibited; anti-SIRPα antibodies can enhance phagocytosis of opsonized targets 
by immobilizing SIRPα (by crosslinking cis homodimers (Lee et al., 2010)) and thereby 
limiting SIRPα accumulation into the phagocytic synapse (Fig. 4.S1). The immunological 
synapse between an antigen-presenting cell and a T-cell also depends on molecular 
segregation for signaling. Third, the cancer cell should be specifically opsonized as 
illustrated here with both pre-loaded targeting Ab’s and with systemic injections. A single 
antibody, such as anti-CD47, has been proposed to both inhibit ‘self’ signaling and to also 
efficiently opsonize a cancer cell (Willingham et al., 2012), but this has become a subject 
of concern in terms of replication and statistical significance (Horrigan et al., 2017).  
Phagocytes are often considered highly motile, but inhibition of cell migration by 
the engulfment process could explain cell accumulation. MФ derived from mouse marrow 
(NSG) or human marrow clearly infiltrate large solid tumors, and the MФ accumulate in 
proportion to engulfment (Fig. 4.1B-F, 4.S6). With solid tumors of low porosity, 
immobilization can in part be due to an inability to ‘eat and run’ since engulfment of two 
nanobeads significantly reduced 3D migration through much larger micro-pores (Fig. 
4.2B-E). Antagonism is already known between endocytic and migratory pathways for 
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very primitive cells such as Dyctiostilium amoeba (Veltman et al., 2014) and fly 
haemocytes (Evans et al., 2013) as well as dendritic cells (Chabaud et al., 2015). 
Overlapping mechanisms in MФ require further study, but competition is likely between 
pathways involving shared cytoskeleton components such as ARP2/3 or Myosin II. 
Nuclear lamins set nuclear stiffness, and a cell with high lamin levels (eg. Fig. 4.S5) is 
already known to be physically impeded in 3D migration (Shin et al., 2013; Thiam et al., 
2016) as will engulfment of another cell with a stiff nucleus (Fig. 4.1B,C). The resulting 
engorge and accumulate mechanism for engineered donor MФ in solid tumors also 
minimizes accumulation in other tissues (Fig. 4.1G, 4.S3).  
No detectable impact on mouse health resulted from the cell + Ab injections that 
drive tumor phagocytosis and shrinkage (Fig. 4.5C, 4.S6). In comparison, systemic 
injection of anti-CD47 causes large decreases in blood cells and platelets (Oldenborg et 
al., 2002; Weiskopf et al., 2013; Willingham et al., 2012), which reflects CD47’s 
ubiquitous expression. Careful attention to species specificity of anti-CD47 is of course 
needed in such studies (Subramanian et al., 2006; Tsai & Discher, 2008), but CD47 
blockade in a clinical setting is expected to sensitize all healthy cells to phagocytosis by 
MФ. Combinations of systemic anti-CD47 with tumor opsonizing antibodies nonetheless 
engage a small number of phagocytic TAMs (confirmed here in Fig. 4.1F, with 
quantitation of tumor cell uptake), and our CD47 knockdown studies document selective 
eating of cells with low CD47, enriching for CD47-high cancer cells (Fig. 4.3C-D, 4.S4). 
This can explain why cancer patients have CD47-high cancer cells (Willingham et al., 
2012).  
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For the infiltrating engineered macrophages studied here, microenvironment 
stiffness of tumors likely contributes to their eventual differentiation, which includes 
upregulation of SIRPα (Fig. 4.4B-F, 4.S5) that provides more opportunity to bind ‘marker 
of self’ CD47. Although RNAi knockdown of SIRPα can also increase phagocytosis of 
Ab-opsonized cells in vitro (Fig. 4.S5), SIRPα-knockdown macrophages can promote 
tumor growth in vivo (Pan et al., 2013) – perhaps related to differentiation. Phagocytosis 
by differentiating donor MФ here is expected to be gradually suppressed, consistent with 
observations from donor MФ RNA-Seq that upregulation of SIRPα and M1/M2 markers 
occur simultaneously. Subsequent injections of marrow cells remain effective and safe 
(Fig. 4.5C, 4.S6), noting that multiple injections of marrow and leukocytes are already 
done in the clinic (Eapen et al., 2004). The findings here thus provide insight into 
mechanisms, utility, and safety of engineering: (i) a highly phagocytic and motile 
macrophage, with (ii) inhibition of ‘self’ signaling by anti-SIRPα, combined with (iii) 
robust target opsonization.  
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4.5 SUPPLEMENT 
 
Figure 4.S1. P84 SIRPα antibody binds to NSG macrophages and immobilizes 
SIRPα   
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Figure 4.S1. P84 SIRPα antibody binds to NSG macrophages and immobilizes 
SIRPα. (A) Affinity of anti-SIRPα for NSG macrophages. Data fit using saturation a 
binding model (All cells: R2 = 0.73, Kd
 = 50 ng; Viable cells: R2 = 0.78, Kd = 72 ng). In 
vitro phagocytosis assay using phorbol myristate acetate (PMA) treated human monocytes 
(THP-1) cell line and a human lung carcinoma cell line (A549, WT and CD47 KD). (B) 
Normalized SIRPα inhibit between injections day 0 and day 3 when tumors are isolated. 
Approximately 53% of SIRPα inhibition remained on macrophages on day 3 (n = 3). (C) 
Representative images of mouse macrophages ± anti-mSIRPα (P84) incubated with 
opsonized mouse RBCs for 30 minutes. Following phagocytosis, cells were fixed and 
stained for mSIRPα and p-Tyr residues. Displayed are epifluorescent images used to 
quantify proteins in phagocytic synapse per (Tsai & Discher, 2008). (D-E) Quantification 
of SIRPα and phosphor-tyrosine residue accumulation in phagocytic synapse of mouse 
macrophages ± anti-mSIRPα. Fluorescent intensity was normalized to macrophages that 
were not undergoing phagocytosis (n = 7). (F) Representative images and analysis of 
FRAP SIRPα-GFP diffusion ± anti-mSIRPα (P84). Sides of cells were bleached and 
allowed to recover (n = 3).  
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Figure 4.S2. Targeting antibodies bind mainly to cancer cells and mouse 
macrophage   
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Figure 4.S2. Targeting antibodies bind mainly to cancer cells and mouse macrophage. 
(A and B) Binding curve for anti-hum against hRBC, A549, EC4s, and IPS-MSC of 
different passage number. Each point is composed of the average intensity of 10,000 cells 
for each. (C) Flow cytometry (gray=isotype control; black=MEG-01) of 67 nM Ab 
binding to MEG-01 cells. Fitting parameters indicate that when B is similar for mRBC 
and hRBC K for mRBC >> hRBC indicating weak affinity to mRBC. Mixing human and 
mouse RBCs did not affect binding to either species. Model: Y=A+B*X/(K+X); hRBC: 
A=80, B=35524, K=26.5nM, R2=0.97; mRBC: A=80, B=14210, K=323427nM, R2=0.22; 
MEG-01: A=80, B=262480, K=97nM, R2=0.99. (D) Verification of anti-hum binding to 
A549 cells, immunofluorescence and Western blot. Immunofluorescence confirms anti-
human antibody binding (left) to A549 in vitro compared to secondary antibody only 
control (right) (scale bar = 10 μm). Images have been adjusted to allow visualization of 
cells in control image. Bar graph below the images reflects true fluorescence of each 
unaltered image. The blot shows three main bands with several lower intensity bands 
which anti-hum binds to. Shown are possible surface proteins identified by mass 
spectrometry that correspond to the molecular weight from the 3 most intense bands. (E-
F) Binding of systemically injected anti-hMUC1 and Cetuximab antibody into NSG mice 
bearing 8 wk old tdTom A549 tumors. Antibody could circulate for 3 hours then the mouse 
was then sacrificed, tumors isolated, disaggregated, and split into two samples. One 
sample was stained for targeting antibody and the other was directly incubated with anti-
MUC1 or Cetuximab (ex vivo) to ensure specific binding and to test non-specific binding. 
After direct incubation, samples were then stained for targeting antibodies. (G) 
Normalized NSG TAM binding data from subcutaneous and intraperitoneal tdTom A549 
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tumors of anti-MUC1 and Cetuximab. 10ug of each antibody was systemically injected 
and 3 hours later the mouse was sacrificed, tumor tissue stained, and analyzed by flow 
cytometry. (H) Normalized In vivo growth curve of tdTom A549 subcutaneous and 
intraperitoneal tumors. Growth of tumors was monitors by tdTom fluorescent intensity. 
Tumors grew at a similar rate for 30 days then were treated with NSG A’PB MФ. All 
tumors shrank comparably until days 9-13 when shrinkage plateaus (n = 3-6). (H, inset) 
Representative fluorescent images of tdTom signal from IP tumors comparing tumor 
intensities of treatment day 0 to day 13. (I) On Day 13, all tumors were removed and 
analyzed by flow cytometry. TdTom A549 cells remaining in the tumors were identified 
by forward scatter (size) and tdTom intensity, while excluding CD11b+ F4/80+ cells. 
Tumors treated with A’PB MФ all showed decreased A549 populations in proportion to 
measured florescent intensity. 
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Figure 4.S3. Donor cells alone inhibit tumor growth, but priming Fcγ receptor on 
APB MФ yields the most effective anti-tumor response   
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Figure 4.S3. Donor cells alone inhibit tumor growth, but priming Fcγ receptor on 
APB MФ yields the most effective anti-tumor response. (A) Schematic of method used 
to analysis disaggregated tumor tissue. Following dissociation and antibody staining, 
samples are analyzed using flow cytometry. (B) Flow cytometry dot plots showing gating 
strategy used to identify and analysis macrophage eating and abundance in tissues. (C) 
Phagocytosis assay using disaggregated tdTom A549 tumors that were treated 24 hours 
prior with A’PB MФ. Cells were platted for 24 hours and analyzed by flow cytometry 
focusing on phagocytosis of tdTom A549 cells by A’PB MФ, donor neutrophils, or 
recipient MФ (TAMs). (D) Three days after injection of APB engineered NSG mouse 
marrow, subcutaneous WT A549 tumor were harvest and analyzed by flow cytometry for 
neutrophils. Abundance of neutrophils in the tumor per 105 cells screened. Despite the 
moderate level of neutrophil eating, the small number of neutrophils in the tumor make 
them an ineffective anti-tumor effector cell type. Recipient neutrophils seem to have 
opposite problem, high number of neutrophils in the tumor, but they are non-phagocytic. 
(E) Immune cells makeup of engineered NSG mouse marrow cells before injections into 
tumor bearing mice. Together macrophages, monocytes, and neutrophils consist of 65% 
of the marrow injected (n=3). (F) Representative histogram of flow data from CFDA 
stained and anti-mSIRPα engineered NSG mouse marrow cells. (G) Fluorescent imaging 
of tdTom CD47 knockdown A549 compared to tdTom WT. (H) In vivo growth curve of 
subcutaneous tdTom A549 tumors. Tumor growth was measured by tdTom intensity. 
Tumor were approximately 70 mm2 in size at the start of treatment. Male mice were 
treated with 10 million NSG mouse donor marrow cells that were SIRPα inhibited and 
Fcγ receptor pre-loaded with anti-hum or pre-immune antibody ex-vivo then tail vein 
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injected back into mice. Donor injection was giving on day 0 with no systemic antibody 
treatment. On treatment day 3, biweekly systemic injection of antibody (n = 6). (I) In vivo 
growth curve of subcutaneous WT tdTom A549 tumors. Tumor growth was measured by 
tdTom intensity. Tumor were approximately 70 mm2 in size at the start of treatment. 
Treatment day 0-10 mice were injected with 10 million marrow donor cells with biweekly 
anti-hum injection. On day 10, a mixture of male and female mice received a second 
treatment donor cells, but with SIRPα inhibit. (n = 4). (J) A’PB MФ accumulation in IP 
tdTom A549 tumors as a function of % tdTom+ MФ within each pollution. Relative 
phagocytosis and accumulation depends on the antibody used to opsonize cancer cells 
with the following order: anti-hum › anti-hMuc1 › Pre-immune (n = 3; R2 = 0.94).  
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Figure 4.S4. Engineered donor macrophages in recipient tumors are assayed for 
phagocytosis and 3D-motility   
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Figure 4.S4. Engineered donor macrophages in recipient tumors are assayed for 
phagocytosis and 3D-motility. (A) Schematic of the 3D-motility assay used to assess 
macrophage eating and migration from primary NSG mouse marrow, lung, and tdTom 
A549 subcutaneous tumors. Bone marrow from donor-1 was harvested, engineered 
(SIRPα inhibited and Fcγ receptor primed with anti-hum), and injected into NSG mice 
with 8 wk old subcutaneous tdTom A549 tumors on both flanks. Three days after injection 
a injection of anti-hum was given and 3 hours later tumors were isolated and plated on 
tops of 3 µm and 5 µm transwells at 300k cells per well and allowed to migrate for 24 
hours. In some conditions marrow from a second donor was spiked with the disaggregated 
tumor. The transwells were scrapped, stained and analyzed by flow cytometry. (B) Plot of 
3D migration of donor marrow, lung, and tumor macrophages as a function of macrophage 
phagocytic activity of tdTom A549 cells on 3 µm (black) and 5 µm (blue) pores (n ≥ 3). 
(B, inset table) macrophage eating of tdTom A549 cells on the bottom of 3 µm (black) 
and 5 µm (blue) transwells along with migration of tdTom A549 tumor cells. Only one 
condition shows eating on bottom (most phagocytic with largest pores) (n =3 -7). (C) 
Transwells with different pore sizes have different numbers of pores (3 µm = 2x106, 5 µm 
= 0.4x106, etc.), which must be accounted for in the total pore area to calculate cell flux 
(#/area). Thus the flux of cells through 5 µm pores should be smaller by 
(5/3)^2(0.4x106/2x106) = 0.56-fold, but the 5 µm transwell instead allows 3-fold more of 
each macrophage phenotype through because the 5 µm constriction is far less severe than 
the 3 µm. The plotted flux of macrophages is therefore 5.4-fold higher for this larger pore, 
whereas the much larger 8 µm pore does not greatly increase this flux, so that 3 µm pores 
are by far the most restrictive. (D, Left) In vivo growth curve of CD47 KD+ during 2 
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periods of no treatment. (n = 8-12). Slope of linear fit = 1.02 mm2/day corresponding to 
tumor growth rate (R2=0.99). (D, insets) Representative fluorescent overlays of untreated 
(left) and Ab treated (right) mice at the end of the treatment period. (D, Right) Tumor 
response to 200 and 600 μg anti-human / mouse followed by removal of antibody and 
subsequent re-administration (n = 4-8). (E) In vivo measured growth of subcutaneous 
tdTom A549 tumors. Correlation of measuring tumors using calipers (cross sectional area) 
or by tdTom intensity over a 30 day period (n = 4 mice). (F) CD47 KD+ cells were further 
sorted to generate CD47 KD++, an ultra-deep knockdown. Xenotransplants in NSG mouse 
flanks show a slight growth advantage for CD47 KD++ (linear fit slope = 1.56 mm2/day, 
R2=0.99) compared to tumors comprised of WT GFP Scr (same as WT/shCtl) either in 
part or in whole (linear fit slope = 1.02 mm2/day, R2=0.98) (n = 4 - 8). (F, inset) Flow 
cytometry of cells used in xenotransplants (gray=isotype; black=CD47 KD++; green 
dashed outline=WT GFP Scr; green fill=Mosaic). 
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Figure 4.S5. Stiff matrix regulation of SIRPα and phagocytosis of a lung cancer cell 
line are enhanced by inhibition of hSIRPα   
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Figure 4.S5. Stiff matrix regulation of SIRPα and phagocytosis of a lung cancer cell 
line are enhanced by inhibition of hSIRPα. (A) Data mining published macrophage 
mRNA sequences for Lamin-A and Lamin-B shows that Lamin-A : Lamin-B ratios 
increase in macrophages with increasing stiffness of resident tissue and flows a linear 
trend on a log-log scale (R2=0.95). Lamin-A : Lamin-B RNA sequence data from 
macrophages data from (4B) shows the same trend as published data. (B) In vitro 
experiment using PMA differentiating THP-1s on different matrix stiffness, (soft-marrow 
and stiff-tumor). After 7 days of culturing, THP-1s were fixed and stained for LAMIN-A, 
LAMIN-B, and SIRPα. Fluorescent intensity for each protein was normalized to the soft 
condition. LAMIN-B remained unchanged, but LAMIN-A and SIRPα significantly 
increased (P<0.05, n = 3). (C) Quantification of Sirpα on A’PB donor macrophages and 
recipient macrophages from large tdTom A549 IP and subcutaneous tumors in NSG mice. 
Tumors were isolated 3 days after tail-vein injection of donor cell. Data is normalized to 
macrophages taken from NSG marrow (n = 3). (D) THP-1 phagocytosis of WT and CD47 
KD A549 was measured by counting the number tdTom A549 cells per THP-1 and 
normalizing to control (cells only) under different eating condition (n≥3). (E) THP-1 
phagocytosis of A549 was measured by counting the number A549 cells per THP-1 and 
normalizing to control (cells only) under different eating condition (n ≥ 4). (E, inset) 
Image of a positive eating event with CD11b stain in green showing THP-1 and tdTom 
fluorescence indicating A549 cancer cell. (F) Quantification of internalized tdTom 
fluorescent intensity of THP-1s and normalizing to tdTom intensity from uneaten A549 
cells. Quantification was done from the samples taken from figure 1A (n ≥ 4). (G) In vitro 
phagocytosis assay using PMA treated THP-1s and human red blood cells. KD of SIRPα 
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in THP-1s resulted in 2.2-fold increase in eating of anti-hum opsonized RBCs over WT 
THP-1s (n = 4).  
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Figure 4.S6. Safety and in vivo confirmation of human donor efficacy   
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Figure 4.S6. Safety and in vivo confirmation of human donor efficacy. (A) Weight 
throughout duration of study (including pre-treatment, treatment, and post-treatment). 
Weight is normalized to weight at date of xenograft implantation. Mice used in Mosaic 
Study (n = 4-8). GFP WT/shCtl, Mosaic, Mosaic+Ab are grouped together and the green 
solid line reflects the linear fit. CD47 KD++ mice show slightly different weight responses 
as shown by the black solid line. Addition of antibody shows a slight decrease in 
hematocrit, but no change in thrombocrit (n ≥ 3). I.V. injection of anti-hum antibody 
shows no specific binding to mouse RBC or platelets in vivo (n ≥ 3 per group). (B) Blood 
profiles taken from male mice treated with APB macrophages (n ≥ 3) before and after 
treatment. Parameters were normalized to day 4 of pre-treated. (C) In vivo growth curve 
of CD47 KD tdTom A549 tumors treated with NSG donor cells and anti-hum antibody. 
Growth was measured by tdTom fluorescent intensity. Tumor grew for 8 wks before 
treatment with human marrow. SIRPα inhibition didn’t significantly increase anti-tumor 
effect in CD47 KD tumors (n = 3). (D) Quantification of CD14+ CD33+ CD66b- human 
macrophages eating in CD47 KD A549 tumors. Three days after injection tumors were 
harvested and human macrophages were analyzed by flow cytometry. Macrophages ± 
SIRPα inhibit had the same eating percentage, 95% (n = 4). (E) However, human 
macrophages with anti-hSIRPα had engulfed an average of 3.5 tdTom A549 tumor cells 
whereas donor only was only 2.2 (n = 4). (F) Quantification of the number of human 
macrophages per 105 cells screened on the flow cytometer (n = 4). (G) Calculation of the 
cumulative phagocytosis index using data from fig. S8D-F. The human APB MФ indexes 
are comparable to indexes from NSG APB MФ from figure 1. (H) In vivo growth curve 
of tdTom A549 tumors. Growth was measured by cross sectional tumor area. Tumor grew 
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for 8 wks before treatment with NSG marrow plus anti-hum at day 0 then (n = 4). 
Treatment day 0-10 mice were injected with 10 million marrow donor cells with biweekly 
anti-hum injection. On day 10, a mixture of male and female mice received a second 
treatment donor cells, but with SIRPα inhibition. 
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Table 4.S1. Relative IgG supplementation   
138 
Table 4.S1. Relative IgG supplementation. Calculated estimate of the IgG percent in 
immunocompetent mouse strains. Calculation assumes a 30 g mouse and 0.6 mg Ab 
injection. % of IgG is calculated as 0.6 mg injected Ab / total mg IgG * 100%. This value 
provides a magnitude of the Ab dosage for comparison with what is present in 
immuncompetent animals. Also as a comparison, a typical 300 μg dose of Rhogam 
represents 0.0006% of total human IgG. Literature values: mouse blood volume1 from, 
C57BL/6 IgG concentration2 from, humanized NSG IgG concentration3 from (Rajesh et 
al., 2010). 
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Table 4.S2. Donor vs. TAM abundance in tumor periphery and core   
Cell Type Tumor Location per 100K Cells
A'PB MФ Periphery 2921
A'PB MФ Periphery 3122
TAM Periphery 3348
TAM Periphery 3599
A'PB MФ Core 3399
A'PB MФ Core 1631
TAM Core 6118
TAM Core 5682
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Table 4.S2. Donor vs. TAM abundance in tumor periphery and core. Flow cytometry 
population analysis of A’PB MФ and TAMs in periphery and core of tdTom A549 
subcutaneous xenografts in NSG mice.  
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Table 4.S3. CD47 cell surface density   
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Table 4.S3. CD47 cell surface density. In vitro (cells used for xenotransplant) and in 
vivo (cells recovered from excised tumors) CD47 surface density determined by flow 
cytometry and immunofluorescence. A549 cell area was determined by measuring area of 
well spread cells imaged by immunofluorescence. This value was multiplied by two 
assuming negligible height for well spread cells. We acknowledge that this method 
underestimates cell area and calculated values for CD47/μm2 are thus likely overestimates. 
CD47 intensity was determined by flow cytometry mean fluorescence intensity and 
normalized to human red blood cells. Arrows indicate IgG treatment responsive cells. We 
previously reported a CD47 surface density value for hRBCs. Multiplying this value by 
the normalized CD47 intensity and scaling by the ratio of A549 area to hRBC area 
previously reported, results in the values presented in the table.  
  
143 
Table 4.S4. Validation of macrophage RNA isolation and sequencing   
Lavin Cell 2014
Bone Marrow Tumor
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Table 4.S4. Validation of macrophage RNA isolation and sequencing. Macrophages 
were isolated from different NSG mouse tissues and sorted on CD11b, F4/80, CFDA, and 
tdTom. RNA was extracted from the sorted cells and sent for sequencing. To verify proper 
cell sorting and RNA isolation, our macrophage sequencing profiles were clustered to 
published data from (Lavin et al., 2014). Our sorted macrophages clustered with the same 
tissues as in previously published works with tumor macrophages clustering differently 
from other tissue macrophages.  
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Table 4.S5. Profiles of human marrow donors   
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Table 4.S5. Profiles of human marrow donors. Human marrow was isolated from 4 
different donors with varying profiles to ensure that donor to donor variation had no effect 
on treatment outcome.  
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Chapter 5: SIRPα inhibition in marrow macrophage 
initiates acquired immunity against primary and 
metastatic melanoma 
 
 
 
This chapter presents work featured in a manuscript to be submitted to Science 
Immunology. 
 
Contributing authors: Cory Alvey, Lucas Smith, and Dennis Discher. 
 
Lucas Smith – Lung metastasis model (Fig. 5.2) 
  
148 
ABSTRACT 
 
Marrow-derived macrophages (MDM)s can be highly phagocytic and have been 
previously shown to shrink human xenografts with SIRPα inhibition. Yet the ability of 
MDMs and tumor-associated macrophages (TAM)s to activate acquired immunity is 
unknown. By inhibiting MDMs from recognizing other cells as ‘self’, tail-vein injected 
donor cells accumulate in solid tumors in proportion to their engorgement on melanoma 
cells opsonized by anti-Trp1 antibody. TAMs failed to impact tumor growth despite a 
modest increase in eating with addition of anti-Trp1. In contrast, engineered macrophages 
had sustained tumor shrinkage for 7 days despite T-cell depletion. Treated tumors 
eventually regrew, but not for treated mice with intact T-cells. ‘Cured’ mice re-challenged 
with melanoma had significantly delayed tumor growth, whereas untreated mice grew 
tumors within days of challenge. Injection of engineered macrophages greatly reduced 
melanoma metastasis to the lungs compared to treatment with anti-Trp1 without donor 
cells. Surprisingly, systemic injection of ‘self’ inhibited macrophages had no measurable 
impact on blood profiles, weight, and did not cause GvHD even after activation of 
acquired immunity against syngeneic tumors.    
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5.1 INTRODUCTION 
 
It was once thought that targeting of the immune system to a foreign invader was 
driven by the presence of an activation signal, but with discovery of ‘self’ markers it is 
now understood that activation of immune cells is facilitated by the absences of ‘self’ 
signaling, in addition to activation signals. A particularly interesting ‘self’ marker is CD47 
as it binds to SIRPα on the surface of phagocytes, inhibiting phagocytosis (Oldenborg et 
al., 2000; Willingham et al., 2012). SIRPα signaling leads to myosin-II inhibition which 
normally makes phagocytosis efficient (Tsai & Discher, 2008). CD47 is expressed on all 
cells and was first identified on solid tumors (Mawby et al., 1994) as most cancers 
overexpress it, with increasing expression correlating with negative clinical prognosis 
(Fujiwara et al., 2011; Lan et al., 2012; Lu-emerson et al., 2013; Majeti et al., 2009; 
Willingham et al., 2012; Zhang et al., 2013). Given this, it is unsurprising that common 
oncogenes regulate expression of ‘self’ markers (Casey et al., 2016). In mice bearing 
human tumor xenografts, combining anti-hCD47 with a distinct Ab that can opsonize 
human tumor cells has been shown to shrink tumors (Chao et al., 2010; Weiskopf et al., 
2013). In syngeneic mouse models of melanoma, in situ knockdown of mCD47 beginning 
~1 week after engraftment can slow tumor growth over the subsequent ~2 weeks (>90%). 
The slowed growth is attributed to tumor-associated macrophages (TAMs), but does not 
include injection of TAM-activating factors (eg. tumor-opsonizing Ab) (Wang et al., 
2013). Indeed, a current controversy in the field is whether inhibition of just the CD47-
SIRPα interaction alone is sufficient to reproducibly shrink tumors: a recent replication 
study (Horrigan et al., 2017) not only failed to demonstrate efficacy as first reported for 
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anti-mCD47 inhibition (Willingham et al., 2012), but also questioned significance of past 
data.  
Conflicting effects of anti-CD47 therapy add to the safety concerns and 
questionable effector cell complications that already exist. Ubiquitous expression of CD47 
causes rapid and reproducible (Horrigan et al., 2017) decreases of blood cells in primates 
(Weiskopf et al., 2013) as well as mice (Willingham et al., 2012) with intravenous 
injection of species-appropriate anti-CD47 antibody. Furthermore, Cd47 knockout mice 
can develop autoimmune disease with auto-antibodies, anemia, and ~60% shorter lifespan 
(Oldenborg et al., 2002). Safety of CD47 inhibition is thus one critical metric in ten new 
clinical trials with intravenous anti-hCD47 or anti-hSIRPα (Archambeaud e atl., 2016; 
Burgess et al., 2015; Chao et al., 2016; Kang, 2011; Sievers et al., 2016a, Takimoto, 2014). 
Safety of intravenous injection of anti-SIRPα is of equal concern (Rodriguez et al., 2013), 
but our recent studies show that blocking SIRPα on marrow macrophages with anti-SIRPα 
before cell injection prevents loss of RBCs. In addition to the safety concerns, TAMs 
prove to be weakly phagocytic when compared to macrophages from other tissues 
(Rodriguez et al., 2013), limiting their role as an effector cell in anti-CD47 therapy. Unlike 
TAMs, undifferentiated marrow-derived macrophages (MDMs) seem to be among the 
most phagocytic, but whether these cells alone can cause tumor remission remains 
unanswered. More evidence is arising that an acquired immune response is ideal for cancer 
therapy as it may eliminate primary and metastatic tumors with the potential to prevent 
relapse.  
Recent anti-CD47 studies in immunocompetent mice suggest that tumor dendritic 
cells (DCs) are responsible for all of the therapeutic effect observed with anti-CD47 
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treatment (Liu et al., 2015). Specifically, DCs phagocytose and then present neoantigens 
to active CD8 T-cells, which seem to be the main effector cell. Interestingly, knockdown 
of SIRPα in DCs enhances their ability to activate an acquired immune response (Liu et 
al., 2016), but it is unknown whether SIRPα inhibited MDMs can initiate an acquired 
immune response or even if that is necessary for complete tumor regression.  
We hypothesized that phagocytosis by MDMs alone has an important role in 
reducing early tumor growth in addition to being able to activate an acquired immune 
response. Here an immunocompetent, syngeneic, mouse model for orthotopic and 
metastatic melanoma is used to study the anti-cancer effect of donor MDMs. This model 
has proven reliable in evaluating the development of an adaptive immune response, while 
also being clinically relevant. Beginning with evidence of in vivo engulfment, engineered 
mouse MDMs (rather than donor DC or lymphocytes) are shown here to accumulate in 
tumors and cause substantial shrinkage before activation of T-cells. However, the 
development of an adaptive immune response is necessary for sustained tumor regression 
and prevention of tumor growth when re-challenged. Blood parameters here are 
unaffected by the SIRPα-inhibited, donor macrophages and their activation of the acquired 
immune system. 
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5.2 MATERIALS AND METHODS 
Antibodies: Anti-mSIRPα antibody (rat anti-mouse CD172a, P84, BD Pharmingen). 
Opsonization Primary antibodies used for flow cytometry and imaging included CD11b-
APC (Biolegend) as well as anti-mouse F4/80-APC/Cy7 (Biolegend) and CD11b-PE/Cy7 
(Biolegend). Secondary antibodies included donkey anti-rabbit Alexa Fluor 488 
(Invitrogen) and donkey anti-rabbit Alexa Fluor 647 (Invitrogen). When required, nuclei 
were stained by either 7-Amino-actinomycin D (7-AAD, Sigma) or Hoechst 33342 
(Invitrogen). 
 
Immunofluorescence: B16F10 cells were seeded on 18 mm circular microscope cover 
slips in a 6-well plate and allowed to adhere overnight. Cells were fixed with 4% 
paraformaldehyde for 15 minutes at room temperature (RT), and then washed three times 
with PBS. Next, cells were blocked for 30 minutes using 3% BSA + 0.05% Tween-20, 
followed by a 2-hour RT primary antibody incubation in blocking buffer. These primary 
antibodies were used at a 1:100 concentration. After incubation, cells were again washed 
three times with PBS. A 1:400 PBS dilution of donkey secondary antibodies (Alexa Fluor 
488 and 647) was added for 1 hour at RT. Hoechst 33342—at a concentration of 1 
μg/mL—was used to stain DNA for 15 minutes at RT. Cover slips were washed a final 
three times with PBS before being mounted on slides with ProLong Gold Antifade 
Reagent (Life Technologies), cured for 24 hours, and sealed with nail polish prior to 
imaging. Images were acquired by an Olympus IX71 inverted microscope with a 300W 
Xenon lamp illumination using 40×, 60×, or 150× objectives with or without 1.6× 
magnification. Image analysis was done in ImageJ (NIH).  
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Flow Cytometry of In Vitro Cultured Cells: B16F10 cells were dissociated using 10 
mM trypsin in PBS, washed, and re-suspended in 2% FBS in PBS. Antibody incubation 
was done at RT for 1 hour, followed by washing and resuspension in 2% FBS. Samples 
were run on a BD LSRII.  
 
Syngeneic Tumor Model: C57 mice were purchased from The Jackson Laboratory and 
were housed in a BSL 2 facility at the University of Pennsylvania. Mice were implanted 
with either 2×105 or 5×105 B16F10 (acquired from ATCC) cells injected into the 
subcutaneous tissue or intravenously. Tumors grew to 10 mm2 before the start of treatment. 
Cross-sectional tumor area was measured by calipers to monitor growth of tumors. Fur 
was dampened to enhance accuracy. During each tumor measurement, mouse body mass 
was measured with an enclosed digital scale. 
 
Antibody Treatment and T-cell Depletion: Mice were warmed under a heat lamp prior 
to tail vein injection. Anti-Trp1 (TA99, Bio X Cell) was given to mice 3-4 times per week 
at 250 µg per animal. CD4 and CD8 T-cells were depleted using anti-mouse CD4 (GK1.5, 
BE0003, Bio X Cell) and anti-mouse CD8 (2.43, BE0061, Bio X Cell), respectively. 
Depletion antibodies were given interperitoneally at 200 µg per mouse biweekly (Liu et 
al., 2015). 
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Adoptive Transfer of Bone Marrow: Femurs and tibias of donor C57 mice were 
removed, and bone marrow was flushed with 5% FBS/PBS. Red cells were lysed by 
incubation with RBC lysis buffer (Sigma) in 4% FBS/PBS for 12 minutes at RT. Cells 
were washed twice and resuspended in warm 5% FBS/PBS. Following the addition of 
1:1000 CFDA-SE (Invitrogen), cells were incubated for 15 minutes at 37°C, and then 
centrifuged again, resuspended in warm complete DMEM medium, and incubated for an 
additional 30-40 minutes at 37°C. When applicable, anti-mSIRPα antibody was added 
during this incubation period. Cells were then washed, resuspended in 5% FBS/PBS, 
counted, and volume was adjusted to allow injection of 106 cells. Remaining cells were 
analyzed by flow cytometry to establish initial composition. 
 
Sorting of Marrow Cells: In some experiments, marrow phagocytes were sorted from 
non-phagocytes and dendritic cells. FACS Aria (Biosciences (Helft et al., 2015)) was used 
to sort 60 million marrow cells using anti-CD135-BV421 (Biosciences,) and anti-SIRPα 
– FITC (P84, Biosciences) into 15 mL conical tubes containing 1mL FBS. This sorting 
process generated 20 tubes, which were subsequently centrifuged for 10 minutes at 4,000 
rpm. After the supernatant was aspirated, cells were resuspended in 5% FBS/PBS, 
incubated with targeting antibody for 1 hour, and centrifuged again. Finally, cells were 
resuspended in 200 µL of 5% FBS/PBS per 10×106 cells and put on ice for tail-vein 
injection. 
 
Ex Vivo Tumor Flow Cytometry Analysis: Unless specified, on the day of tumor 
isolation mice in the treatment cohort were injected with the standard antibody dose, as 
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described above. Mice were euthanized by cervical dislocation 1.5-2 hours after injection. 
Tissues were removed and placed in 20% FBS, and tumor core and periphery tissue were 
segregated. Tumor tissue was cut into 1-3 mm pieces, transferred to 15 mL centrifuge 
tubes, and centrifuged to remove media. Tissue was then resuspended in 3 mL warm 
Dispase (STEMCELL Technologies) supplemented with 3 mg/mL Collagenase (Sigma) 
and 200 µL of 1 mg/mL DNase I (Roche). Samples were mixed by pipetting for 1-3 
minutes until cloudy but not stringy. Dissociation was quenched by addition of 10 mL 
room temperature PBS, and then the suspension was filtered through a 70 µm cell strainer. 
The filtrate was centrifuged, the supernatant discarded, and the pellet resuspended in 2% 
FBS for antibody incubation. Spleens were prepared by mechanical dissociation, filtration, 
and red blood cell lysis using Red Cell Lysing Buffer (Sigma). Lysed samples were 
washed and resuspended in 2% FBS for antibody incubation. Prior to antibody incubation, 
samples were blocked with 1:500 Fc Block (BD Pharmingen) for at least 5 minutes at RT. 
CD47-AF647 (1:25), donkey anti-rabbit AF488 or AF700 (1:400), donkey anti-rat AF647 
(1:400), F4/80 APC-Cy7 (3:50), CD11b PE-Cy7 (1:25), Gr-1 APC (1:25), hCD47 AF647 
(1.5:50), and Hoescht 33342 (1:1250) were incubated at RT for 1 hour. Following 
incubation, cells were washed and resuspended in 2% FBS.  
 
Analysis of Mouse Blood Profiles: 100 µL of blood was isolated from anesthetized mice 
by retro-orbital bleeds. Blood was collected in Eppendorf tubes containing EDTA. Blood 
was kept at room temperature and immediately analyzed using a Drew Scientific Hemovet 
(HV950).  
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Graft vs. Host Disease: Mice were monitored 3 times a week by researchers and 
veterinarian technicians at the University of Pennsylvania Perelman School of Medicine 
mouse facilities for general health and for development of GvHD. Classic signs of GvHD 
include weight loss (>15%), ruffled fur, loss of fur on the head and rear of the mouse, 
hunched posture, and reduced activity (Ali et al., 2012; Hartung et al., 2003; King et al., 
2009). Development of GvHD is a common occurrence at these facilities as numerous 
users study CAR T-cell therapies, which frequently cause GvHD (Covassin et al., 2011; 
Jacoby et al., 2016). 
 
Quantification and Statistical Analysis: All statistical analyses were performed using 
GraphPad Prism 4. Unless otherwise noted, all statistical comparisons were made by 
unpaired two-tailed Student t tests and were considered significant if p < 0.05. Unless 
mentioned, all plots show mean ± SEM. “n” indicates the number of tumors, cells, or wells 
quantified in each experiment and is ≥3 in all experiments, except for RNA sequencing 
data which is for ≥ 2 samples per condition. Figure legends specify the exact meaning of 
“n” for each figure. 
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5.3 RESULTS 
Donor macrophage phagocytose and accumulate in syngeneic melanoma tumors 
causing depletion of Trp1 positive cancer cells 
Immunocompetent C57 mice were orthotopically challenged with the standard 
B16F10 mouse melanoma line. Unlike the first anti-mCD47 inhibition studies 
(Willingham et al., 2012) that used an orthotopic mouse breast tumor that can 
spontaneously regress and undermine reproducibility (Horrigan et al., 2017), we observed 
that (i) all subcutaneous injections of B16F10 cells (105) gave rise to palpable tumors with 
the similar growth rates (to ~100 mm2 by 17 ± 3 days) as reported for studies of in situ 
knockdown of mCD47 (Wang et al., 2013), and we observed that (ii) zero tumors 
spontaneously regressed. Previous studies using this model have transitioned to clinical 
trial(s) for melanoma immunotherapy within years after publishing [eg. (Ali et al., 2009); 
ClinicalTrials.gov NCT01753089]. C57 mouse marrow was sorted for 
monocyte/macrophage, and both anti-mSIRPα inhibition and a targeting antibody (anti-
Trp1) were added to the two separated fractions (Fig. 5.1A). Antibody inhibition of SIRPα 
is used as previous studies show that SIRPα knockdown in macrophages can promote 
tumor growth (Pan et al., 2013). The melanocyte-specific protein Trp1 involved in 
melanin synthesis (Tyrosinase-related protein 1, TYRP1) is targetable (Steitz et al., 2000) 
as it is expressed on the surface of melanomas (Fig. 5.S1).  
Antibody primed plus anti-SIRPα blocked MDMs (A’PB MФ) are abundant when 
isolated from the B16F10 tumors and show a dominant fraction of macrophages with high 
DNA intensity that indicates uptake of B16F10 tumor cells as the intensity is equivalent 
to one B16F10 (Fig. 5.1B). Recipient macrophages in tumors treated with anti-Trp1 show 
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the same shift, but with far fewer Hoechst high cells. The anti-Trp1 treatment significantly 
increases eating by TAMs, but this level of engulfment is matched by non-engineered 
donor cells (Fig. 5.1C). Fully primed donor macrophages (A’PB with anti-Trp1) showed 
the highest phagocytic activity with 75% of these cells engulfing a cancer cell. Inhibiting 
SIRPα on donor cells without anti-Trp1 causes a moderate level of eating, suggesting non-
specific opsonizing signals in this immunocompetent C57 model to be consistent with 
previous studies (Wang et al., 2013). Interestingly, A’PB MФ shows the greatest donor 
accumulation in tumors (Fig. 5.1D), which approximates recipient macrophage numbers 
in untreated tumors. Furthermore, a plot of donor MФ abundance as a function of the %-
phagocytic MФ shows that higher phagocytic activity strongly correlates with more tumor 
infiltration (Fig. 5.1E). The results thus suggest an “engorge and accumulate” mechanism 
in this syngeneic orthotopic tumor model, which was previously shown in human A549 
tumor xenografts in NSG mice. 
Tumor depletion of B16F10 cells by A’PB MФ was assessed by the percent of 
Trp1 positive cells remaining in the tumor after 10 days post cell injection. Flow 
cytometry confirms that A’PB MФ treated tumors had a reduction in Trp1 positive 
B16F10 cells (2%) whereas tumors treated with anti-Trp1 only were composed of ~35% 
(Fig. 5.1G). Indeed, multiple A’PB MФ treated tumors had a 10-fold decrease in Trp1 
expressing B16F10 cells compared to anti-Trp1 only and untreated tumors which were 
composed of 30% B16F10 cells (Fig. 5.1F). Despite anti-Trp1 increasing phagocytosis of 
recipient TAMs (Fig. 5.1C), this alone seems insufficient to deplete B16F10 tumor cells. 
This suggests two possible outcomes: (i) recruitment of adaptive immune cells may be 
necessary for sufficient B16F10 depletion and TAMs are poor activators or (ii) a high 
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level of phagocytosis is required to significantly disrupt B16F10 tumor growth with 
macrophages alone.     
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Figure 5.1. Donor macrophages phagocytose and accumulate in syngeneic 
melanoma tumors causing depletion of Trp1 positive cancer cells   
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Figure 5.1. Donor macrophages phagocytose and accumulate in syngeneic melanoma 
tumors causing depletion of Trp1 positive cancer cells. (A) C57 mice with established 
melanoma tumors (B16F10) received tail-vein injections of SIRPα inhibited C57 donor 
marrow macrophages that were CFDA labeled. Mice also received tail-vein injections 
every other day of targeting antibody, anti-Trp1 (APB MФ). In some experiments, Fc 
receptors on donor macrophages were primed with targeting Ab prior to cell injection 
(A’PB MФ). (B) After anti-Trp1 Ab injection on day 2, mice were sacrificed ~2 hours 
later, and tumors were disaggregated for flow cytometry. Hoechst intensity for tumor-
isolated donor A’PB MФ and recipient TAM after anti-Trp1 injection shows two 
populations with the Hoechst-high macrophages shifted from Hoechst-low macrophages 
by an intensity equivalent to one B16F10 cancer cell, consistent with phagocytosis. (C-D) 
Hoechst high macrophages isolated from B16F10 tumors give % phagocytic MФ among 
the total number of macrophages per 105 tumors cells (n ≥ 4 tumors). (E) Plotting Donor 
macrophages accumulation as a function of phagocytic activity. (F-G) Flow cytometry 
analysis of B16F10 Trp1 expressing cells in disaggregated orthotopic B16F10 tumors. 
Analysis includes all non-aggregated cells that stain for Hoechst. Tumors were isolated 
when control mice reached 100mm2 (n ≥ 3).  
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Donor macrophages reduce the growth of orthotopic melanoma and lung metastasis 
 To assess whether A’PB MФ could impact B16F10 tumor growth, marrow cells 
engineered with SIRPα block and anti-Trp1 were sorted into a fraction of non-phagocytes 
(eg. lymphocytes) with DCs and a fraction of monocytes/macrophages. These cells were 
tail-vein injected at day 13 into mice with established tumors (10 mm2 area). Sorted A’PB 
MФ considerably delayed growth for 10 days compared to untreated mice and mice 
treated with non-phagocytes plus DCs (with SIRPα inhibition and anti-Trp1), which 
showed no effect on tumor growth (Fig. 5.2A). Marrow DCs are far less abundant than 
marrow MФ’s (by ~50-fold), and so it is possible that more DCs could impact tumor 
growth (via T-cells) as observed elsewhere (Liu et al., 2015). Post treatment survival 
curves show A’PB MФ significantly increases the survival of challenged mice compared 
to non-phagocytes plus DCs, anti-Trp1 only, and untreated mice which only survived ~7 
days post treatment (Fig. 5.2B). Interestingly, ~50% of tumors treated with sorted A’PB 
MФ completely regressed and never reappeared 30+ days after treatment.  
 Though A’PB MФ can significantly reduce the growth of primary orthotopic 
melanoma tumors, metastasis is often the cause of death in most cancers. To evaluate 
A’PB MФ effect on metastatic melanoma, lungs were isolated from mice challenged with 
melanoma at day 15 and 22 post challenge. Almost all A’PB MФ treated mice had no lung 
metastasis at 22 days post challenge when treated with 20M cells, whereas anti-Trp1 only 
and untreated mice had ~15 melanoma lung nodules at day 15 post challenge (Fig. 5.2C, 
5.S2). Reducing A’PB MФ dose to10M cells, a standard adoptive T-cell injection (Garcia-
Hernandez et al., 2010; Sample et al., 2008; Zoon et al., 2015), still resulted in significant 
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reduction in melanoma lung nodules though more nodules were present than when treated 
with 20M cells. 
In addition to efficacy, safety is a concern whenever inhibiting MФ recognition of 
‘self’ based on past findings that systemic injections of anti-CD47 rapidly clear some 
blood cells (Weiskopf et al., 2013; Willingham et al., 2012) and can lead to an adaptive 
immune response (Yi et al., 2015). Blood was therefore drawn periodically from treated 
mice. Blood was isolated one and five days before treatment to establish pretreatment 
variation in blood profiles then again at day 11 and 14 (Fig. 5.S2). Along with blood 
collection, mice were observed 3 times a week for signs of anomalous mouse behavior 
(there were none). RBC count, hemoglobin levels, percent hematocrit, and platelet count 
all remained within the normal range for all treated mice at 4 days post treatment (Fig. 
5.2D). There was a notable decrease in WBC for A’PB MФ treated mice which may 
reflect A’PB MФ ability to recruit other immune effector cells to tumors. When blood 
parameters are compared to pretreatment no significant change was observed (Fig. 5.2S). 
Furthermore, no mouse showed signs of weight change (Fig. 5.2A, inset) or acute signs 
of graft vs host disease (GvHD: weight loss, rough fur, and hair loss on face or rear) 
attributable to donor lymphocytes (Ali et al., 2012; Hartung et al., 2003; King et al., 2009) 
over the 30+ days post injection. These results indicate that the engineered donor 
macrophages are the primary marrow effector cell and appear to be safe.  
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Figure 5.2. Donor macrophages reduce the tumor growth of orthotopic and lung 
metastasis of melanoma   
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Figure 5.2. Donor macrophages reduce the tumor growth of orthotopic and lung 
metastasis of melanoma. Mice were challenged with 2x105 orthotopic B16F10 tumor 
cells and allowed to grow until palpable (5-10 mm2) before treated. Tumor growth was 
measured by calipers and normalized to individual tumors at treatment day. (A) On 
treatment day, mice received tail-vein injection of sorted MDM cells (10M sorted cells 
per mouse). Tumor growth was significantly delayed only with the A’PB MФ fraction 
and not with the marrow DC fraction. (Inset) Weight measurements are normalized to the 
time of donor injection, and monitoring also proved negative for acute symptoms of 
GvHD: fur loss, hunched posture, and changes in activity (n ≥ 6). (B) Kaplan-Meier curve 
for survivable B16F10 tumor burden in C57 mice. A tumor larger than 100 mm2 was 
considered terminal as our IACUC does not allow death by tumor burden and recommends 
euthanization. The plateau for A’PB MФ treated mice (blue line, treatment day 18+) 
indicates complete tumor regression (n ≥ 12). (C) Number of lung nodules in C57 mice 
challenged with 5x105 non-aggregated B16F10 cells. Mice were treated with A’PB MФ 
anti-Trp1 at day 8 post challenge followed by lung isolation on day 15 and 22. Mice 
received 3 anti-Trp1 injections per week after treatment started (n ≥ 3). (D) Blood profiles 
from C57 mice challenged with 2x105 non-aggregated B16F10 cells. Mice started 
treatment on day 10 post challenge followed by injection of anti-Trp1 on day 11 and 13 
(n = 5).  
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Donor macrophages initiate initial shrinkage, but acquired immunity is necessary 
for long-term tumor regression 
To determine whether T-cells contribute to shrinkage of syngeneic tumors within 
2 days of treatment as concluded recently from injections of anti-mCD47 without 
opsonizing Ab (Liu et al., 2015), CD4 and CD8 T-cells were depleted prior to tail-vein 
injection of A’PB MФ. Surprisingly, depletion of T-cells lacked any significant effect on 
tumor shrinkage for 6+ days after treatment (Fig. 5.3A) and no systemic toxicity from 
either T-cell depletion nor treatment with A’PB MФ was observed (Fig. 5.3A, inset). This 
is consistent with little to no activation of T-cells by MDMs upon inhibiting mCD47 as 
concluded in the same studies (Liu et al., 2015). Therefore, the initial effector cell again 
seems to be the A’PB MФ, but after day 18 a significant difference in tumor size was 
observed between T-cell depleted mice and control mice treated with A’PB MФ (Fig. 
5.3A). To address whether T-cells are important for long-term tumor regress, tumor 
survival was compared between the two treatment groups. Indeed, all T-cell depleted mice 
died within 12 days after treatment. Although this was significantly longer survival than 
untreated mice, which had a max survival of 5 days, mice treated with A’PB MФ with no 
T-cell depletion had 50% of all tumors completely regress for 30+ days post treatment 
(Fig. 5.3B). This suggests that not only is A’PB MФ phagocytosis important for acute 
tumor shrinkage, but may also be efficient at presenting and activating T-cells for long-
term tumor regression when compared to TAMs. 
To ensure that an acquired immune response against B16F10 contributes to long-
term regression, mice treated with A’PB MФ that had complete regression (cured) were 
re-challenged with 2x105 B16F10 cells 100 days after the start of treatment. No 
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measurable tumor growth occurred in cured mice until day 26 post challenge whereas 
control mice had measurable growth at day 5 (Fig. 5.3C). Tumor analysis of cured mice 
that were re-challenged shows depletion of Trp1 positive B16F10 similar to initial 
treatment with A’PB MФ (Fig. 5.3D). This suggests that A’PB MФ treated mice develop 
acquired immunity against Trp1 expressing cancer cells and possibly other neoantigens 
expressed in B16F10. However, negative selection against these antigens leaves cancer 
cells that are unable to be cleared by the immune system leading to eventual tumor growth. 
Taken together, A’PB MФ macrophages, not TAMs, can shrink tumors and initiate an 
acquired immune response which is necessary for complete regression of orthotopic 
melanoma tumors.  
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Figure 5.3. Donor macrophages initiate initial shrinkage, but acquired immunity is 
necessary for long-term tumor regression   
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Figure 5.3. Donor macrophages initiate initial shrinkage, but acquired immunity is 
necessary for long-term tumor regression. (A) At day-9, donor marrow cells (20M; 
~half are MФ) prepared as A’PB MФ were tail-vein injected. CD4 and CD8 T-cells were 
depleted with biweekly (IP) injection of anti-CD4 and anti-CD8 Abs beginning at the time 
of donor cell injection (n ≥ 6). (Inset) Weight measurements are normalized to the time 
of donor injection, and monitoring also proved negative for acute symptoms of GvHD: 
fur loss, hunched posture, and changes in activity (n ≥ 6). (B) Kaplan-Meier curve for 
survivable B16F10 tumor burden in C57 mice with T cell depletion. A tumor larger than 
100 mm2 was considered terminal as our IACUC does not allow death by tumor burden 
and recommends euthanization. The plateau for A’PB MФ treated mice (blue line, 
treatment day 18+) indicates complete tumor regression. (C) Kaplan-Meier curve of event 
free survival of A’PB MФ cured mice re-challenged with B16F10 tumor cells. Re-
challenge started 100 days after initial treatment of A’PB MФ. (D) Flow cytometry 
analysis of B16F10 Trp1 expressing cells in disaggregated orthotopic B16F10 tumors. 
Analysis includes all non-aggregated cells that stain for Hoechst. Tumors were isolated if 
B16F10 re-challenged tumors grew and reached 100mm2.  
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5.4 DISCUSSION 
A’PB MФ alone can acutely shrink tumors without the need for T-cell activation, 
but T-cell recruitment and activation is necessary to prevent tumor recursion (Fig. 5.3A). 
Recent studies identified DCs as an important activator of T-cells with anti-CD47 
treatment (Liu et al., 2015). Here, SIRPα blocked, anti-Trp1 targeted DCs had no impact 
on tumor growth (Fig. 5.2A-B). This could reflect the aggressiveness of the melanoma 
model used or an insufficient dose of DCs as only 1% of all marrow cells are mature DCs. 
Regardless, T-cell influence on tumor shrinkage adds complexity in predicting cancer cell 
depletion solely by measuring MФ phagocytosis (Fig. 5.1C, 5.2A) as injection of anti-
Trp1 increases eating by TAMs, but has no impact on tumor growth (Fig. 5.1F, 5.2B-C). 
TAMs have proven to be weakly phagocytic (Rodriguez et al., 2013) which could 
contribute to their poor activation of acquired immunity as a minimum phagocytic 
threshold may be required, or perhaps TAMs have low expression of key proteins involved 
in presentation (i.e. MHCII). Unlike TAMs, undifferentiated SIRPα inhibited marrow 
macrophages can initiate an acquired immune response, leading to sustained primary 
tumor regression (Fig. 5.3B-D). Interestingly, SIRPα inhibition of MDMs without 
addition of anti-Trp1 significantly increased phagocytosis compared to MDMs without 
SIRPα blocking (Fig. 5.1C). This suggests non-specific opsonizing signals in this 
immunocompetent C57 model which is consistent with previous studies (Wang et al., 
2013) rather than opsonization from dissociating SIRPα blocking antibodies. Though 
B16F10 cells have high SIRPα expression (Fig. 5.S1), it unlikely that 5 µg of SIRPα 
blocking antibody (amount added to cells before washout) has any opsonizing effect as 
recent studies show injection of 200 µg of this antibody given 3 times a week for 2 weeks 
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(1200 µg, ~240-fold more) only reduces tumor growth by 50% (Yanagita et al., 2017). 
Regardless, addition of anti-Trp1 to A’PB MФ can also greatly reduce lung metastasis of 
melanoma at 22 days post challenge, with almost no melanoma lung nodules detected 
across numerous mice and experiments (Fig. 5.2C, 5.S2).  
Along with being efficacious, A’PB MФ had no detectable impact on mouse health 
which resulted from phagocytosis of melanoma cells or activation of acquired immunity. 
Blood profiles, body weight (Fig. 5.2A, 5.2D, 5.3A, 5.S2), and close observation of mouse 
activity for development of GvHD all suggest a degree of safety to the overall approach. 
In comparison, systemic injection of anti-CD47 causes reproducible decreases in blood 
cells and platelets as well as increased reticulocytes (Oldenborg et al., 2002; Weiskopf et 
al., 2013; Willingham et al., 2012), which are all a consequence of ubiquitous expression 
of CD47 and perhaps some level of opsonization of these components. Careful attention 
to species specificity of anti-CD47 is, of course, needed in such studies (Subramanian et 
al., 2006; Tsai & Discher, 2008), but CD47 blockade in a clinical setting is expected to 
sensitize all healthy cells to clearance by MФ. Increased reticulocyte production may 
mask the loss of RBCs at late time points, reinforcing the need for blood collection at 
early and late time points (Yanagita et al., 2017). Although reticulocytes may compensate 
for the loss of RBCs, increased clearance by phagocytes can lead to auto immunity against 
RBCs, causing severe anemia (Oldenborg et al., 2002). The findings here thus provide 
insight into macrophage dependent shrinkage of tumors and illustrate the role T-cells play. 
Furthermore, SIRPα inhibited marrow macrophages can efficiently and safely activate 
acquired immunity against syngeneic melanoma tumors. 
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5.5 SUPPLEMENT 
 
Figure 5.S1. Antibody binding and protein profiles in B16F10 cancer cells  
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Figure 5.S1. Antibody binding and protein profiles in B16F10 cancer cells. (A) 
Verification of anti-Trp1 binding to disaggregated orthotopic B16F10 tumors in C57 mice. 
Histogram is composed 5k B16F10 cells for each condition with ~10-fold intensity shift. 
(B-C) mSirpα and mCd47 expression and antibody binding. 
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Figure 5.S2. Safety and efficacy of A’PB MФ treatments in mice with lung 
melanoma metastasis   
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Figure 5.S2. Safety and efficacy of A’PB MФ treatment in mice with lung melanoma 
metastasis. (A) Number of lung nodules in C57 mice challenged with 2x105 non-
aggregated B16F10 cells. Mice were treated with A’PB MФ anti-Trp1 at day 10 post 
challenge followed by lung isolation on day 14. Mice received additional antibody 
injections on day 11 and 13 (n = 5). (B) Blood profiles from C57 mice challenged with 
5x105 non-aggregated B16F10 cells. Each parameter is normalized to mice treated with 
anti-Trp1 only. Mice started treatment on day 8 post challenge followed by every other 
day injection of Trp1 antibody (n ≥ 3). 
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Chapter 6: Conclusions and Future Work 
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This dissertation provides evidence that at least three features of a macrophage 
must be optimized for efficient engulfment of cancer cells in vivo. First, the phagocytic 
potential must be considered. Prior to this dissertation TAMs were thought to be sufficient 
at controlling tumor growth with anti-CD47 treatment and in some studies requiring an 
additional opsonization antibody (Gholamin et al., 2017; Weiskopf et al., 2013; 
Willingham et al., 2012). Here we found that even with >80% KD of CD47 and high 
opsonization, TAMs can only shrink tumors by 20% over 1-2 weeks compared to a A’PB 
MФ shrinkage of 50% in 10 days. We conclude that the difference in phagocytic potential 
between marrow macrophages and TAMs is caused by a 10-fold higher expression of 
SIRPα in TAMs. However, changes in other proteins important for phagocytosis could be 
occurring as well. Future work should focus on isolating TAMs, then inhibiting or 
knocking down SIRPα followed by phagocytosis assays comparing TAMs and marrow 
macrophages. If marrow macrophages continue to have a higher phagocytic index, then it 
would suggest that other mechanisms, in addition to high SIRPα, cause TAMs to be poor 
eaters.   
The second parameter that should be considered for a macrophage anti-cancer 
therapy is CD47-SIRPα inhibition. Anti-SIRPα antibodies can enhance phagocytosis of 
opsonized targets by immobilizing SIRPα (by crosslinking cis homodimers (Lee et al., 
2010)), and thereby limiting SIRPα accumulation into the phagocytic synapse (Fig. 4.S1). 
In recent in vitro experiments using THP-1s and human RBCs, we have found 
macrophages to be more efficient at eating CD47 expressing targets when plated on 
extremely stiff surfaces (Fig. 6.1A). On softer, more biologically relevant matrixes, 
phagocytosis is independent of matrix stiffness. When CD47-SIRPα signaling is inhibited 
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phagocytosis across all degrees of stiffness becomes equivalent (Fig. 6.1B). This suggests 
that CD47-SIRPα signaling is hindered when macrophages are plated on extremely stiff 
matrix. Staining of SIRPα on macrophages shows that SIRPα increases with increasing 
surface stiffness as previously shown (Fig. 6.1C). However, a minimal increase in SIRPα 
is found between the highest biologically relevant matrix and plastic (extremely stiff). 
Given these data, we hypothesis that SIRPα motility decreases with increasing matrix 
stiffness, likely reducing phagocytic synapse accumulation and preventing recognition of 
CD47. To compensate, macrophages increase surface expression of SIRPα, but this 
upregulation of SIRPα has a maximum. When macrophages are plated on plastic, a 
relatively small increase in SIRPα occurs which does not compensate for a relatively large 
decrease in SIRPα motility. Future work will verify this hypothesis using FRAP analysis 
to quantify SIRPα motility when macrophages are plated on matrices with a range of 
stiffness.  
Lastly, a cancer cell should be specifically opsonized for sufficient engulfment by 
macrophages to occur. A single antibody, such as anti-CD47, has been proposed to both 
inhibit ‘self’ signaling and to also efficiently opsonize a cancer cell (Willingham et al., 
2012), but this has become a subject of concern in terms of replication and statistical 
significance (Horrigan et al., 2017). In this dissertation, SIRPα inhibition of MDMs 
without addition of anti-Trp1 in immunocompetent mice significantly increased 
phagocytosis compared to MDMs without SIRPα blocking (Fig. 5.1C). This suggested 
that non-specific opsonizing signals in this immunocompetent C57 model which was 
consistent with previous studies (Wang et al., 2013), rather than opsonization from 
dissociating SIRPα blocking antibody. Other studies have proposed that calreticulin, 
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which is highly expressed on apoptotic and cancerous cells, is sufficient to drive eating 
with anti-CD47 inhibition (Chao et al., 2010; Feng et al., 2015; Gardai et al., 2005). 
However, the consensus from researchers, and the conclusion of this dissertation, is that 
additional antibody opsonization is required. Use of human-specific antibodies that target 
human cancers in mice yield relatively low off-target toxicity (i.e. antibodies against 
hRBC, hMucin-1, and hEGFR). However, finding antibodies that target mouse cancers in 
mice or human cancers in human that do not produce toxic side effects with donor 
macrophage therapy is challenging. Emerging RNA sequencing technology will be critical 
at developing personalized medicine where a patient’s neoantigens are identified and 
appropriate antibodies are selected. Future work will utilize the metastatic B16F10 tumor 
model to study DNA damage that occurs at primary and metastatic tumor sites. We will 
focus on DNA damage that occurs as a cancer cell travels in the blood and whether damage 
at these two sites cause new neoantigens to develop.   
Given these 3 requirements, this dissertation has shown that SIRPα inhibition 
combined with adoptive macrophage therapy using marrow-derived macrophages is an 
effective approach for shrinking primary solid tumors. A’PB MФ were also shown to 
greatly reduce lung metastasis of melanoma, as 22 days post challenge almost no 
melanoma lung nodules were detected across numerous mice and experiments (Fig. 5.2C, 
5.S2). Using tumor growth to evaluate macrophage based therapies is useful, but profiling 
macrophages directly from tumors has revealed additional information which was 
previously unknown. In this dissertation, macrophage phagocytosis of tumor cells in vivo 
measured at the single cell level predicted initial rates of tumor shrinkage. Donor 
macrophages proved to be more effective at phagocytosing cancer cells than TAMs, and 
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accumulate in tumors in various tissues based on their phagocytic potential. This method 
of analyzing macrophages builds on past studies that use clodronate, which depletes 
phagocytic cells, or tissue staining for F4/80 abundance to implicate a role for 
macrophages as the primary effector cell (Gholamin et al., 2017; Wang et al., 2013). 
However, clodronate causes high variability in tumor growth, making statistical analysis 
difficult and using one simple surface marker to distinguish macrophages from the 10-20 
different cell types in a tumor is unreliable at best. Our single cell analysis also gave us 
insight into macrophage differentiation. Previous studies concluded that anti-CD47 
treatment enhanced eating by macrophages and drove them to an M1 phenotype (Zhang 
et al., 2016). The studies conducted here suggest that no matter the phagocytic potential 
of a macrophage, prolonged residency in stiff tumors drives differentiation towards SIRPα 
high, non-phagocytic, tumor promoting macrophages (Fig. 4.4B-F, 4.S5). It is likely that 
anti-CD47 antibody treatments lead to recruitment of circulating monocytes into tumors 
which would have a higher M1/M2 ratio rather than directly converting TAMs into a 
phagocytic phenotype. 
Though this dissertation implicates microenvironment stiffness of tumors as a 
contributor to macrophage differentiation, phagocytosis could also be involved as it is a 
mechanically intensive process which causes similar cytoskeleton stress. Phagocytosis is 
favored by the stiffness of a cell or particle, and myosin-II has again been shown to be key 
(Sosale et al., 2015; Tsai & Discher, 2008). Myosin-II thus has a vital role in multiple, 
cytoskeletal-intensive activities of macrophages which could control differentiation. 
Intuitively, it seems possible that nature has designed macrophages to negatively regulate 
phagocytosis to prevent off-target eating and autoimmune response from presentation of 
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‘self’ antigens. Future work will focus on the relationship between phagocytosis and 
differentiation by setting up time dependent phagocytosis experiments followed by 
M1/M2 staining and RNA Sequencing.  
Understanding factors that influence macrophage differentiation is currently a hot 
topic and a major hurdle for donor macrophage therapy which is thoroughly studied in 
this dissertation. RNAi knockdown of SIRPα seems like an obvious approach to prevent 
differentiation of macrophages to non-phagocytic TAMs, but SIRPα-knockdown 
macrophages can enhance tumor growth in vivo (Pan et al., 2013). Staining of M1/M2 
markers and SIRPα on differentiating donor MФ shows simultaneous upregulation of 
SIRPα and M2 marker. Unfortunately, a causal relationship cannot be established between 
SIRPα and macrophage differentiation given the data in this dissertation. Future work 
should consider the transcriptional changes that occur in macrophages with SIRPα 
knockdown or overexpression and how it affects macrophage differentiation, and maybe 
even migration, as TAMs seemed to migrate less than marrow macrophages (Fig. 4.S4).   
It is well established that phagocytes are highly motile, but whether macrophage 
migration could be inhibited by phagocytosis of cancers was unknown. Marrow-derived 
macrophages from mouse (NSG) or human infiltrated large solid tumors and accumulated 
proportionally to their engulfment of cancer cells (Fig. 4.1B-F, 4.S6). In solid tumors of 
low porosity, immobilization can in part be due to an inability to ‘eat and run.’ The 
stiffness of the nucleus is well-known to hinder migration (Harada et al., 2014; Shin et al., 
2013; Thiam et al., 2016). Therefore, it is unsurprising that a macrophage with two nuclei 
(one from the cancer cell and one of its own) has difficulty migrating. However, 
engulfment of two nanobeads significantly reduced 3D migration through much larger 
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micro-pores (Fig. 4.2B-E). This suggests an antagonism exists between phagocytic and 
migratory pathways in macrophages, which has already been proposed for very primitive 
cells such as Dyctiostilium amoeba (Veltman et al., 2014) and fly haemocytes (Evans et 
al., 2013), as well as dendritic cells (Chabaud et al., 2015). We hypothesize that this 
antagonism causes competition between overlapping proteins involved in cytoskeleton 
components such as ARP2/3 or Myosin II wherein the proteins are sequestered by the 
dominate function, phagocytosis. Future work should focus on identifying the overlapping 
proteins and use live imaging during migration eating experiments to confirm protein 
reallocation from migration to phagocytosis.   
The “engorge and accumulate” mechanism for engineered donor macrophage in 
solid tumors adds an additional safety component to this therapy as it minimizes 
accumulation of engineered macrophages in other tissues (Fig. 4.1G, 4.S3). Throughout 
this dissertation, there was no detectable impact on mouse health resulting from the 
numerous donor cell injections that drive tumor phagocytosis and shrinkage (Fig. 4.5C, 
4.S6) even in immunocompetent mice where T-cells were activated against melanoma 
cells (Fig. 5.2A, 5.2D, 5.3A, 5.S2). Subsequent injections of marrow cells remain 
effective and safe (Fig. 4.5C, 4.S6), and it is worth noting that multiple injections of 
marrow and leukocytes are already done in the clinic (Eapen et al., 2004). Our approach 
of adding SIRPα blocking antibody directly to monocyte/macrophage ex vivo greatly 
reduces the amount of blocking antibody required compared to systemic injections of anti-
CD47 or anti-SIRPα aiming to block ‘self’ on tumor cells. Furthermore, most of the 
engineered marrow cells injected are monocytes which may require tissue residency to 
differentiate into phagocytic macrophages and, therefore, are unable to eat RBCs they 
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encounter in circulation. Once monocytes infiltrate a tissue (likely the tumor, according 
to our research), strong opsonization toward cancer cells directs them to phagocytose 
tumor cells rather than RBCs. In comparison, systemic injection of anti-CD47 causes 
blockade of CD47 on blood cells and platelets (Oldenborg et al., 2002; Weiskopf et al., 
2013; Willingham et al., 2012) leading to clearance by splenic and liver macrophages 
which normally screen the blood for foreign cells. Our CD47 knockdown studies 
document selective eating of cells with low CD47, enriching for CD47-high cancer cells 
(Fig. 4.3C-D, 4.S4). Therefore, older RBCs with less CD47 are likely cleared first. This 
can also explain why cancer patients have CD47-high cancer cells (Willingham et al., 
2012) and oncogenes that drive CD47 expression are favored (Casey et al., 2016). Careful 
attention to species specificity of anti-CD47 is, of course, needed in all safety studies 
(Subramanian et al., 2006; Tsai & Discher, 2008) as CD47 blockade in a clinical setting 
is expected to sensitize all healthy cells to phagocytosis by macrophages. Acute depletion 
of RBCs can be compensated with erythropoietin injection or blood transfusion, but 
autoimmune concerns exist leading to chronic anemia as IgG against mouse RBCs is 
observed in preclinical models (Oldenborg et al., 2002). Therefore, understanding 
activation of acquired immunity by macrophages is an important area of study not only 
for chronic autoimmune diseases, but cancer therapy. 
This dissertation has shown that A’PB MФ alone can acutely shrink tumors 
without the need for T-cell activation in immune incompetent and competent mice that 
are T-cells depleted. However, T-cell recruitment and activation is necessary to prevent 
tumor recursion (Fig. 5.3A). Recent studies identified DCs as an important activator of T-
cells with anti-CD47 treatment (Liu et al., 2015). Here, SIRPα blocked, antibody targeted 
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DCs had no impact on tumor growth. This could have reflected the aggressiveness of the 
tumor models used, or an insufficient dose of DCs, as only 1% of all marrow cells are 
mature DCs. Regardless, T-cell influence on tumor shrinkage added complexity in 
predicting cancer cell depletion solely by measuring macrophage phagocytosis. TAMs 
have proven to be weakly phagocytic (Rodríguez et al., 2013) which could have 
contributed to their poor activation of acquired immunity (Liu et al., 2015), as a minimum 
phagocytic threshold may be required, or perhaps TAMs have low expression of key 
proteins involved in presentation (i.e. MHCII). Unlike TAMs, undifferentiated SIRPα 
inhibited marrow macrophages could initiate an acquired immune response leading to 
sustained primary tumor regression (Fig. 5.3B-D). However, the understanding of T-cell 
activation by macrophages reached in this dissertation is incomplete (chapter 5). 
Our immediate work will be directed towards proving donor macrophages not only 
activate T-cells, but are more efficient than TAMs. The re-challenge experiment 
conducted in this dissertation is unfinished and should be replicated with more mice (Fig. 
5.3C, D). If successful, we would identify which B16F10 antigens T-cells are targeting. 
Based on the depletion of Trp1 expressing cells in re-challenged mice, we are concerned 
that T-cells are only being developed against Trp1. Therefore, we plan to knockout Trp1 
in B16F10 and create mosaic tumors, then treat with A’PB MФ targeting Trp1. Since 
A’PB MФ selectively phagocytosis opsonized cells, Trp1 knockout cells should be 
unaffected by macrophages. If 60% (% regression observed in WT B16F10 tumors) of 
tumors continue to regress it would suggest that T-cells are targeting different antigens 
beside Trp1, and confirms that other immune cells must be involved as macrophages are 
unable to clear Trp1 knockout cells. Once T-cell activation by donor macrophages is 
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verified, these experiments will be repeated using TAMs as a source of donor cells to 
study their ability to initiate an acquired immune response.  
The findings in his dissertation thus provide insight into the mechanisms, utility, 
and safety of engineering (i) a highly phagocytic and motile macrophage, with (ii) 
inhibition of ‘self’ signaling by anti-SIRPα, combined with (iii) robust target opsonization. 
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Figure 6.1. Matrix stiffness inhibits SIRPα motility 
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Figure 6.1. Matrix stiffness inhibits SIRPα motility. Phagocytosis assay using a THP-
1 cell line co-cultured with opsonized human RBCs for 30 mins on gels with varying 
stiffness. (A) Normalized phagocytic index (Percent phagocytic THP-1s multiplied by the 
number of cells engulfed per THP-1) as a function of matrix stiffness without CD47 
inhibition and (B) with CD47 inhibition. It appears THP-1s on very stiff matrix are more 
efficient at phagocytosis, but with CD47 inhibition THP-1 engulfment of RBCs is 
independent of matrix stiffness. (C) SIRPα staining of THP-1s on different degrees of 
stiffness. In a biologically relevant range of matrix stiffness SIRPα increases, but no 
significant difference is measured beyond this range.  
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